<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="chapter-article"><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><?noissn?><front><journal-meta><journal-id journal-id-type="publisher-id">978-3-7091-1544-2</journal-id><journal-id journal-id-type="doi">10.1007/978-3-7091-1544-2</journal-id><journal-id journal-id-type="nlm-ta">Imaging Brain Diseases</journal-id><journal-title-group><journal-title>Imaging Brain Diseases</journal-title><journal-subtitle>A Neuroradiology, Nuclear Medicine, Neurosurgery, Neuropathology and Molecular Biology-based Approach</journal-subtitle></journal-title-group><isbn publication-format="print">978-3-7091-1543-5</isbn><isbn publication-format="electronic">978-3-7091-1544-2</isbn></journal-meta><article-meta><article-id pub-id-type="pmcid">7120597</article-id><article-id pub-id-type="publisher-id">26</article-id><article-id pub-id-type="doi">10.1007/978-3-7091-1544-2_26</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Infections: Viruses</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Weis</surname><given-names>Serge</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Sonnberger</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Dunzinger</surname><given-names>Andreas</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Voglmayr</surname><given-names>Eva</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Aichholzer</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Kleiser</surname><given-names>Raimund</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Strasser</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.9970.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 1941 5140</institution-id><institution>Division of Neuropathology, Neuromed Campus, </institution><institution>Kepler University Hospital, Johannes Kepler University, </institution></institution-wrap>Linz, Austria </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.9970.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 1941 5140</institution-id><institution>Department of Neuroradiology, Neuromed Campus, </institution><institution>Kepler University Hospital, Johannes Kepler University, </institution></institution-wrap>Linz, Austria </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="GRID">grid.9970.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 1941 5140</institution-id><institution>Department of Neuro-Nuclear Medicine, Neuromed Campus, </institution><institution>Kepler University Hospital, Johannes Kepler University, </institution></institution-wrap>Linz, Austria </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="GRID">grid.9970.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 1941 5140</institution-id><institution>Department of Neurosurgery, Neuromed Campus, </institution><institution>Kepler University Hospital, Johannes Kepler University, </institution></institution-wrap>Linz, Austria </aff><aff id="Aff12"><label>12</label>PMU University Institute for Medical &#x00026; Chemical Laboratory Diagnostics, Salzburg, Austria </aff></contrib-group><pub-date pub-type="epub"><day>12</day><month>2</month><year>2019</year></pub-date><fpage>693</fpage><lpage>747</lpage><permissions><copyright-statement>&#x000a9; Springer-Verlag GmbH Austria, part of Springer Nature 2019</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Viruses can cause meningitis, encephalitis, myelitis, arteritis when affecting the nervous system. Viruses are classified as DNA viruses and RNA viruses. Imaging of viral encephalitis is often nonspecific showing focal or diffuse edema (acute infection) or focal atrophy (chronic infection). Location of the lesion depends on causative agent, thus, HSV encephalitis displays an almost pathognomonic involvement of the limbic system.</p><p id="Par2">The various steps in the pathogenesis include entry into the body, delivery of the virus to the target tissue, interaction of virus with target tissue, cytopathogenesis, host responses, immunopathology, virus production in a tissue with release of the virus to other people (contagion), and transmission of viruses.</p><p id="Par3">Treatment consists of administration of antiviral drugs which aim at altering virion disruption, attachment, penetration and uncoating, RNA synthesis, genome replication, virion assembly and release. Clinical outcome depends on age of infection, nature of disease, severity of disease, and progression of viral disease.</p><p id="Par4">Human immunodeficiency virus (HIV)-1 infection is a serious health problem worldwide as 33 million adults and 2 million children are infected with HIV-1. The brain is often involved which leads to the HIV-associated neurocognitive disorders (HAND) of which asymptomatic neurocognitive impairment (ANI), mild neurocognitive disorder (MND), and HIV-associated dementia (HAD) represent various stages. The neuropathologic changes in HIV-1 induced lesions, i.e. HIV-1 encephalitis (characterized by multiple disseminated foci composed of microglia, macrophages, and multinucleated giant cells (MGCs) predominantly located in the cortex, deep gray matter, and the white matter), HIV-1 leukoencephalopathy (diffuse damage to the white matter), lymphocytic meningitis (LM), perivascular lymphocytic infiltration (PLI), vacuolar myelopathy (VM), vacuolar leukoencephalopathy (VL) are described. Therapy might lead to the immune restituiton inflammatory syndrome (IRIS). The sequelae of HIV-1 infection of the nervous system include changes in neuronal number, neuronal size, synapses, dendrites, nerve fibers, astroglia, oligodendroglia, microglia/macrophages, vessels, vascular endothelial cells, and capillaries. Pathogenetic mechanisms deal with the mode of entrance of HIV-1 into the brain, target cells of HIV-1, mechanisms of brain lesions, and interactions between the blood&#x02013;brain-barrier (BBB) and HIV.</p><p id="Par5">Cytomegalovirus infection (CMV), progressive multifocal leukoencephalopathy (PML), Herpes Simplex Virus (HSV) encephalitis, and Tick-borne encephalitis are further described.</p></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag GmbH Austria, part of Springer Nature 2019</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Clinical Signs and Symptoms</title><p id="Par6">Signs and symptoms of (Table <xref rid="Tab1" ref-type="table">26.1</xref>):<list list-type="bullet"><list-item><p id="Par7">Meningitis</p></list-item><list-item><p id="Par8">Encephalitis<list list-type="bullet"><list-item><p id="Par9">Cerebral dysfunctions (delirium, lethargy, confusion, stupor, coma)</p></list-item><list-item><p id="Par10">Seizures</p></list-item><list-item><p id="Par11">Focal neurologic deficits</p></list-item></list></p></list-item></list><table-wrap id="Tab1"><label>Table 26.1</label><caption><p>Neurologic signs and syndromes related to affected regions</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Localization</th><th>Syndrome</th><th>Neurologic signs</th></tr></thead><tbody><tr><td>Meninges</td><td>&#x02022;&#x02002;Meningitis</td><td><p>&#x02022;&#x02002;Headache</p><p>&#x02022;&#x02002;Vomiting</p><p>&#x02022;&#x02002;Photophobia</p><p>&#x02022;&#x02002;Focal neurologic deficits</p><p>&#x02022;&#x02002;Alterations in consciousness</p></td></tr><tr><td>Brain parenchyma diffuse</td><td>&#x02022;&#x02002;Encephalitis</td><td><p>&#x02022;&#x02002;Alterations in consciousness</p><p>&#x02022;&#x02002;Seizures</p><p>&#x02022;&#x02002;Multifocal neurologic deficits</p></td></tr><tr><td>Brain parenchyma focal</td><td><p>&#x02022;&#x02002;Encephalitis</p><p>&#x02022;&#x02002;Cerebritis</p></td><td><p>&#x02022;&#x02002;Focal neurologic deficits</p><p>&#x02022;&#x02002;Seizures</p></td></tr><tr><td>Brain stem and posterior cranial fossa</td><td><p>&#x02022;&#x02002;Brain stem encephalitis</p><p>&#x02022;&#x02002;Cerebellitis</p></td><td><p>&#x02022;&#x02002;Opto- and pupillomotor disturbances</p><p>&#x02022;&#x02002;Nuclear cranial nerve lesions</p><p>&#x02022;&#x02002;Dysarthria</p><p>&#x02022;&#x02002;Bilateral pyramidal tract signs</p><p>&#x02022;&#x02002;Alterations in consciousness</p><p>&#x02022;&#x02002;Breathing insufficiency</p><p>&#x02022;&#x02002;Vegetative signs</p></td></tr><tr><td>Spinal cord</td><td>&#x02022;&#x02002;Myelitis</td><td><p>&#x02022;&#x02002;Paraplegia</p><p>&#x02022;&#x02002;Brown S&#x000e9;quard syndrome</p></td></tr><tr><td>Arteries</td><td>&#x02022;&#x02002;Arteritis</td><td>&#x02022;&#x02002;Sudden focal neurologic deficit</td></tr><tr><td>Veins</td><td>&#x02022;&#x02002;Septic venous sinus thrombosis</td><td><p>&#x02022;&#x02002;Headache</p><p>&#x02022;&#x02002;Seizures</p><p>&#x02022;&#x02002;Raised brain pressure</p><p>&#x02022;&#x02002;Focal neurologic deficits</p></td></tr></tbody></table></table-wrap></p></sec><sec id="Sec2"><title>Classification of Viruses</title><p id="Par12">Classification of viruses based on their nuclei acid into (Tables <xref rid="Tab2" ref-type="table">26.2</xref> and <xref rid="Tab3" ref-type="table">26.3</xref>):<list list-type="bullet"><list-item><p id="Par13">DNA viruses</p></list-item><list-item><p id="Par14">RNA viruses</p></list-item></list><table-wrap id="Tab2"><label>Table 26.2</label><caption><p>Subdivision of viruses</p></caption><table frame="hsides" rules="groups"><tbody><tr><td rowspan="2">DNA viruses</td><td>Enveloped</td><td><p>&#x02022;&#x02002;Pox</p><p>&#x02022;&#x02002;Herpes</p><p>&#x02022;&#x02002;Hepadna</p></td></tr><tr><td>Naked capsid</td><td><p>&#x02022;&#x02002;Polyoma, Papilloma, Adeno</p><p>&#x02022;&#x02002;Parvo</p></td></tr><tr><td rowspan="4">RNA viruses</td><td>+RNA</td><td><p>&#x02022;&#x02002;Naked capsid: Picorna, Calici</p><p>&#x02022;&#x02002;Enveloped: Toga, Flavi, Corona</p></td></tr><tr><td>&#x02013;RNA</td><td>&#x02022;&#x02002;Enveloped: Rhabdo, Filo, Orthomyxo, Paramyxo, Bunya, Arena</td></tr><tr><td>&#x000b1;RNA</td><td>&#x02022;&#x02002;Double capsid: Reo</td></tr><tr><td>+RNA via DNA</td><td>&#x02022;&#x02002;Enveloped: Retro</td></tr></tbody></table></table-wrap><table-wrap id="Tab3"><label>Table 26.3</label><caption><p>A detailed subdivision of viruses</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2">Viral genome</th><th>Family name of virus</th><th>Family members</th></tr></thead><tbody><tr><td rowspan="4">DNA</td><td rowspan="3">Double-stranded</td><td>Herpesviridae</td><td><p>&#x02022;&#x02002;HSV-1</p><p>&#x02022;&#x02002;HSV-2</p><p>&#x02022;&#x02002;Varicella-zoster virus</p><p>&#x02022;&#x02002;Cytomegalovirus</p><p>&#x02022;&#x02002;Epstein-Barr virus</p><p>&#x02022;&#x02002;Human herpesvirus 6</p><p>&#x02022;&#x02002;Human herpesvirus 7</p><p>&#x02022;&#x02002;Human herpesvirus 8</p><p>&#x02022;&#x02002;Herpes simiae</p></td></tr><tr><td>Adenoviridae</td><td>&#x02022;&#x02002;Adenovirus</td></tr><tr><td>Papovaviridae</td><td><p>&#x02022;&#x02002;JC virus</p><p>&#x02022;&#x02002;Simian virus 40</p></td></tr><tr><td>Single-stranded</td><td>Parvoviridae</td><td>&#x02022;&#x02002;Parvovirus B19</td></tr><tr><td rowspan="12">RNA</td><td>Double-stranded</td><td>Reoviridae</td><td><p>&#x02022;&#x02002;Coltivirus</p><p>&#x02022;&#x02002;Seadornavirus</p></td></tr><tr><td rowspan="3">Single-stranded sense non-segmented</td><td>Retroviridae</td><td><p>&#x02022;&#x02002;Deltaretrovirus</p><p>&#x02022;&#x02002;Lentivirus</p></td></tr><tr><td>Coronaviridae</td><td>&#x02022;&#x02002;Coronavirus</td></tr><tr><td>Togaviridae</td><td>&#x02022;&#x02002;Alphavirus</td></tr><tr><td/><td>Flaviviridae</td><td>&#x02022;&#x02002;Flavivirus</td></tr><tr><td/><td>Picornaviridae</td><td>&#x02022;&#x02002;Enterovirus</td></tr><tr><td rowspan="2">Single-stranded antisense segmented</td><td>Bunyaviridae</td><td><p>&#x02022;&#x02002;Orthobunyavirus</p><p>&#x02022;&#x02002;Phlebovirus</p></td></tr><tr><td>Arenaviridae</td><td>&#x02022;&#x02002;Arenavirus</td></tr><tr><td rowspan="4">Single-stranded antisense non-segmented</td><td>Orthomyxoviridae</td><td>&#x02022;&#x02002;Influenza viruses</td></tr><tr><td>Paramyxoviridae</td><td><p>&#x02022;&#x02002;Henipavirus</p><p>&#x02022;&#x02002;Morbilivirus</p><p>&#x02022;&#x02002;Rubulavirus</p></td></tr><tr><td>Rhabdoviridae</td><td><p>&#x02022;&#x02002;Rabies</p><p>&#x02022;&#x02002;Borna</p></td></tr><tr><td>Filoviridae</td><td>&#x02022;&#x02002;Ebola</td></tr></tbody></table></table-wrap></p><p id="Par15">The diseases caused by viruses are listed in Table <xref rid="Tab4" ref-type="table">26.4</xref> while brain diseases caused by viruses are depicted in Tables <xref rid="Tab5" ref-type="table">26.5</xref> and <xref rid="Tab6" ref-type="table">26.6</xref>.<table-wrap id="Tab4"><label>Table 26.4</label><caption><p>List of viruses and related diseases of viruses</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Viral family</th><th>Virus</th><th>Disease</th></tr></thead><tbody><tr><td rowspan="13">DNA</td><td>Papillomavirus</td><td/><td><p>&#x02022;&#x02002;Warts</p><p>&#x02022;&#x02002;Condylomas</p><p>&#x02022;&#x02002;Cervical cancer</p></td></tr><tr><td rowspan="2">Polyomaviridae</td><td>BK virus</td><td>&#x02022;&#x02002;Renal disease</td></tr><tr><td>JC virus</td><td>&#x02022;&#x02002;Progressive multifocal leukoencephalopathy</td></tr><tr><td>Adenoviridae</td><td/><td><p>&#x02022;&#x02002;Respiratory disease</p><p>&#x02022;&#x02002;Meningoencephalitis</p></td></tr><tr><td rowspan="3">Alphaherpesvirinae</td><td>Herpesvirus 1</td><td>&#x02022;&#x02002;Encephalitis</td></tr><tr><td>Herpesvirus 2</td><td>&#x02022;&#x02002;Encephalitis</td></tr><tr><td>Varicella-zoster virus</td><td>&#x02022;&#x02002;Encephalitis</td></tr><tr><td>Gammaherpesvirinae</td><td>Epstein-Barr virus</td><td>&#x02022;&#x02002;Encephalitis</td></tr><tr><td>Betaherpesvirinae</td><td>Cytomegalovirus</td><td>&#x02022;&#x02002;Encephalitis</td></tr><tr><td>Poxviruses</td><td/><td>&#x02022;&#x02002;Smallpox</td></tr><tr><td>Parvoviruses</td><td/><td>&#x02022;&#x02002;Erythema infectiosum</td></tr><tr><td rowspan="2">Picornaviruses</td><td>Enterovirus</td><td><p>&#x02022;&#x02002;Encephalitis</p><p>&#x02022;&#x02002;Meningitis</p><p>&#x02022;&#x02002;Poliovirus infections (polyomyelitis, paralytic polio)</p></td></tr><tr><td>Hepatovirus</td><td>&#x02022;&#x02002;Hepatitis</td></tr><tr><td rowspan="15">RNA</td><td rowspan="4">Picornaviridae</td><td>Poliovirus</td><td><p>&#x02022;&#x02002;Poliomyelitis</p><p>&#x02022;&#x02002;Postpolio syndrome</p></td></tr><tr><td>Enteroviruses</td><td/></tr><tr><td>Cardiovirus genus</td><td/></tr><tr><td>Encephalomyocarditis virus</td><td/></tr><tr><td rowspan="4">Arboviruses</td><td>Togaviridae, alphavirus genus</td><td><p>&#x02022;&#x02002;Eastern equine encephalitis</p><p>&#x02022;&#x02002;Western equine encephalitis</p><p>&#x02022;&#x02002;Venezuelan equine encephalitis</p></td></tr><tr><td>Flaviviridae</td><td><p>&#x02022;&#x02002;Japanese encephalitis</p><p>&#x02022;&#x02002;St. Louis Encephalitis</p><p>&#x02022;&#x02002;Russian spring-summer encephalitis</p><p>&#x02022;&#x02002;Central European encephalitis</p><p>&#x02022;&#x02002;Kyasanur forest disease</p><p>&#x02022;&#x02002;Murray valley encephalitis</p><p>&#x02022;&#x02002;Rocio</p></td></tr><tr><td>Bunyaviridae</td><td><p>&#x02022;&#x02002;La Crosse encephalitis</p><p>&#x02022;&#x02002;Snowshoe hare virus</p><p>&#x02022;&#x02002;California encephalitis</p><p>&#x02022;&#x02002;Jamestown canyon encephalitis</p></td></tr><tr><td>Reoviridae</td><td>&#x02022;&#x02002;Colorado tick fever</td></tr><tr><td rowspan="3">Paramyxoviruses</td><td>Measles virus</td><td>&#x02022;&#x02002;Measles</td></tr><tr><td>Parainfluenza virus</td><td>&#x02022;&#x02002;Limited respiratory tract infection</td></tr><tr><td>Mumps virus</td><td>&#x02022;&#x02002;Mumps</td></tr><tr><td>Orthomyxoviruses</td><td>Influenza A and B viruses</td><td>&#x02022;&#x02002;Influenza</td></tr><tr><td>Rhabdoviruses</td><td>Rhabdovirus</td><td>&#x02022;&#x02002;Rabies</td></tr><tr><td rowspan="2">Retroviruses</td><td>Oncovirinae (HTLV)</td><td>&#x02022;&#x02002;Tropical spastic paraparesis</td></tr><tr><td>Lentivirinae (HIV)</td><td>&#x02022;&#x02002;Acquired immune deficiency syndrome (AIDS)</td></tr></tbody></table></table-wrap><table-wrap id="Tab5"><label>Table 26.5</label><caption><p>Viral infections of the brain and their causative viral agents</p></caption><table frame="hsides" rules="groups"><tbody><tr><td>Encephalitis</td><td><p>&#x02022;&#x02002;HSV-1</p><p>&#x02022;&#x02002;Toga, Flavi, Bunya encephalitis viruses</p><p>&#x02022;&#x02002;Picornaviruses</p><p>&#x02022;&#x02002;Arboencephalitis virus</p><p>&#x02022;&#x02002;Varicella-zoster virus</p><p>&#x02022;&#x02002;Rabies virus</p><p>&#x02022;&#x02002;Polioviruses</p><p>&#x02022;&#x02002;Coxsackie A and B viruses</p></td></tr><tr><td>Meningitis</td><td><p>&#x02022;&#x02002;HSV-2</p><p>&#x02022;&#x02002;Picornaviruses</p><p>&#x02022;&#x02002;Mumps virus</p><p>&#x02022;&#x02002;Enteroviruses</p><p>&#x02003;&#x02013;&#x02003;Echoviruses</p><p>&#x02003;&#x02013;&#x02003;Coxsackie virus</p><p>&#x02003;&#x02013;&#x02003;Poliovirus</p><p>&#x02022;&#x02002;Adenoviruses</p></td></tr><tr><td>Paralysis</td><td><p>&#x02022;&#x02002;Poliovirus</p><p>&#x02022;&#x02002;Enterovirus 70 and 71</p><p>&#x02022;&#x02002;Coxsackie A7 virus</p></td></tr><tr><td>Postinfectious encephalitis (immune mediated)</td><td><p>&#x02022;&#x02002;Measles virus</p><p>&#x02022;&#x02002;Mumps virus</p><p>&#x02022;&#x02002;Rubella virus</p><p>&#x02022;&#x02002;Varicella-zoster virus</p><p>&#x02022;&#x02002;Influenza virus</p></td></tr><tr><td>Other</td><td><p>&#x02022;&#x02002;JC virus-progressive multifocal leukoencephalopathy (PML)</p><p>&#x02022;&#x02002;Human Immunodeficiency Virus (HIV)</p><p>&#x02022;&#x02002;Human T-cell lymphotropic virus 1 (HTLV-1) (tropical spastic paraparesis)</p><p>&#x02022;&#x02002;Measles variant (subacute sclerosing panencephalitis)</p></td></tr></tbody></table></table-wrap><table-wrap id="Tab6"><label>Table 26.6</label><caption><p>Acute and chronic viral infection affecting the brain</p></caption><table frame="hsides" rules="groups"><tbody><tr><td>Acute viral infection</td><td><p>&#x02022;&#x02002;Aseptic meningitis</p><p>&#x02022;&#x02002;Polyomyelitis</p><p>&#x02022;&#x02002;Neonatal enteroviral encephalitis</p><p>&#x02022;&#x02002;Herpesvirus infections</p><p>&#x02003;&#x02013;&#x02002;Herpes simplex virus infection</p><p>&#x02003;&#x02013;&#x02002;Atypical herpes simplex encephalitis</p><p>&#x02003;&#x02013;&#x02002;Chronic granulomatous herpes simplex encephalitis</p><p>&#x02003;&#x02013;&#x02002;Necrotizing myelopathy</p><p>&#x02003;&#x02013;&#x02002;Neonatal HSV encephalitis</p><p>&#x02003;&#x02013;&#x02002;Varicella-zoster virus (ZVZ) infection</p><p>&#x02003;&#x02013;&#x02002;Epstein-Barr virus (EBV) infection</p><p>&#x02003;&#x02013;&#x02002;Cytomegalovirus (CMV) infection</p><p>&#x02003;&#x02013;&#x02002;Human herpesviruses 6 and 7</p><p>&#x02022;&#x02002;Adenovirus</p><p>&#x02022;&#x02002;Paramyxoviruses</p><p>&#x02003;&#x02013;&#x02002;Mumps virus</p><p>&#x02003;&#x02013;&#x02002;Measles</p><p>&#x02022;&#x02002;Rubella encephalitis</p><p>&#x02022;&#x02002;Rabies</p><p>&#x02022;&#x02002;Arbovirus infections</p></td></tr><tr><td>Chromic and subacute viral infections</td><td><p>&#x02022;&#x02002;Chronic enteroviral encephalomyelitis</p><p>&#x02022;&#x02002;Subacute measles encephalitis</p><p>&#x02022;&#x02002;Subacute sclerosing panencephalitis (SSPE)</p><p>&#x02022;&#x02002;Progressive rubella panencephalitis</p><p>&#x02022;&#x02002;Progressive multifocal leukoencephalopathy (PML)</p><p>&#x02022;&#x02002;Human T-cell leukemia/lymphotropic virus-1 (HTLV-1)</p><p>&#x02022;&#x02002;Human immunodeficiency virus (HIV)</p><p>&#x02022;&#x02002;Rasmussen encephalitis</p></td></tr></tbody></table></table-wrap></p></sec><sec id="Sec100"><title>Epidemiology</title><p id="Par9000">
<list list-type="bullet"><title>Incidence</title><list-item><p id="Par17">1.5&#x02013;7 cases/100,000 inhabitants/year, excluding epidemics</p></list-item><list-item><p id="Par18">True incidence of these infections is difficult to determine because<list list-type="bullet"><list-item><p id="Par19">Many cases are unreported.</p></list-item><list-item><p id="Par20">The diagnosis may not be considered.</p></list-item><list-item><p id="Par21">A specific viral etiology is never confirmed.</p></list-item></list></p></list-item></list>
<list list-type="bullet"><title>Age Incidence</title><list-item><p id="Par22">all ages possible</p></list-item><list-item><p id="Par23">CMV: congenital, adulthood</p></list-item><list-item><p id="Par24">HIV: adulthood</p></list-item></list>
<list list-type="bullet"><title>Sex Incidence</title><list-item><p id="Par25">dependent on virus<list list-type="bullet"><list-item><p id="Par26">HIV: predominantly males</p></list-item><list-item><p id="Par27">CMV: equal distribution</p></list-item></list></p></list-item></list>
<list list-type="bullet"><title>Localization</title><list-item><p id="Par28">Brain, any region</p></list-item><list-item><p id="Par29">Temporal lobe for HSV</p></list-item></list>
</p></sec><sec id="Sec101"><title>Neuroimaging Findings</title><p id="Par16">
<list list-type="bullet"><title>General Imaging Findings</title><list-item><p id="Par30">Viral CNS infections can either lead to meningitis or (meningo-)encephalitis.</p></list-item><list-item><p id="Par31">Imaging of viral encephalitis often nonspecific&#x02014;like focal or diffuse edema (acute infection) or focal atrophy (chronic infection)&#x02014;except HSV encephalitis showing an almost pathognomonic involvement of limbic system.</p></list-item><list-item><p id="Par32">Location depends on causative agent.</p></list-item></list>
<list list-type="bullet"><title>CT Non-Contrast-Enhanced</title><list-item><p id="Par33">Meningitis: Normal</p></list-item><list-item><p id="Par34">Encephalitis: Hypodense edema, loss of gray-white matter differentiation, chronic infection may cause brain atrophy</p></list-item></list>
<list list-type="bullet"><title>CT Contrast-Enhanced</title><list-item><p id="Par35">Meningitis: Meningeal enhancement often missing</p></list-item><list-item><p id="Par36">Encephalitis: Enhancement possible</p></list-item></list>
<list list-type="bullet"><title>MRI-T2</title><list-item><p id="Par37">Encephalitis: Hyperintensity of involved brain areas</p></list-item></list>
<list list-type="bullet"><title>MRI-FLAIR</title><list-item><p id="Par38">Encephalitis: Hyperintensity of involved brain areas</p></list-item></list>
<list list-type="bullet"><title>MRI-T1</title><list-item><p id="Par39">Encephalitis: Hypointense edema with loss of gray-white matter differentiation</p></list-item></list>
<list list-type="bullet"><title>MRI-T1 Contrast-Enhanced</title><list-item><p id="Par40">Meningitis: Weak meningeal enhancement</p></list-item><list-item><p id="Par41">Encephalitis: Variable enhancement</p></list-item></list>
<list list-type="bullet"><title>MRI-T2&#x02217;/SWI</title><list-item><p id="Par42">Encephalitis: Hemorrhages (HSV, VZV, Japanese encephalitis)</p></list-item></list>
<list list-type="bullet"><title>MR-Diffusion Imaging</title><list-item><p id="Par43">Encephalitis: Diffusion restriction common</p></list-item></list>
</p><p id="Par44">Typical MR imaging patterns of specific viral encephalitides are listed in Table <xref rid="Tab7" ref-type="table">26.7</xref>.<table-wrap id="Tab7"><label>Table 26.7</label><caption><p>Typical MR imaging patterns of specific viral encephalitides</p></caption><table frame="hsides" rules="groups"><tbody><tr><td>HSV</td><td><p>&#x02022;&#x02002;Limbic system and temporal lobe</p><p>&#x02022;&#x02002;Often hemorrhages and enhancement</p></td></tr><tr><td>CMV</td><td><p>&#x02022;&#x02002;Periventricular white matter, subependymal enhancement</p><p>&#x02022;&#x02002;Calcifications in perinatal CMV</p></td></tr><tr><td>EBV</td><td><p>&#x02022;&#x02002;Symmetric involvement of basal ganglia, thalami, cortex, or brain stem</p><p>&#x02022;&#x02002;Rarely EBV-cerebellitis</p></td></tr><tr><td>VZV</td><td><p>&#x02022;&#x02002;Multifocal cortical areas</p><p>&#x02022;&#x02002;Hemorrhagic infarctions possible</p></td></tr><tr><td>HIV</td><td><p>&#x02022;&#x02002;Brain atrophy</p><p>&#x02022;&#x02002;Symmetric confluent white matter lesions (periventricular, basal ganglia, centrum semiovale, brain stem, cerebellum),</p><p>&#x02022;&#x02002;No enhancement</p></td></tr><tr><td>Rabies virus</td><td>&#x02022;&#x02002;Diffuse involvement of basal ganglia, thalami, periventricular white matter, brain stem, and hippocampi</td></tr><tr><td>TBEV (Tick-borne encephalitis virus)</td><td><p>&#x02022;&#x02002;MRI and CT often normal</p><p>&#x02022;&#x02002;Rarely lesions in thalamus, cerebellum, caudate nucleus, and brain stem</p></td></tr><tr><td>JC Virus (PML)</td><td><p>&#x02022;&#x02002;Confluent subcortical white matter lesions, predominantly in parieto-occipital lobes</p><p>&#x02022;&#x02002;U-fibers involved</p></td></tr><tr><td>JEV (Japanese encephalitis virus)</td><td>&#x02022;&#x02002;Bilateral symmetric lesions in thalami, basal ganglia, and midbrain</td></tr><tr><td>Enteroviruses</td><td>&#x02022;&#x02002;Posterior medulla oblongata and pons, dentate nuclei, and midbrain</td></tr></tbody></table></table-wrap><list list-type="bullet"><title>Nuclear Medicine Imaging Findings</title><list-item><p id="Par46">In HIV-infected patients<list list-type="bullet"><list-item><p id="Par47">Reduced brain perfusion SPECT and reduced FDG-PET uptake of cortical structures (medial frontal, temporoparietal) are described.</p></list-item><list-item><p id="Par48">FDG shows diffuse hypermetabolism in subcortical and deep white matter, basal ganglia, and thalami in some cases.</p></list-item></list></p></list-item><list-item><p id="Par49">In herpes simplex encephalitis<list list-type="bullet"><list-item><p id="Par50">HMPAO showed increased uptake followed by a decrease in tracer uptake in the recovery phase and ECD decreased uptake of the affected temporal lobe (most likely due to disturbed membrane and intracellular metabolism).</p></list-item><list-item><p id="Par51">FDG-PET shows hippocampal hypermetabolism in the acute phase of herpes simplex encephalitis followed by hypometabolism after 3&#x02013;9&#x000a0;months, but it is reported, that hypometabolism can persist for years.</p></list-item></list></p></list-item><list-item><p id="Par52">Studies with various imaging agents are performed to assess different pathologic steps in neuroinflammation.</p></list-item></list></p></sec><sec id="Sec102"><title>Neuropathology Findings</title><p id="Par9002">
<list list-type="bullet"><title>Macroscopic Features</title><list-item><p id="Par53">No discernible lesion</p></list-item><list-item><p id="Par54">Hemorrhagic lesion</p></list-item><list-item><p id="Par55">Necrotic lesion</p></list-item></list>
<list list-type="bullet"><title>Microscopic Features</title><list-item><p id="Par56">See specific subchapters</p></list-item><list-item><p id="Par57">Perivascular lymphocytic cuffing</p></list-item><list-item><p id="Par58">Gliomesenchymal nodules</p></list-item><list-item><p id="Par59">Multinucleated giant cells</p></list-item><list-item><p id="Par60">Large cells with inclusion bodies</p></list-item><list-item><p id="Par61">Reactive astrogliosis</p></list-item><list-item><p id="Par62">Leukoencephalopathies</p></list-item></list>
<list list-type="bullet"><title>Immunohistochemical Staining Characteristics</title><list-item><p id="Par63">Antibodies directed against a specific virus or part of the virus</p></list-item><list-item><p id="Par64">HIV: p24, gp41</p></list-item></list>
<list list-type="bullet"><title>Differential Diagnosis</title><list-item><p id="Par65">Necrosis of malignant tumors or metastases</p></list-item><list-item><p id="Par66">Necrosis from other infectious agents</p></list-item></list>
</p></sec><sec id="Sec3"><title>Molecular Neuropathology</title><p id="Par45">
<list list-type="bullet"><list-item><p id="Par67">Properties of viruses, i.e., DNA versus RNA viruses (Table <xref rid="Tab8" ref-type="table">26.8</xref>)</p></list-item><list-item><p id="Par68">Entry into the body<list list-type="bullet"><list-item><p id="Par69">Viral receptors (Table <xref rid="Tab9" ref-type="table">26.9</xref>)</p></list-item></list></p></list-item><list-item><p id="Par70">Delivery of the virus to the target tissue</p></list-item><list-item><p id="Par71">Interaction of virus with target tissue<list list-type="bullet"><list-item><p id="Par72">Stability of virus in the body</p></list-item><list-item><p id="Par73">Ability to establish viremia</p></list-item><list-item><p id="Par74">Ability to spread through the reticuloendothelial system</p></list-item></list></p></list-item><list-item><p id="Par75">Cytopathogenesis<list list-type="bullet"><list-item><p id="Par76">Failed infection (abortive infection)</p></list-item><list-item><p id="Par77">Cell death (lytic infection)</p></list-item><list-item><p id="Par78">Replication without cell death (persistent infection)</p></list-item><list-item><p id="Par79">Presence of virus without production but with potential for reactivation (latent-recurrent infection)</p></list-item></list></p></list-item><list-item><p id="Par80">Host responses<list list-type="bullet"><list-item><p id="Par81">Antigen-nonspecific (innate) host defenses</p></list-item><list-item><p id="Par82">Antigen-specific immune responses</p></list-item><list-item><p id="Par83">Viral mechanisms of escape to immune responses</p></list-item></list></p></list-item><list-item><p id="Par84">Immunopathology<list list-type="bullet"><list-item><p id="Par85">Interferon</p></list-item><list-item><p id="Par86">T-cell responses: cell killing, inflammation</p></list-item><list-item><p id="Par87">Antibody: complement, antibody-dependent cellular cytotoxicity, immune complexes</p></list-item><list-item><p id="Par88">Other inflammatory responses</p></list-item></list></p></list-item><list-item><p id="Par89">Virus production in a tissue with release of the virus to other people (contagion)</p></list-item><list-item><p id="Par90">Transmission of viruses depends<list list-type="bullet"><list-item><p id="Par91">On source of the virus (tissue site of viral replication and secretion)</p></list-item><list-item><p id="Par92">Ability of the virus to endure hazards and barriers of the environment</p></list-item></list></p></list-item></list>
<table-wrap id="Tab8"><label>Table 26.8</label><caption><p>Properties of DNA viruses and RNA viruses</p></caption><table frame="hsides" rules="groups"><thead><tr><th>DNA viruses</th><th>RNA viruses</th></tr></thead><tbody><tr><td><p>&#x02022;&#x02002;DNA is not transient or labile.</p><p>&#x02022;&#x02002;Many DAN viruses establish persistent infections.</p><p>&#x02022;&#x02002;DNA genomes reside in the nucleus.</p><p>&#x02022;&#x02002;Viral DNA resembles host DNA for transcription and replication.</p><p>&#x02022;&#x02002;Viral genes must interact with host transcriptional machinery.</p><p>&#x02022;&#x02002;Viral gene transcription is temporally regulated.</p><p>&#x02022;&#x02002;Early genes encode DNA-binding proteins and enzymes.</p><p>&#x02022;&#x02002;Late genes encode structural and other proteins.</p><p>&#x02022;&#x02002;DNA polymerases require a primer to replicate the viral genome.</p><p>&#x02022;&#x02002;The larger DNA viruses encode means and promote efficient replication of their genome.</p></td><td><p>&#x02022;&#x02002;RNA is labile and transient.</p><p>&#x02022;&#x02002;Most RNA viruses replicate in the cytoplasm.</p><p>&#x02022;&#x02002;Cells cannot replicate RNA. RNA viruses must encode an RNA-dependent RNA polymerase.</p><p>&#x02022;&#x02002;The genome structure determines the mechanism of transcription and replication.</p><p>&#x02022;&#x02002;RNA viruses are prone to mutation.</p><p>&#x02022;&#x02002;The genome structure and polarity determine how viral messenger RNA is generated and proteins are processed.</p><p>&#x02022;&#x02002;RNA viruses, except (+) RNA genome, must carry polymerases</p><p>&#x02022;&#x02002;All (&#x02212;) RNA viruses are enveloped.</p></td></tr></tbody></table></table-wrap>
<table-wrap id="Tab9"><label>Table 26.9</label><caption><p>Viral receptors</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Virus</th><th>Target cell</th><th>Receptor</th></tr></thead><tbody><tr><td>Epstein-Barr virus</td><td>B-cell</td><td>C3d complement receptor CR2 (CD21)</td></tr><tr><td>Human immunodeficiency virus</td><td>Helper T-cell</td><td>CD4 molecule and chemokine co-receptor</td></tr><tr><td>Rhinovirus</td><td>Epithelial cells</td><td>ICAM-1 (immunoglobulin superfamily protein)</td></tr><tr><td>Poliovirus</td><td>Epithelial cells</td><td>Immunoglobulin superfamily protein</td></tr><tr><td>Herpes simplex virus</td><td>Many cells</td><td>Herpesvirus entry mediator (HVEM), nectin 1</td></tr><tr><td>Rabies virus</td><td>Neuron</td><td>Acetylcholine receptor, NCAM</td></tr><tr><td>Influenza A virus</td><td>Epithelial cells</td><td>Sialic acid</td></tr><tr><td>B19 parvovirus</td><td>Erythroid precursors</td><td>Erythrocyte P antigen (globoside)</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec4"><title>Treatment and Prognosis</title><p id="Par93">TreatmentAntiviral drugs aim at altering:<list list-type="bullet"><list-item><p id="Par94">Virion disruption</p></list-item><list-item><p id="Par95">Attachment</p></list-item><list-item><p id="Par96">Penetration and uncoating</p></list-item><list-item><p id="Par97">RNA synthesis</p></list-item><list-item><p id="Par98">Genome replication</p></list-item><list-item><p id="Par99">Protein synthesis</p></list-item><list-item><p id="Par100">Virion assembly and release</p></list-item></list></p><p id="Par101">Antiviral drugs include:<list list-type="bullet"><list-item><p id="Par102">Nucleoside analogs<list list-type="bullet"><list-item><p id="Par103">Acyclovir</p></list-item><list-item><p id="Par104">Ganciclovir</p></list-item></list></p></list-item><list-item><p id="Par105">Nonnucleoside polymerase inhibitors</p></list-item><list-item><p id="Par106">Protease inhibitors</p></list-item><list-item><p id="Par107">Immunomudulators</p></list-item></list><list list-type="bullet"><title>Biologic Behavior&#x02013;Prognosis&#x02013;Prognostic Factors</title><list-item><p id="Par108">Age of infection<list list-type="bullet"><list-item><p id="Par109">Congenital</p></list-item></list></p></list-item><list-item><p id="Par110">Nature of disease<list list-type="bullet"><list-item><p id="Par111">Target tissue</p></list-item><list-item><p id="Par112">Portal of entry of virus</p></list-item><list-item><p id="Par113">Access of virus to target tissue</p></list-item><list-item><p id="Par114">Tissue tropism of virus</p></list-item><list-item><p id="Par115">Permissiveness of cells for viral replication</p></list-item><list-item><p id="Par116">Pathogenic activity (strain)</p></list-item></list></p></list-item><list-item><p id="Par117">Severity of disease<list list-type="bullet"><list-item><p id="Par118">Cytopathic ability of virus</p></list-item><list-item><p id="Par119">Immune status</p></list-item><list-item><p id="Par120">Competence of the immune system</p></list-item><list-item><p id="Par121">Prior immunity to the virus</p></list-item><list-item><p id="Par122">Immunopathology</p></list-item></list></p></list-item><list-item><p id="Par123">Progression of viral disease<list list-type="bullet"><list-item><p id="Par124">Acquisition</p></list-item><list-item><p id="Par125">Activation of innate protections</p></list-item><list-item><p id="Par126">Incubation period</p></list-item><list-item><p id="Par127">Target tissue</p></list-item><list-item><p id="Par128">Host responses</p></list-item><list-item><p id="Par129">Contagion</p></list-item><list-item><p id="Par130">Resolution or persistent infection/chronic disease</p></list-item></list></p></list-item></list></p></sec><sec id="Sec5"><title>Unspecified Nodular Encephalitis</title><p id="Par131">The only histological finding in unspecified nodular encephalitis is the presence of gliomesenchymal nodules (GMN) (Fig. <xref rid="Fig1" ref-type="fig">26.1a&#x02013;d</xref>). The finding is indicative of a viral infection.<fig id="Fig1"><label>Fig. 26.1</label><caption><p>Unspecified nodular encephalitis (<bold>a</bold>&#x02013;<bold>d</bold>) (Stain: H&#x00026;E)</p></caption><graphic xlink:href="309569_1_En_26_Fig1_HTML" id="MO1"/></fig></p><p id="Par132">GMN are:<list list-type="bullet"><list-item><p id="Par133">composed of microglia, macrophages, and reactive astrocytes</p></list-item><list-item><p id="Par134">found in the gray and white matter</p></list-item><list-item><p id="Par135">absence of multinucleated giant cells (MGC) or large cells containing inclusion bodies</p></list-item></list></p><p id="Par136">The differential diagnosis for GMN includes<list list-type="bullet"><list-item><p id="Par137">HIV-1 encephalopathy/leukoencephalopathy</p></list-item><list-item><p id="Par138">Cytomegalovirus encephalitis<list list-type="bullet"><list-item><p id="Par139">The nodules are very suspicious to contain CMV when further serial sectioning is performed.</p></list-item></list></p></list-item><list-item><p id="Par140">Toxoplasma gondii encephalitis</p></list-item></list></p><p id="Par141">Complete clarification and identification of an infectious agent is sometimes not possible.</p></sec><sec id="Sec6"><title>RNA Viruses: Human Immunodeficiency Virus (HIV)-1</title><p id="Par142">Human immunodeficiency virus (HIV)-1 infection is a serious health problem worldwide as 33 million adults and 2 million children are infected with HIV-1. Despite preventive efforts, the epidemic continues to spread rapidly and the socioeconomic consequences of the neurologic dysfunction caused by HIV-1 infection are of enormous proportions. Most of the affected patients live in developing countries, where antiretroviral medications are not available.</p><p id="Par143">HIV-viruses (1, 2) are<list list-type="bullet"><list-item><p id="Par144">Retroviruses, lentivirinae subfamily</p></list-item><list-item><p id="Par145">Roughly spheric, enveloped, RNA viruses</p></list-item><list-item><p id="Par146">Diameter of 80&#x02013;120 nm</p></list-item><list-item><p id="Par147">RNA-dependent DNA polymerase</p></list-item><list-item><p id="Par148">Encode accessory genes<list list-type="bullet"><list-item><p id="Par149"><italic>Gag</italic>: group-specific antigen: core and capsid proteins</p></list-item><list-item><p id="Par150"><italic>Int</italic>: integrase</p></list-item><list-item><p id="Par151"><italic>Pol</italic>: polymerase: reverse transcriptase, protease, integrase</p></list-item><list-item><p id="Par152"><italic>Pro</italic>: protease</p></list-item><list-item><p id="Par153"><italic>Env</italic>: envelope: glycoproteins</p></list-item><list-item><p id="Par154"><italic>Tat</italic>: transactivation of viral and cellular genes</p></list-item><list-item><p id="Par155"><italic>Rev</italic>: regulation of RNA splicing and promotion of export to cytoplasm</p></list-item><list-item><p id="Par156"><italic>Nef</italic>: decreases cell surface CD4, facilitates T-cell activation, progression to AIDS</p></list-item><list-item><p id="Par157"><italic>Vif</italic>: virus infectivity, promotion of assembly, blocks a cellular antiviral protein</p></list-item><list-item><p id="Par158"><italic>Vpu</italic>: facilitates virion assembly and release, induces degradation of CD4</p></list-item><list-item><p id="Par159"><italic>Vpr</italic>: transport of complementary DNA to nucleus, arresting of cell growth, replication in macrophages</p></list-item><list-item><p id="Par160">LTR: promoter, enhancer elements</p></list-item></list></p></list-item></list></p><p id="Par161">Following involvement of the lung (75&#x02013;85%), the brain is the second most frequently affected organ (60&#x02013;80%) in HIV-1 infection.</p><p id="Par162">Neurological signs and symptoms are seen:<list list-type="bullet"><list-item><p id="Par163">In about 50% of HIV-1-infected patients.</p></list-item><list-item><p id="Par164">In approximately 10% of the cases, they are the first presentation of the disease.</p></list-item></list></p><p id="Par165">The term &#x0201c;AIDS dementia complex (ADC)&#x0201d; was coined in 1986 (Navia et al. <xref ref-type="bibr" rid="CR100">1986a</xref>, <xref ref-type="bibr" rid="CR101">b</xref>) to describe impaired memory and concentration, psychomotor slowing and behavioral disturbances in 65% of patients, and has been attributed mainly to subcortical damage of AIDS brains (subcortical dementia). The name ADC was later changed into HIV-1-associated cognitive and motor complex with HIV-1-associated dementia complex (motor)/(behavior) (HAD) and HIV-1-associated myelopathy as its severe manifestations and HIV-1-associated minor cognitive/motor disorder as its mild manifestation (Force <xref ref-type="bibr" rid="CR43">1991</xref>).</p><p id="Par166">Classification of HIV-associated neurocognitive disorders (HAND) (Antinori et al. <xref ref-type="bibr" rid="CR7">2007</xref>)<list list-type="bullet"><list-item><p id="Par167">Asymptomatic neurocognitive impairment (ANI)<list list-type="bullet"><list-item><p id="Par168">No evidence of pre-existing cause. Cognitive impairment must be attributable to HIV and no other etiology (e.g., dementia, delirium).</p></list-item><list-item><p id="Par169">The cognitive impairment does not interfere with activities of daily living.</p></list-item><list-item><p id="Par170">Involves at least two cognitive areas (memory, attention, language, processing speed, sensory perceptual, motor skills) documented by performance of &#x0003e;1 standard deviation below the mean of standardized neuropsychological testing.</p></list-item><list-item><p id="Par171">30% prevalence in combination antiretroviral therapies (CART)-treated HIV+ individuals.</p></list-item></list></p></list-item><list-item><p id="Par172">Mild neurocognitive disorder (MND)<list list-type="bullet"><list-item><p id="Par173">No evidence of pre-existing cause. Cognitive impairment must be attributable to HIV and no.</p></list-item><list-item><p id="Par174">Other etiology (e.g., dementia, delirium).</p></list-item><list-item><p id="Par175">At least mild interference in &#x0003e;1 activities of daily living including mental acuity, inefficiency at work, homemaking or social functioning.</p></list-item><list-item><p id="Par176">20&#x02013;30% prevalence in combination antiretroviral therapies (CART)-treated HIV+ individuals.</p></list-item></list></p></list-item><list-item><p id="Par177">HIV-associated dementia (HAD)<list list-type="bullet"><list-item><p id="Par178">No evidence of another pre-existing cause for dementia (i.e., CNS infections, CNS neoplasm, cerebrovascular disease).</p></list-item><list-item><p id="Par179">Marked interference in activities of daily living.</p></list-item><list-item><p id="Par180">Marked cognitive impairment involving at least two cognitive domains by performance of &#x0003e;2 standard deviation below the mean of standardized neuropsychological tests, especially in learning of new information, slowed information processing and defective attention or concentration.</p></list-item><list-item><p id="Par181">2&#x02013;8% prevalence in combination antiretroviral therapies (CART)-treated HIV+ individuals.</p></list-item></list></p></list-item></list></p><p id="Par182">Despite the introduction of antiretroviral therapies with a greater life expectancy of HIV-1-infected individuals, epidemiologic data suggest that involvement of the brain in AIDS patients continues to be a frequent autopsy finding.</p><p id="Par183">Neuropathological examinations show in up to 95% of the brains changes that may be due to:<list list-type="bullet"><list-item><p id="Par184">primary effect of HIV-1</p></list-item><list-item><p id="Par185">probable effect of HIV-1</p></list-item><list-item><p id="Par186">opportunistic agents</p></list-item><list-item><p id="Par187">neoplasias</p></list-item></list></p><p id="Par188">The neuropathological changes seen in the brains (Table <xref rid="Tab10" ref-type="table">26.10</xref>) and peripheral nerve and skeletal muscle (Table <xref rid="Tab11" ref-type="table">26.11</xref>) of HIV-1-infected patients are manifold.<table-wrap id="Tab10"><label>Table 26.10</label><caption><p>The neuropathological changes seen in the brains of HIV-1-infected patients</p></caption><table frame="hsides" rules="groups"><tbody><tr><td>Changes primarily due to HIV-1</td><td><p>&#x02022;&#x02003;HIV-1 encephalitis (HIVE)</p><p>&#x02022;&#x02003;HIV-1 leukoencephalopathy (HIVL)</p><p>&#x02022;&#x02003;HIV-1 myelitis</p><p>&#x02022;&#x02003;Lymphocytic meningitis (LM)</p><p>&#x02022;&#x02003;Meningeal lymphocytic infiltration (MLI)</p><p>&#x02022;&#x02003;Perivascular lymphocytic infiltration (PLI)</p></td></tr><tr><td>Changes probably due to HIV-1</td><td><p>&#x02022;&#x02003;Vacuolar myelopathy</p><p>&#x02022;&#x02003;Vacuolar leukoencephalopathy</p></td></tr><tr><td>Opportunistic infections&#x02014;viruses</td><td><p>&#x02022;&#x02003;Cytomegalovirus infection (CMV)</p><p>&#x02022;&#x02003;Progressive multifocal leukoencephalopathy (PML)</p><p>&#x02022;&#x02003;Herpes simplex virus 1</p><p>&#x02022;&#x02003;Herpes simplex virus 2</p><p>&#x02022;&#x02003;Herpes zoster</p><p>&#x02022;&#x02003;HTLV-1</p><p>&#x02022;&#x02003;Varicella-zoster virus</p></td></tr><tr><td>Opportunistic infections&#x02014;parasites</td><td><p>&#x02022;&#x02003;Toxoplasma gondii</p><p>&#x02022;&#x02003;Acanthamoeba</p><p>&#x02022;&#x02003;Leptomyxid amoeba</p><p>&#x02022;&#x02003;Trypanosoma cruzi</p><p>&#x02022;&#x02003;Strongyloides</p></td></tr><tr><td>Opportunistic infections&#x02014;fungi</td><td><p>&#x02022;&#x02003;Aspergillus fumigatus</p><p>&#x02022;&#x02003;<italic>Candida albicans</italic></p><p>&#x02022;&#x02003;<italic>Cryptococcus neoformans</italic></p><p>&#x02022;&#x02003;Others including: Histoplasma, Phycomyces, Coccidioides, Blastomyces, Acremonium, Cladosporium</p></td></tr><tr><td>Opportunistic infections&#x02014;bacteria</td><td><p>&#x02022;&#x02003;Pyogenic: <italic>Escherichia coli</italic>, Listeria, Staphylococcus, Salmonella</p><p>&#x02022;&#x02003;Mycobacterial: <italic>Mycobacterium tuberculosis</italic>, <italic>Mycobacterium avium</italic> intracellulare</p><p>&#x02022;&#x02003;Spirochetal: Treponema pallidum</p><p>&#x02022;&#x02003;Filamentous: Nocardia</p><p>&#x02022;&#x02003;Miscellaneous: Whipple&#x02019;s disease</p></td></tr><tr><td>Neoplasias</td><td><p>&#x02022;&#x02003;Lymphoma (primary and secondary)</p><p>&#x02022;&#x02003;Kaposi sarcoma</p></td></tr></tbody></table></table-wrap><table-wrap id="Tab11"><label>Table 26.11</label><caption><p>The changes occurring in the peripheral nervous system and in skeletal muscles of HIV-1-infected patients</p></caption><table frame="hsides" rules="groups"><tbody><tr><td>Peripheral nervous system</td><td><p>&#x02022;&#x02003;Acute inflammatory demyelinating (poly) (radiculo) neuropathy</p><p>&#x02022;&#x02003;Chronic inflammatory demyelinating (poly) (radiculo) neuropathy</p><p>&#x02022;&#x02003;Axonal neuropathy</p><p>&#x02022;&#x02003;Ganglionitis, ganglioradiculitis, (poly) (radiculo) neuritis</p><p>&#x02022;&#x02003;necrotizing vasculitis, vasculitic neuropathy</p></td></tr><tr><td>Skeletal muscle</td><td><p>&#x02022;&#x02003;(Poly) myositis</p><p>&#x02022;&#x02003;Necrotizing myopathy</p><p>&#x02022;&#x02003;Nemaline rod myopathy</p><p>&#x02022;&#x02003;Vesicular myopathy, mitochondrial myopathy</p><p>&#x02022;&#x02003;Necrotizing vasculitis</p></td></tr></tbody></table></table-wrap></p><sec id="Sec7"><title>HIV-1 Encephalitis (HIVE)</title><p id="Par189">Since HIV-1 is rarely the cause of focal macroscopic lesions even in severely infected patients, systematic sampling of specimens for histological examination is required. If focal lesions are present, they are almost always due to opportunistic infections, cerebrovascular complications, or neoplasms.</p><sec id="Sec104"><title>Neuroimaging Findings</title><p id="Par9005">
<list list-type="bullet"><title>General Imaging Features</title><list-item><p id="Par190">Brain atrophy and symmetric confluent white matter lesions (periventricular, basal ganglia, centrum semiovale, brain stem, cerebellum), no enhancement</p></list-item></list>
<list list-type="bullet"><title>CT Non-Contrast-Enhanced</title><list-item><p id="Par191">Brain atrophy</p></list-item><list-item><p id="Par192">Symmetric confluent white matter hypodensities</p></list-item></list>
<list list-type="bullet"><title>CT Contrast-Enhanced</title><list-item><p id="Par193">No enhancement</p></list-item></list>
<list list-type="bullet"><title>MRI-T2/FLAIR (Fig. <xref rid="Fig2" ref-type="fig">26.2a&#x02013;d</xref>)</title><list-item><p id="Par194">Focal white matter hyperintensities</p></list-item><list-item><p id="Par195">Diffuse white matter hyperintensities</p></list-item></list>
<list list-type="bullet"><title>MRI-T1 (Fig. <xref rid="Fig2" ref-type="fig">26.2e, f</xref>)</title><list-item><p id="Par196">Lesions usually not seen</p></list-item></list>
<list list-type="bullet"><title>MRI-T1 Contrast-Enhanced (Fig. <xref rid="Fig2" ref-type="fig">26.2g, h</xref>)</title><list-item><p id="Par197">No enhancement</p></list-item></list>
<list list-type="bullet"><title>MRI-DWI (Fig. <xref rid="Fig2" ref-type="fig">26.2i, j</xref>)</title><list-item><p id="Par198">No restricted diffusion.</p></list-item></list>
<fig id="Fig2"><label>Fig. 26.2</label><caption><p>HIV encephalopathy, T2 (<bold>a</bold>, <bold>b</bold>), FLAIR (<bold>c</bold>, <bold>d</bold>), T1 (<bold>e</bold>, <bold>f</bold>), T1 contrast (<bold>g</bold>, <bold>h</bold>), DWI (<bold>i</bold>, <bold>j</bold>)</p></caption><graphic xlink:href="309569_1_En_26_Fig2a_HTML" id="d29e2553"/><graphic xlink:href="309569_1_En_26_Fig2b_HTML" id="d29e2554"/><graphic xlink:href="309569_1_En_26_Fig2c_HTML" id="d29e2555"/></fig>
</p></sec><sec id="Sec8"><title>Microscopical Findings</title><p id="Par199">HIV-1 encephalitis is characterized by (Fig. <xref rid="Fig3" ref-type="fig">26.3a&#x02013;j</xref>)<list list-type="bullet"><list-item><p id="Par200">Multiple disseminated foci composed of microglia, macrophages, and multinucleated giant cells (MGCs). The foci are predominantly located in the cortex, deep gray matter, and the white matter.</p></list-item><list-item><p id="Par201">The multinucleated giant cells (MGC) are the hallmark for HIV-1 encephalitis.<list list-type="bullet"><list-item><p id="Par202">They contain up to 20 round or elongated and basophilic nuclei which are usually arranged at the periphery of the cell.</p></list-item><list-item><p id="Par203">The cytoplasm is eosinophilic and appears densely stained in the center and vacuolated at the periphery.</p></list-item><list-item><p id="Par204">The cells are of monocyte/histiocyte lineage which includes microglia and macrophages.</p></list-item><list-item><p id="Par205">They are derived from HIV-1-mediated fusion of infected microglia and macrophages.</p></list-item><list-item><p id="Par206">The nucleic acids of HIV proteins have been demonstrated to be located in their cytoplasm.</p></list-item></list></p></list-item><list-item><p id="Par207">In their absence, the presence of HIV-antigen or HIV nucleic acids has to be demonstrated either by immunohistochemistry, i.e., gp41 and p24 (Fig. <xref rid="Fig3" ref-type="fig">26.3j</xref>) or by in situ hybridization.</p></list-item><list-item><p id="Par208">HIVE usually occurs in the later stages of the AIDS infection.</p></list-item><list-item><p id="Par209">The electron microscopical analysis revealed retroviral particles either free in the cytoplasm or in cytoplasmic cisternae.</p></list-item><list-item><p id="Par210">Microglia/macrophages and MGC are capable of HIV synthesis and, thus, constitute the major reservoir and vehicle for the spread of the virus.</p></list-item><list-item><p id="Par211">Synonyms previously used: giant cell encephalitis, multifocal giant cell encephalitis, multinucleated cell encephalitis, subacute encephalitis</p></list-item></list><fig id="Fig3"><label>Fig. 26.3</label><caption><p>HIV-1-encephalitis: multinucleated giant cells (<bold>a</bold>&#x02013;<bold>i</bold>) (<bold>a</bold>&#x02013;<bold>h</bold>: Stain: H&#x00026;E; <bold>i</bold>: Stain: cresyl violet). HIV-1 antigen shown in a small gliomesenchymal nodule (<bold>j</bold>: stain: immunohistochemistry for p24)</p></caption><graphic xlink:href="309569_1_En_26_Fig3a_HTML" id="d29e2633"/><graphic xlink:href="309569_1_En_26_Fig3b_HTML" id="d29e2634"/></fig></p><p id="Par212">There is no strong correlation between HIVE and the clinical stages of the HAD.</p><p id="Par213">Despite the introduction of HAART with a greater life expectancy of infected individuals, epidemiologic data suggest that the prevalence of HIVE is on the rise.</p></sec></sec><sec id="Sec9"><title>HIV-1 Leukoencephalopathy (HIVL)</title><p id="Par214">HIV-1 leukoencephalopathy is chararcterized by (Fig. <xref rid="Fig4" ref-type="fig">26.4a&#x02013;j</xref>)<list list-type="bullet"><list-item><p id="Par215">diffuse damage to the white matter including<list list-type="bullet"><list-item><p id="Par216">myelin loss</p></list-item><list-item><p id="Par217">reactive astrogliosis</p></list-item><list-item><p id="Par218">macrophages</p></list-item><list-item><p id="Par219">multinucleated giant cells</p></list-item></list></p></list-item><list-item><p id="Par220">Myelin pallor is usually found around the gliomesenchymal nodule containing the MGC.</p></list-item><list-item><p id="Par221">Little or no inflammatory infiltrates are seen.</p></list-item><list-item><p id="Par222">In the absence of multinucleated giant cells, the presence of HIV-antigen or HIV nucleic acids has to be demonstrated either by immunohistochemistry or by in situ hybridization.</p></list-item><list-item><p id="Par223">Axonal damage can be demonstrated with immunohistochemistry for &#x003b2;-amyloid precursor protein.</p></list-item><list-item><p id="Par224">HIVL usually occur in the later stages of the AIDS infection.</p></list-item><list-item><p id="Par225">Synonyms previously used: progressive diffuse leukoencephalopathy</p></list-item></list><fig id="Fig4"><label>Fig. 26.4</label><caption><p>HIV-leukoencephalopathy: presence of multinucleated giant cells in the white matter (<bold>a</bold>, <bold>b</bold>: H&#x00026;E, <bold>c</bold>: LFB, <bold>d</bold>: cresyl violet) and myelin pallor loss (<bold>e</bold>&#x02013;<bold>j</bold>)</p></caption><graphic xlink:href="309569_1_En_26_Fig4a_HTML" id="d29e2710"/><graphic xlink:href="309569_1_En_26_Fig4b_HTML" id="d29e2711"/></fig></p></sec><sec id="Sec10"><title>Lymphocytic Meningitis (LM) and Perivascular Lymphocytic Infiltration (PLI)</title><p id="Par226"><italic>Lymphocytic meningitis (LM)</italic> is characterized by (Fig. <xref rid="Fig5" ref-type="fig">26.5a&#x02013;f</xref>)<list list-type="bullet"><list-item><p id="Par227">Significant lymphocytic infiltrates in the leptomeninges.</p></list-item><list-item><p id="Par228">No opportunistic pathogens are encountered in the meninges.</p></list-item></list><fig id="Fig5"><label>Fig. 26.5</label><caption><p>Meningeal lymphocytic infiltrates (<bold>a</bold>&#x02013;<bold>f</bold>: Stain: H&#x00026;E). Perivascular lymphocytic infiltrates (<bold>g</bold>&#x02013;<bold>j</bold>: Stain: H&#x00026;E)</p></caption><graphic xlink:href="309569_1_En_26_Fig5a_HTML" id="d29e2749"/><graphic xlink:href="309569_1_En_26_Fig5b_HTML" id="d29e2750"/></fig></p><p id="Par229"><italic>Perivascular lymphocytic infiltration (PLI)</italic> is characterized by (Fig. <xref rid="Fig5" ref-type="fig">26.5g&#x02013;j</xref>)<list list-type="bullet"><list-item><p id="Par230">Significant lymphocytic infiltrates in the perivascular spaces of the brain tissue.</p></list-item><list-item><p id="Par231">No opportunistic pathogens are encountered in the perivascular brain tissue.</p></list-item></list></p><p id="Par232">It seems that lymphocytic infiltrates in the leptomeninges and in the perivascular spaces of the brain tissue constitute changes occurring in the early stages of the HIV-1 infection.</p></sec><sec id="Sec11"><title>Vacuolar Myelopathy (VM) and Vacuolar Leukoencephalopathy (VL)</title><p id="Par233"><italic>Vacuolar myelopathy</italic> is characterized by (Fig. <xref rid="Fig6" ref-type="fig">26.6a&#x02013;f</xref>)<list list-type="bullet"><list-item><p id="Par234">Numerous vacuolar myelin swellings.</p></list-item><list-item><p id="Par235">Macrophages in multiple areas of the spinal cord.</p></list-item><list-item><p id="Par236">Predominant involvement of the dorsolateral spinal tracts.</p></list-item><list-item><p id="Par237">Some macrophages may be found in the vacuoles.</p></list-item><list-item><p id="Par238">Might not be specific for HIV-1 since they can occur in the absence of HIV.</p></list-item><list-item><p id="Par239">The axon is at first unaffected, but it is damaged in the later stages of the disease.</p></list-item><list-item><p id="Par240">VM might not be specific for HIV-1</p></list-item></list><fig id="Fig6"><label>Fig. 26.6</label><caption><p>Spinal cord showing vacuolar myelopathy of the dorsal tracts (<bold>a</bold>&#x02013;<bold>d</bold>: stain LFB, <bold>e</bold>: stain H&#x00026;E, <bold>f</bold>: stain: Woelcke&#x02019;s myelin stain)</p></caption><graphic xlink:href="309569_1_En_26_Fig6_HTML" id="MO6"/></fig></p><p id="Par241"><italic>Vacuolar leukoencephalopathy</italic> is characterized by<list list-type="bullet"><list-item><p id="Par242">Numerous vacuolar myelin swellings in the central white matter.</p></list-item><list-item><p id="Par243">Some macrophages may be found in the vacuoles.</p></list-item><list-item><p id="Par244">VL is a rare condition.</p></list-item></list></p></sec><sec id="Sec12"><title>Neuropathological Changes in Early Stages of HIV-1 Infection</title><p id="Par245">Brain changes in HIV-1 seropositive, non-AIDS cases include:<list list-type="bullet"><list-item><p id="Par246">Cerebral vasculitis was significantly more frequent and marked in HIV seropositive cases and was often associated with lymphocytic meningitis (Gray et al. <xref ref-type="bibr" rid="CR54">1992</xref>).</p></list-item><list-item><p id="Par247">Granular ependymitis, myelin pallor with reactive astrocytosis, and microglial proliferation were also more frequent and more severe in HIV seropositive cases. Immunohistochemistry was negative for HIV-antigens. Highly expressed cytokines (tumor necrosis factor-&#x003b1;, interleukin (IL)-1,4,6) (Gray et al. <xref ref-type="bibr" rid="CR54">1992</xref>).</p></list-item><list-item><p id="Par248">Perivascular lymphocytic infiltrates (PLI) as well as lymphocytic infiltrates in the meninges (MLI) were found in 62.8% of the cases. PLI alone was seen in 61% of the cases, MLI alone in 43% of the cases, and the combination of PLI and MLI in 34% of the cases (Weis et al., unpublished data).</p></list-item></list></p></sec><sec id="Sec13"><title>Neuropathological Changes in HIV-1-Infected Children</title><p id="Par249">Children born to HIV-1-infected mothers are in 10&#x02013;40% of the cases also infected by the virus (Kozlowski et al. <xref ref-type="bibr" rid="CR76">1993</xref>). These children develop symptoms before the age of 2&#x000a0;years.<list list-type="bullet"><list-item><p id="Par250">About 30% of the HIV-1 children develop opportunistic infection or HIV-1 encephalopathy within the first year of life.</p></list-item><list-item><p id="Par251">Brain growth is impaired leading to intellectual deficiency.</p></list-item><list-item><p id="Par252">The gross-anatomical analysis shows brains which are too small for the age.</p></list-item><list-item><p id="Par253">Sometimes atrophic gyri may be noted.</p></list-item><list-item><p id="Par254">Microcephaly and/or brain atrophy is present.</p></list-item><list-item><p id="Par255">The most common findings in brains of HIV-1-infected children are<list list-type="bullet"><list-item><p id="Par256">Mineralization of predominantly small vessels found in 95% of the case.</p></list-item><list-item><p id="Par257">Myelin pallor and gliosis are the noted changes of the white matter that occur in 78% of the cases.</p></list-item><list-item><p id="Par258">MGC are seen in 62% of HIV-1-infected children.</p></list-item></list></p></list-item><list-item><p id="Par259">Opportunistic infections are comparatively uncommon.</p></list-item></list></p></sec><sec id="Sec14"><title>Therapy: HAART Effects and Therapy-Induced Immune Restitution Inflammatory Syndrome (IRIS)</title><p id="Par260">In 1995/1996, highly active antiretroviral therapies (HAART) were introduced which combine<list list-type="bullet"><list-item><p id="Par261">nucleoside reverse transcriptase inhibitors (NRTI)<list list-type="bullet"><list-item><p id="Par262">specifically inhibit the viral reverse transcriptase enzyme necessary for DNA chain elongation of the virus</p></list-item></list></p></list-item><list-item><p id="Par263">protease inhibitors (PI)<list list-type="bullet"><list-item><p id="Par264">prevent the production of active virus by interfering with the cleavage of proteins necessary for viral assembly</p></list-item></list></p></list-item></list></p><p id="Par265">Effects of the therapy results in:<list list-type="bullet"><list-item><p id="Par266">The frequency of HIV-1-related CNS diseases has been reduced through<list list-type="bullet"><list-item><p id="Par267">the reduction of both viral load in the blood</p></list-item><list-item><p id="Par268">the reduced continuous penetration of virus into the brain (Tardieu <xref ref-type="bibr" rid="CR1320">1999</xref>)</p></list-item></list></p></list-item><list-item><p id="Par269">HIV-positive patients live longer.</p></list-item><list-item><p id="Par270">The median survival<list list-type="bullet"><list-item><p id="Par271">following AIDS increased from 19.6&#x000a0;months in 1993&#x02013;1995 to 39.6&#x000a0;months for those diagnosed in 1996&#x02013;2000</p></list-item><list-item><p id="Par272">following ADC increased from 11.9&#x000a0;months in 1993&#x02013;1995 to 48.2 in 1996&#x02013;2000.</p></list-item></list></p></list-item><list-item><p id="Par273">The proportion of patients with AIDS dementia complex (ADC) increased from 5.2% in 1993&#x02013;1995 to 6.8% in 1996&#x02013;2000.</p></list-item></list></p><p id="Par274">Larger cohort autopsy studies of HIV-infected patients over longer time periods suggest that, despite the beneficial effects of modern antiretroviral combination therapy, involvement of the brain in AIDS subjects continues to be a frequent autopsy finding (Gray et al. <xref ref-type="bibr" rid="CR53">1988</xref>, <xref ref-type="bibr" rid="CR55">2003</xref>; Jellinger et al. <xref ref-type="bibr" rid="CR66">2000</xref>; Langford et al. <xref ref-type="bibr" rid="CR78">2003</xref>) (Tables <xref rid="Tab12" ref-type="table">26.12</xref> and <xref rid="Tab13" ref-type="table">26.13</xref>).<table-wrap id="Tab12"><label>Table 26.12</label><caption><p>Review of 1597 consecutive autopsies of HIV-1-positive patients performed between 1984 and 2000, and division into four time periods on the basis of the therapeutic regimens available (Vago et al. (<xref ref-type="bibr" rid="CR138">2002</xref>) reproduced with kind permission by Wolters Kluver Health)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Year</th><th>Therapy</th><th><italic>n</italic></th><th>HIV-E/L</th><th>Opportunistic infections</th></tr></thead><tbody><tr><td>1984&#x02013;1987</td><td>No therapy</td><td>119</td><td>53.8</td><td>40.3</td></tr><tr><td>1988&#x02013;1994</td><td>Monotherapy (zidovudine)</td><td>1116</td><td>32.2</td><td>46.8</td></tr><tr><td>1995&#x02013;1996</td><td>Dual combination therapy with nucleoside reverse transcriptase inhibitors</td><td>256</td><td>17.9</td><td>42.6</td></tr><tr><td>1997&#x02013;2000</td><td>Triple combination therapy including two NRTIs and at least one protease inhibitor or non-NRTI</td><td>106</td><td>15.1</td><td>42.5</td></tr></tbody></table></table-wrap><table-wrap id="Tab13"><label>Table 26.13</label><caption><p>Frequencies for various neuropathological changes in pre-HAART era compared to HAART era</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Author (year)</th><th/><th><italic>n</italic></th><th>HIVE</th><th>HIVL</th><th>CMV</th><th>PML</th><th>TOXO</th><th>LYM</th></tr></thead><tbody><tr><td>Gray et al. (<xref ref-type="bibr" rid="CR53">1988</xref>)</td><td>Pre-HAART</td><td>40</td><td>37.5</td><td>Nip</td><td>20.0</td><td>5.0</td><td>47.5</td><td>2.5</td></tr><tr><td>Gray et al. (<xref ref-type="bibr" rid="CR55">2003</xref>)<sup>a</sup></td><td>HAART</td><td>23</td><td>17.4</td><td>Nip</td><td>8.7</td><td>17.4</td><td>13.0</td><td>13.0</td></tr><tr><td rowspan="2">Jellinger et al. (<xref ref-type="bibr" rid="CR66">2000</xref>)</td><td>Pre-HAART</td><td>352</td><td>8.5</td><td>4.3</td><td>18.5</td><td>7.1</td><td>22.2</td><td>8.5</td></tr><tr><td>HAART</td><td>98</td><td>8.0</td><td>5.0</td><td>11.0</td><td>5.0</td><td>8.0</td><td>6.0</td></tr><tr><td rowspan="2">Langford (<xref ref-type="bibr" rid="CR78">2003</xref>)</td><td>Pre-HAART</td><td>62</td><td>25.8</td><td>Nip</td><td>16.1</td><td>6.4</td><td>6.4</td><td>19.3</td></tr><tr><td>HAART</td><td>89</td><td>43.8</td><td>Nip</td><td>16.8</td><td>5.6</td><td>0.0</td><td>8.9</td></tr></tbody></table><table-wrap-foot><p><italic>n</italic> sample size, <italic>HIVE</italic> HIV-1 encephalitis, <italic>HIVL</italic> HIV-1 leukoencephalopathy, <italic>CMV</italic> cytomegalovirus encephalitis, <italic>PML</italic> progressive multifocal leukoencephalopathy, <italic>TOXO</italic> toxoplasma gondii encephalitis, <italic>LYM</italic> primary non-Hodgkin lymphoma</p><p><sup>a</sup>Frequencies for pre-HAART could not be calculated due to lack of original data in their paper</p></table-wrap-foot></table-wrap></p><p id="Par275">Immune reconstitution inflammatory syndrome (IRIS) is a syndrome that emerges when the immune system recovers after an immune deficiency state (Table <xref rid="Tab14" ref-type="table">26.14</xref>) (Nelson et al. <xref ref-type="bibr" rid="CR102">2017</xref>; Chahroudi and Silvestri <xref ref-type="bibr" rid="CR28">2012</xref>; McCarthy and Nath <xref ref-type="bibr" rid="CR94">2010</xref>). IRIS is an adverse clinical manifestation that occurs in HIV-infected individuals treated successfully with ART and consists of a paradoxical deterioration of clinical status despite improved CD4-T-cell counts and immunologic conditions.<table-wrap id="Tab14"><label>Table 26.14</label><caption><p>Clinical manifestations of IRIS in patients with HIV-1 infection on cART modified after McCarthy and Nath (<xref ref-type="bibr" rid="CR94">2010</xref>) reproduced with kind permission by Springer Nature</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Infection</th><th>Typical clinical manifestations</th><th>Atypical clinical manifestations</th></tr></thead><tbody><tr><td>HIV encephalitis</td><td><p>&#x02022;&#x02003;Asymptomatic</p><p>&#x02022;&#x02003;Mild cognitive decline</p></td><td>&#x02022;&#x02003;Fulminant decline in mental status over days with brain swelling and inflammation</td></tr><tr><td>PML with JCV</td><td>&#x02022;&#x02003;Subacute focal neurologic deficits</td><td>&#x02022;&#x02003;Focal areas of contrast enhancement and swelling</td></tr><tr><td>Varicella-zoster virus</td><td><p>&#x02022;&#x02003;Shingles</p><p>&#x02022;&#x02003;CNS vasculitis</p></td><td>&#x02022;&#x02003;Strokes without skin rash</td></tr><tr><td>Cytomegalovirus</td><td><p>&#x02022;&#x02003;Retinitis</p><p>&#x02022;&#x02003;Cerebritis</p></td><td>&#x02022;&#x02003;Vasculitis</td></tr><tr><td>Epstein-Barr virus</td><td>&#x02022;&#x02003;CNS lymphoma</td><td>&#x02022;&#x02003;Optic neuropathy</td></tr><tr><td>Tuberculosis</td><td>&#x02022;&#x02003;Meningitis</td><td><p>&#x02022;&#x02003;Cerebral infarcts</p><p>&#x02022;&#x02003;Subarachnoid hemorrhage</p></td></tr><tr><td>Cryptococcus</td><td>&#x02022;&#x02003;Meningitis</td><td>&#x02022;&#x02003;Enhancing mass lesions in posterior fossa</td></tr><tr><td>Candida</td><td>&#x02022;&#x02003;Meningitis</td><td>&#x02022;&#x02003;Vasculitis with strokes</td></tr></tbody></table></table-wrap></p><p id="Par276">A new variant of HIVE has emerged in the era of HAART as a severe leukoencephalopathy with significant perivascular infiltration of macrophages and lymphocytes which is assumed to be the result of an exaggerated response from a newly reconstituted immune system (Persidsky and Gendelman <xref ref-type="bibr" rid="CR108">2003</xref>).</p><p id="Par277">Neuropathological examination revealed<list list-type="bullet"><list-item><p id="Par278">Severe inflammatory lesions.</p></list-item><list-item><p id="Par279">Demyelinating lesions with marked intraparenchymal and perivascular infiltration by macrophages and T-lymphocytes.</p></list-item><list-item><p id="Par280">In some cases, abundant viral proliferation was identified by immunocytochemistry or in situ hybridization, but in others the infectious agent could only be detected using PCR.</p></list-item><list-item><p id="Par281">T-lymphocytes were predominantly CD8(+).</p></list-item><list-item><p id="Par282">In those cases with the more favorable course, inflammation was less severe with marked macrophage activation and a number of CD4(+) lymphocytes.</p></list-item><list-item><p id="Par283">In the lethal cases, inflammation was severe and mostly composed of CD8(+) cytotoxic lymphocytes.</p></list-item></list></p></sec><sec id="Sec15"><title>The Sequalae of HIV-1 Infection of the&#x000a0;Nervous System</title><p id="Par284">In summary, the following changes of the brain have been described to be due to the HIV-1 infection:<list list-type="bullet"><list-item><p id="Par285">Brain weight (Weis, unpublished data)<list list-type="bullet"><list-item><p id="Par286">no changes</p></list-item></list></p></list-item><list-item><p id="Par287">Brain edema (Weis, unpublished data)<list list-type="bullet"><list-item><p id="Par288">no significant difference</p></list-item></list></p></list-item><list-item><p id="Par289">Gross-anatomy (Gelman and Guinto <xref ref-type="bibr" rid="CR47">1992</xref>)<list list-type="bullet"><list-item><p id="Par290">No apparent macroscopical signs of atrophy are seen by bare visual inspection.</p></list-item><list-item><p id="Par291">Cerebrospinal fluid (CSF) space greater than two standard deviations above the mean of the age-matched control subjects.</p></list-item><list-item><p id="Par292">CSF spaces expanded most in the frontal and temporal lobe.</p></list-item></list></p></list-item><list-item><p id="Par293">Ventricular system (Weis, unpublished data) (Gelman and Guinto <xref ref-type="bibr" rid="CR47">1992</xref>)<list list-type="bullet"><list-item><p id="Par294">Widening of the lateral ventricles.</p></list-item><list-item><p id="Par295">Ventricular spaces expanded more than the sulcal spaces.</p></list-item></list></p></list-item><list-item><p id="Par296">Volume of brain regions (Oster et al. <xref ref-type="bibr" rid="CR106">1993</xref>; Subbiah et al. <xref ref-type="bibr" rid="CR130">1996</xref>; Weis et al. <xref ref-type="bibr" rid="CR147">1993c</xref>)<list list-type="bullet"><list-item><p id="Par297">No significant changes in volume, surface area, mean cortical thickness.</p></list-item><list-item><p id="Par298">Reduction of the mean volume of the neocortex.</p></list-item><list-item><p id="Par299">Reduction in volume of the central brain nuclei.</p></list-item><list-item><p id="Par300">Reduction in volume of the internal capsule.</p></list-item><list-item><p id="Par301">Mean neocortical thickness was reduced by 12%.</p></list-item><list-item><p id="Par302">There were no differences in white matter volumes between groups.</p></list-item><list-item><p id="Par303">The mean volume of the white matter was reduced by 13%.</p></list-item><list-item><p id="Par304">Mean ventricular volume was increased by 55%.</p></list-item><list-item><p id="Par305">There were no significant differences between the AIDS groups with and without HIV-associated dementia.</p></list-item></list></p></list-item><list-item><p id="Par306">Neuronal number<list list-type="bullet"><list-item><p id="Par307">Cerebral cortex (Ketzler et al. <xref ref-type="bibr" rid="CR73">1990</xref>; Weis et al. <xref ref-type="bibr" rid="CR146">1993b</xref>)<list list-type="bullet"><list-item><p id="Par308">Loss of neurons in different cortical regions.</p></list-item><list-item><p id="Par309">Neuronal loss is not be correlated with development of dementing symptoms and of HIV-specific neuropathology.</p></list-item></list></p></list-item><list-item><p id="Par310">Basal ganglia<list list-type="bullet"><list-item><p id="Par311">decrease in neuronal density (21%) in the putamen especially in those cases with HIV-1 encephalitis (Everall et al. <xref ref-type="bibr" rid="CR41">1993</xref>).</p></list-item></list></p></list-item><list-item><p id="Par312">Cerebellum<list list-type="bullet"><list-item><p id="Par313">significant reduction of the volume density, the numerical density of neurons as well as neuronal size was apparent in the cerebellar dentate nucleus and in both inferior olivary nuclei (Abe et al. <xref ref-type="bibr" rid="CR1">1996</xref>)</p></list-item></list></p></list-item><list-item><p id="Par314">Substantia nigra<list list-type="bullet"><list-item><p id="Par315">The total number of neuronal cell bodies was 25% lower in AIDS than in age-matched controls although the volume density of neuronal melanin did not differ from that of controls because the percentage of pigmented cell bodies was higher and the cell bodies were more fully packed with melanin in AIDS (Reyes et al. <xref ref-type="bibr" rid="CR111">1991</xref>).</p></list-item><list-item><p id="Par316">The size of total neurons (pigmented and non-pigmented neurons) and of pigmented neurons was significantly reduced in all investigated nuclei (antero-medial, antero-intermediolateral, posterolateral, and posteromedial nuclei) of HIV-1-infected brains.</p></list-item><list-item><p id="Par317">Furthermore, the nigral neuronal loss showed no relationship with immunohistochemical detection of HIV-1 antigens (gp41, p24).</p></list-item><list-item><p id="Par318">The numerical density of non-pigmented large neurons (type II neurons) was significantly increased in HIV-1-infected brains suggesting that (1) non-pigmented, dopaminergic neurons or non-pigmented, non-dopaminergic neurons might be relatively preserved in the SN of HIV-1 infection, or (2) that pigmented dopaminergic neurons loose their melanin pigments during the early stages of degeneration, which also might be responsible for functional deterioration (Itoh et al. <xref ref-type="bibr" rid="CR64">2000</xref>).</p></list-item></list></p></list-item></list></p></list-item><list-item><p id="Par319">Neuronal size (Weis et al. <xref ref-type="bibr" rid="CR146">1993b</xref>)<list list-type="bullet"><list-item><p id="Par320">no changes in perikaryal size</p></list-item></list></p></list-item><list-item><p id="Par321">Synapses (Wiley et al. <xref ref-type="bibr" rid="CR153">1991</xref>)<list list-type="bullet"><list-item><p id="Par322">Loss of synapses as shown by a decrease in the immunoreactivity against synaptophysin</p></list-item></list></p></list-item><list-item><p id="Par323">Dendrites (Masliah et al. <xref ref-type="bibr" rid="CR92">1992a</xref>, <xref ref-type="bibr" rid="CR93">b</xref>)<list list-type="bullet"><list-item><p id="Par324">Apical dendrites<list list-type="bullet"><list-item><p id="Par325">dilated, vacuolated, and tortuous</p></list-item><list-item><p id="Par326">decreased length and branching</p></list-item></list></p></list-item><list-item><p id="Par327">Basal and oblique dendrites<list list-type="bullet"><list-item><p id="Par328">show the same alterations, but to a lesser extent</p></list-item></list></p></list-item><list-item><p id="Par329">Some dendrites present lacunae and filopodia consistent with remodeling.</p></list-item><list-item><p id="Par330">40&#x02013;60% decrease in spine density throughout the entire length of dendrites.</p></list-item><list-item><p id="Par331">Fewer spines on neurons; 55% fewer on the first segment, 40% fewer on the second, 45% fewer on the third, 60% fewer on the fourth, and 65% fewer in the fifth segment.</p></list-item><list-item><p id="Par332">Aberrant spines in regions of abnormal second-order dendritic branches.</p></list-item></list></p></list-item><list-item><p id="Par333">Nerve fibers<list list-type="bullet"><list-item><p id="Par334">White matter<list list-type="bullet"><list-item><p id="Par335">Loss of nerve fibers in the white matter</p></list-item></list></p></list-item><list-item><p id="Par336">Corpus callosum (Wohlschlaeger et al. <xref ref-type="bibr" rid="CR156">2009</xref>)<list list-type="bullet"><list-item><p id="Par337">Reduced thickness of the myelin sheath of nerve fibers in the corpus callosum.</p></list-item><list-item><p id="Par338">Calculation of the <italic>g</italic>-ratio revealed a relative increase in size of the axon and a relative decrease in the myelin sheath thickness.</p></list-item><list-item><p id="Par339">The data indicated a reduction in the size of nerve fibers and axons as well as thinner myelin sheaths, whereas in other callosal regions axons and myelin sheaths were swollen and enlarged.</p></list-item><list-item><p id="Par340">These changes were observed in regions which are unaffected, as revealed by light-microscopic analysis of sections stained for myelin.</p></list-item></list></p></list-item><list-item><p id="Par341">Optic nerve (Tenhula et al. <xref ref-type="bibr" rid="CR133">1992</xref>)<list list-type="bullet"><list-item><p id="Par342">Degeneration was often severe and was scattered throughout all of the AIDS-affected optic nerves.</p></list-item><list-item><p id="Par343">Despite the approximate 40% loss of axons in the AIDS-affected optic nerves, the mean axonal population was markedly lower than the mean obtained from normal optic nerves (880,000 vs. 1,507,000).</p></list-item><list-item><p id="Par344">The mean axonal diameters were not markedly different, that the changes may not only be secondary to damage at the retina, but may reflect an AIDS-associated primary optic neuropathy.</p></list-item></list></p></list-item></list></p></list-item><list-item><p id="Par345">Astroglia (Weis et al. <xref ref-type="bibr" rid="CR145">1993a</xref>; Ciardi et al. <xref ref-type="bibr" rid="CR30">1990</xref>)<list list-type="bullet"><list-item><p id="Par346">no change in the number of all astrocytes (i.e., GFAP-positive and GFAP-negative astrocytes)</p></list-item><list-item><p id="Par347">reduction of the number of GFAP-negative cells</p></list-item><list-item><p id="Par348">increase of reactive GFAP-positive astrocytes</p></list-item><list-item><p id="Par349">not correlated with loss of nerve cells</p></list-item><list-item><p id="Par350">increase in nuclear size of GFAP-negative and GFAP-positive astrocytes</p></list-item><list-item><p id="Par351">increase of the size of the cytoplasm of GFAP-positive astroglia</p></list-item><list-item><p id="Par352">no correlation between the neuronal loss and the pattern of reactive astrocytosis</p></list-item></list></p></list-item><list-item><p id="Par353">Oligodendroglia (Esiri et al. <xref ref-type="bibr" rid="CR40">1991</xref>)<list list-type="bullet"><list-item><p id="Par354">significant increase in the number of oligodendrocytes associated with mild degree of myelin damage</p></list-item><list-item><p id="Par355">decrease of oligodendrocytes in severely affected areas</p></list-item><list-item><p id="Par356">slight increase in immunoreactivity for the enzymes carbonic anhydrase II and 2&#x02032;,3&#x02032;-cyclic nucleotide 3&#x02032;-phosphodiesterase</p></list-item><list-item><p id="Par357">significant increase in the numerical density of transferrin-immunopositive cells of the white matter</p></list-item><list-item><p id="Par358">an initial reactive hyperplasia which may represent an attempt to repair myelin damage taking place already early during the HIV-1 infection</p></list-item></list></p></list-item><list-item><p id="Par359">Microglia/macrophages (Weis et al. <xref ref-type="bibr" rid="CR148">1994</xref>)<list list-type="bullet"><list-item><p id="Par360">Activated in gray and white matter of all brain regions.</p></list-item><list-item><p id="Par361">Activation pattern is not correlated with the presence of HIV-antigen gp41 and p24 in the brain tissue.</p></list-item></list></p></list-item><list-item><p id="Par362">Vessels (Buttner et al. <xref ref-type="bibr" rid="CR24">1996</xref>; Weis et al. <xref ref-type="bibr" rid="CR149">1996</xref>)<list list-type="bullet"><list-item><p id="Par363">Significant increase in the diameter of cortical vessels</p></list-item><list-item><p id="Par364">Increase of the volume fraction, surface area of vessels</p></list-item><list-item><p id="Par365">No changes in length density indicating no changes in the number of vessels</p></list-item><list-item><p id="Par366">Increase of the numerical density of vessels in the gray matter</p></list-item><list-item><p id="Par367">No changes in the numerical density of vessels in the white matter</p></list-item><list-item><p id="Par368">Thinning of the basal lamina as seen by electron microscopy</p></list-item><list-item><p id="Par369">Reduced immunoreactivity for collagen IV and laminin (thinning of the basal lamina)</p></list-item></list></p></list-item><list-item><p id="Par370">Vascular endothelial cell (Buttner et al. <xref ref-type="bibr" rid="CR24">1996</xref>; Weis et al. <xref ref-type="bibr" rid="CR149">1996</xref>)<list list-type="bullet"><list-item><p id="Par371">loss of glycoproteins SBA, UEA-I, and WGA of the endothelial cell membrane</p></list-item><list-item><p id="Par372">decrease of immunoreactivity for von Willebrand factor (Factor VIII)</p></list-item><list-item><p id="Par373">no significant differences RCA-I</p></list-item><list-item><p id="Par374">No changes in size at the electron microscopic level</p></list-item></list></p></list-item><list-item><p id="Par375">Capillaries (Weis and Haug <xref ref-type="bibr" rid="CR144">1989</xref>)<list list-type="bullet"><list-item><p id="Par376">region-specific changes</p></list-item><list-item><p id="Par377">increased capillary profile area</p></list-item><list-item><p id="Par378">increased capillary diameter</p></list-item><list-item><p id="Par379">decreased basal lamina thickness</p></list-item><list-item><p id="Par380">increased endothelial cell size</p></list-item><list-item><p id="Par381">unchanged pericyte size</p></list-item></list></p></list-item></list></p></sec><sec id="Sec16"><title>Pathogenetic Mechanisms</title><sec id="Sec17"><title>Mode of Entrance of HIV-1 to the&#x000a0;Brain</title><p id="Par382">HIV-1 enters the CNS by<list list-type="bullet"><list-item><p id="Par383">HIV-1 is passively carried by T-lymphocytes and monocytes&#x02014;the &#x0201c;Trojan Horse&#x0201d; hypothesis.</p></list-item><list-item><p id="Par384">Cell-free HIV-1 particles may also penetrate brain microvascular endothelial cells.</p></list-item><list-item><p id="Par385">After crossing the BBB into the CNS, macrophages spread productive HIV-1 infection to neighboring microglia.</p></list-item><list-item><p id="Par386">Microglia serve as<list list-type="bullet"><list-item><p id="Par387">a reservoir for persistent viral infection and replication</p></list-item><list-item><p id="Par388">a vehicle for viral dissemination throughout the brain</p></list-item><list-item><p id="Par389">a major source of neurotoxic products that affect glial function, the blood&#x02013;brain barrier and neuronal function, and finally lead to cell death</p></list-item></list></p></list-item><list-item><p id="Par390">Microglia and monocyte-derived macrophages express both the CD4 and chemokine coreceptors (CCR5, CXCR4), the prerequisite for HIV-1 to enter a cell.</p></list-item><list-item><p id="Par391">The potential role of the cerebrospinal fluid or the choroid plexus as a means for HIV-1 entry in the brain is still unclear.</p></list-item><list-item><p id="Par392">At the time of primary HIV-1 infection, an acute aseptic meningitis or encephalitis indicates central nervous system invasion.</p></list-item><list-item><p id="Par393">The point in time when the migration of HIV-1-infected lymphocytes into the brain takes place is not known. It has been shown that, at the time of seroconversion, HIV-1 can be detected in the CSF; this is the time when, clinically, a subacute meningitis develops, thus, suggesting that HIV-1 enters the CNS at a very early stage of the disease.</p></list-item><list-item><p id="Par394">Opportunistic infectious agents or drugs of abuse disturbing the BBB may further attract more HIV-1-infected T-lymphocytes and macrophages into the brain.</p></list-item></list></p></sec><sec id="Sec18"><title>Target Cells of HIV-1 Infection</title><p id="Par395">The cells in the brain identified to contain HIV-1 are:<list list-type="bullet"><list-item><p id="Par396">Microglia</p></list-item><list-item><p id="Par397">Macrophages</p></list-item><list-item><p id="Par398">Multinucleated giant cells</p></list-item><list-item><p id="Par399">Astrocytes (possibly)</p></list-item><list-item><p id="Par400">Endothelial cells (possibly)</p></list-item><list-item><p id="Par401">Oligodendrocytes (possibly)</p></list-item></list><list list-type="bullet"><title>Mechanisms of Brain Lesions</title><list-item><p id="Par402">The development of brain lesions due to opportunistic infections and lymphomas might be explained by the lack of a competent immunologic defense system.</p></list-item><list-item><p id="Par403">One might assume that the changes described in Sect. <xref rid="Sec14" ref-type="sec">26.5.8</xref> might result by direct infection with HIV-1.<list list-type="bullet"><list-item><p id="Par404">However, it has been shown that neither neurons, nor astrocytes nor endothelial cells are infected with HIV-1.</p></list-item><list-item><p id="Par405">Thus, these changes more probably result from indirect toxic factors that are produced either by infected multinucleated giant cells or by activated microglia.</p></list-item></list></p></list-item><list-item><p id="Par406">Neuronal dropout occurs in brain regions<list list-type="bullet"><list-item><p id="Par407">That are free from any neuropathological changes.</p></list-item><list-item><p id="Par408">Neuronal damage in AIDS was, at least, partly due to apoptosis.</p></list-item><list-item><p id="Par409">No correlation was found between the presence and severity of neuronal loss or of neuronal apoptosis and a history of cognitive disorders.</p></list-item><list-item><p id="Par410">No correlation between the presence of HIV-1 proteins and neuronal loss.</p></list-item></list></p></list-item><list-item><p id="Par411">The reactive astrogliosis was not correlated with the loss of nerve cells, indicating that this reaction pattern is rather a response to toxic factors secreted into the brain tissue.</p></list-item><list-item><p id="Par412">The number of activated microglia/macrophages is significantly increased in all brain regions. This activation of microglia is not correlated with the presence of HIV-1 antigen in the brain tissue. Activated microglia/macrophages, rather than MGCs, most probably secrete toxic factors.</p></list-item><list-item><p id="Par413">The neurotoxicity associated with HIV-1 infection is mediated, in part, through<list list-type="bullet"><list-item><p id="Par414">cytokines</p></list-item><list-item><p id="Par415">arachidonic acid metabolites</p></list-item><list-item><p id="Par416">produced during cell-to-cell interactions between HIV-1-infected brain macrophages and astrocytes</p></list-item></list></p></list-item><list-item><p id="Par417">Pathobiological events underlying the neurodegenerative processes in HIV-1-associated dementia are believed to begin with productive infection of monocytes/macrophages by HIV-1.<list list-type="bullet"><list-item><p id="Par418">Peripheral activation causes the differentiation of macrophages to produce a variety of immune products that lead to the upregulation of adhesion molecules on brain microvascular endothelial cells and the expression of adhesins on the monocyte-macrophage cell surface.</p></list-item><list-item><p id="Par419">After penetration of the BBB, the differentiated brain macrophages and microglia can be vehicles for viral dissemination throughout the brain and focal reservoirs for productive HIV-1 replication.</p></list-item><list-item><p id="Par420">The neurotoxic events in the brain are caused by neurotoxins produced by these cells which are primed by HIV-1 and secondarily activated by factors such as immune stimuli or by T-cells trafficking through the nervous system.</p></list-item><list-item><p id="Par421">The primed and immune-activated brain macrophages/microglia secrete a variety of factors which affect neural and glial function and eventually lead to CNS inflammation.</p></list-item><list-item><p id="Par422">A pro-inflammatory cytokine response from blood-derived monocytes/macrophages, microglia, and astrocytes is amplified and leads finally to neurodegeneration.</p></list-item><list-item><p id="Par423">Immune neurotoxic factors may contribute to the breakdown of the BBB and affect the generation of chemokines, leading to transendothelial migration of monocytes into the brain perpetuating the inflammatory cascade.</p></list-item><list-item><p id="Par424">As a result of the neurotoxic activities of activated macrophages/microglia, astrocytes may suppress or increasemacrophages/microglia secretory functions and toxicity, depending on the astrocytic functional status.</p></list-item><list-item><p id="Par425">Cytolytic T-lymphocytes serve to eliminate infected cells, but are lost in late-stage HIV-1 disease, allowing the virus-induced, neurodegenerative response to continue unabated.</p></list-item></list></p></list-item><list-item><p id="Par426">Other factors include:<list list-type="bullet"><list-item><p id="Par427">viral proteins</p></list-item><list-item><p id="Par428">CA<sup>2+</sup> channels</p></list-item><list-item><p id="Par429">NMDA receptors</p></list-item><list-item><p id="Par430">chemokines and cytokines</p></list-item></list></p></list-item><list-item><p id="Par431">Expression of developmental proteins (Malik and Eugenin <xref ref-type="bibr" rid="CR89">2016</xref>):<list list-type="bullet"><list-item><p id="Par432">Dickkopf homolog 1 (DKK1): upregulated</p></list-item><list-item><p id="Par433">Rho-associated, coiled-coil containing protein kinase 2 (ROCK2)&#x02014;upregulated</p></list-item><list-item><p id="Par434">Low density lipoprotein receptor-related protein-associated protein 1 (LRPAP1)&#x02014;upregulated</p></list-item><list-item><p id="Par435">Low density lipoprotein receptor-related protein 5-like (LRP5L)&#x02014;downregulated</p></list-item><list-item><p id="Par436">Low density lipoprotein-related protein 12 (LRP12)&#x02014;upregulated</p></list-item><list-item><p id="Par437">Low density lipoprotein receptor-related protein 8, apolipoprotein e receptor (LRP8)&#x02014;downregulated</p></list-item><list-item><p id="Par438">Catenin (cadherin-associated protein), alpha-like 1 (CTNNAL1)&#x02014;upregulated</p></list-item><list-item><p id="Par439">Catenin, beta-like 1 (CTNNBL1)&#x02014;downregulated</p></list-item><list-item><p id="Par440">Catenin (cadherin-associated protein), delta 1 (CTNND1)&#x02014;downregulated</p></list-item><list-item><p id="Par441">Catenin (cadherin-associated protein), alpha-like 1 (CTNNAL1)&#x02014;upregulated</p></list-item><list-item><p id="Par442">Glycogen synthase kinase 3 beta (GSK3B)&#x02014;downregulated</p></list-item><list-item><p id="Par443">Wingless-type MMTV integration site family, member 10A (WNT10A)&#x02014;downregulated</p></list-item></list></p></list-item><list-item><p id="Par444">For more details, see (Zayyad and Spudich <xref ref-type="bibr" rid="CR158">2015</xref>; Singh <xref ref-type="bibr" rid="CR126">2016</xref>; Ru and Tang <xref ref-type="bibr" rid="CR115">2017</xref>; Rao et al. <xref ref-type="bibr" rid="CR110">2014</xref>; Malik and Eugenin <xref ref-type="bibr" rid="CR89">2016</xref>; Lamers et al. <xref ref-type="bibr" rid="CR77">2016</xref>; Joseph et al. <xref ref-type="bibr" rid="CR68">2016</xref>; Chen et al. <xref ref-type="bibr" rid="CR29">2014</xref>; Carroll and Brew <xref ref-type="bibr" rid="CR27">2017</xref>).</p></list-item></list></p><p id="Par445">Interactions between the blood&#x02013;brain barrier (BBB) and HIV (Hong and Banks <xref ref-type="bibr" rid="CR60">2015</xref>)</p><p id="Par446">Mechanisms involving the BBB in HIV-infection<list list-type="bullet"><list-item><p id="Par447">Passage of HIV cell-free virus across the BBB<list list-type="bullet"><list-item><p id="Par448">Transcytotic (mannose 6 phosphate receptor dependent)</p></list-item><list-item><p id="Par449">Paracellular (tight junction dissolution)</p></list-item></list></p></list-item><list-item><p id="Par450">Passage of HIV-1 proteins (gp120, Tat) across the BBB</p></list-item><list-item><p id="Par451">Increased immune Ccll trafficking across the BBB<list list-type="bullet"><list-item><p id="Par452">Activated and infected T cells</p></list-item><list-item><p id="Par453">Activated and infected monocytes</p></list-item></list></p></list-item><list-item><p id="Par454">Transport of cytokines across the BBB</p></list-item><list-item><p id="Par455">Induction of cytokine release from barrier cells</p></list-item><list-item><p id="Par456">Increased BBB leakiness</p></list-item><list-item><p id="Par457">Brain-to-blood efflux of antivirals<list list-type="bullet"><list-item><p id="Par458">Protease inhibitors by P-glycoprotein</p></list-item><list-item><p id="Par459">AZT by organic ion transporter</p></list-item></list></p></list-item><list-item><p id="Par460">Altered BBB transporter expression and function (e.g., P-glycoprotein)</p></list-item><list-item><p id="Par461">Neurovascular unit effects</p></list-item></list></p><p id="Par462">Therapeutic effects on involved pathways are illustrated in Table <xref rid="Tab15" ref-type="table">26.15</xref>.<table-wrap id="Tab15"><label>Table 26.15</label><caption><p>Therapy and effects on involved pathways (Sanchez and Kaul <xref ref-type="bibr" rid="CR121">2017</xref>) reproduced with kind permission from MDPI open access</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>HIV or methamphetamine or HIV&#x000a0;+&#x000a0;Meth</th><th>HIV&#x000a0;+&#x000a0;cART</th><th>HIV&#x000a0;+&#x000a0;METH&#x000a0;+&#x000a0;cART</th></tr></thead><tbody><tr><td>Microglia activation</td><td>&#x02191;</td><td>&#x02191;</td><td>&#x02191;</td></tr><tr><td>Astrocytosis</td><td>&#x02191;</td><td>&#x02191;</td><td>&#x02191;</td></tr><tr><td>Alteration of neurotransmission</td><td>&#x02191;</td><td/><td>&#x02191;</td></tr><tr><td>HAND/HAD</td><td>&#x02191;</td><td>&#x02193;</td><td/></tr><tr><td>Oxidative stress</td><td>&#x02191;</td><td>&#x02191;</td><td>&#x02191;</td></tr><tr><td>Mitochondrial impairment</td><td>&#x02191;</td><td/><td/></tr><tr><td>ER stress</td><td/><td>&#x02191;</td><td/></tr><tr><td>Autophagy</td><td/><td/><td>&#x02193;</td></tr><tr><td>Neuronal dendrites</td><td>&#x02193;</td><td/><td>&#x02193;</td></tr><tr><td>Synapses</td><td>&#x02193;</td><td/><td>&#x02193;</td></tr><tr><td>Neuronal ATP</td><td>&#x02193;</td><td>&#x02193;</td><td>&#x02193;</td></tr><tr><td>Viral load</td><td/><td>&#x02193;</td><td/></tr></tbody></table></table-wrap></p></sec></sec></sec><sec id="Sec19"><title>DNA-Virus: Cytomegalovirus Infection (CMV)</title><p id="Par9007">
<list list-type="bullet"><title>Cytomegalovirus</title><list-item><p id="Par464">Herpesviruses, subfamily Betaherpesvirinae</p></list-item><list-item><p id="Par465">Large, enveloped viruses containing double-stranded DNA</p></list-item><list-item><p id="Par466">150 nm in diameter</p></list-item></list>
</p><sec id="Sec107"><title>Neuroradiology Findings</title><p id="Par9008">
<list list-type="bullet"><title>General Imaging Features</title><list-item><p id="Par467">Periventricular white matter lesions, subependymal enhancement</p></list-item><list-item><p id="Par468">Calcifications in perinatal CMV</p></list-item></list>
<list list-type="bullet"><title>CT Non-Contrast-Enhanced (Fig. <xref rid="Fig7" ref-type="fig">26.7a</xref>)</title><list-item><p id="Par469">Periventricular hypodense lesions</p></list-item><list-item><p id="Par470">Periventricular hyperdense calcifications in perinatal CMV</p></list-item></list>
<list list-type="bullet"><title>CT Contrast-Enhanced</title><list-item><p id="Par471">Subependymal enhancement possible</p></list-item></list>
<list list-type="bullet"><title>MRI-T2/FLAIR (Fig. <xref rid="Fig7" ref-type="fig">26.7b, c</xref>)</title><list-item><p id="Par472">Periventricular hyperintensities</p></list-item></list>
<list list-type="bullet"><title>MRI-T1 (Fig. <xref rid="Fig7" ref-type="fig">26.7e</xref>)</title><list-item><p id="Par473">Subependymal enhancement</p></list-item></list>
<list list-type="bullet"><title>MRI-T1 Contrast-Enhanced (Fig. <xref rid="Fig7" ref-type="fig">26.7e</xref>)</title><list-item><p id="Par474">Subependymal enhancement</p></list-item></list>
<list list-type="bullet"><title>MRI-T2&#x02217;/SWI (Fig. <xref rid="Fig7" ref-type="fig">26.7f</xref>)</title><list-item><p id="Par475">Periventricular hypointense calcifications in perinatal CMV</p></list-item></list>
</p></sec><sec id="Sec108"><title>Neuropathology Findings</title><p id="Par463">
<list list-type="bullet"><title>Macroscopic Features</title><list-item><p id="Par476">In general, there are no gross-anatomical changes.</p></list-item><list-item><p id="Par477">Rarely, some small areas of necrosis are seen lining the ventricles, i.e., necrotizing ependymitis.</p></list-item></list>
<list list-type="bullet"><title>Microscopic Features (Fig. <xref rid="Fig8" ref-type="fig">26.8a&#x02013;j</xref>)</title><list-item><p id="Par478">Microglial nodules are seen scattered throughout the nervous system.</p></list-item><list-item><p id="Par479">Large cells containing inclusion bodies are found within the microglial nodules.</p></list-item><list-item><p id="Par480">The microglial nodules located in the gray and white matter are usually not surrounded by a necrotic area.</p></list-item><list-item><p id="Par481">Along the periventricular spaces CMV-containing cells are found within the necrotic areas.</p></list-item></list>
<fig id="Fig7"><label>Fig. 26.7</label><caption><p>Cytomegalovirus (CMV) infection: periventricular calcifications after perinatal CMV. CT non-contrast (<bold>a</bold>), T2 (<bold>b</bold>, <bold>c</bold>), T1 (<bold>d</bold>), T1 contrast (<bold>e</bold>), T2&#x02217; (<bold>f</bold>)</p></caption><graphic xlink:href="309569_1_En_26_Fig7a_HTML" id="d29e4498"/><graphic xlink:href="309569_1_En_26_Fig7b_HTML" id="d29e4499"/></fig>
<fig id="Fig8"><label>Fig. 26.8</label><caption><p>Cytomegalovirus (CMV) infection (<bold>a</bold>&#x02013;<bold>n</bold>). Cells with inclusion bodies (<bold>a</bold>&#x02013;<bold>j</bold>) (stain: H&#x00026;E); cytomegalic cell with inclusion body (<bold>k</bold>&#x02013;<bold>n</bold>) (stain: immunohistochemistry for CMV)</p></caption><graphic xlink:href="309569_1_En_26_Fig8a_HTML" id="d29e4528"/><graphic xlink:href="309569_1_En_26_Fig8b_HTML" id="d29e4529"/><graphic xlink:href="309569_1_En_26_Fig8c_HTML" id="d29e4530"/></fig>
</p></sec></sec><sec id="Sec20"><title>Progressive Multifocal Leukoencephalopathy (PML)</title><p id="Par482">John Cunningham Virus (JCV) is a member of the Polyomaviridae family</p><p id="Par9009">Polyomaviruses BK and JC are ubiquitous.<list list-type="bullet"><list-item><p id="Par484">Are 45 nm in diameter.</p></list-item><list-item><p id="Par485">Contain less than 5000 base pairs.</p></list-item><list-item><p id="Par486">Genomes of BK and JC are closely related.<list list-type="bullet"><list-item><p id="Par487">divided in early, late, and non-coding regions</p></list-item></list></p></list-item></list><list list-type="bullet"><list-item><p id="Par488">JC virus etiological agent of the progressive multifocal leukoencephalopathy (PML)</p></list-item><list-item><p id="Par489">JC is an ubiquitous, neurotropic virus:<list list-type="bullet"><list-item><p id="Par490">50&#x02013;90% of adult healthy individuals have been exposed to this virus.</p></list-item><list-item><p id="Par491">19&#x02013;27% of those people shedding JCV in their urine.</p></list-item></list></p></list-item><list-item><p id="Par492">The seroprevalence increases with age but acquisition of this virus is not associated with a clinical syndrome.</p></list-item><list-item><p id="Par493">JC binds to sialylated carbohydrates and serotonin receptors to enter glial cells by endocytosis.</p></list-item><list-item><p id="Par494">DNA genome is uncoated and delivered to the nucleus.</p></list-item></list></p><sec id="Sec110"><title>Clinical Signs and Symptoms</title><p id="Par9010">
<list list-type="bullet"><list-item><p id="Par495">The pre-AIDS era<list list-type="bullet"><list-item><p id="Par496">Impaired vision<list list-type="bullet"><list-item><p id="Par497">homonymous hemianopsia</p></list-item></list></p></list-item><list-item><p id="Par498">Motor weakness<list list-type="bullet"><list-item><p id="Par499">hemiparesis or hemiplegia</p></list-item></list></p></list-item><list-item><p id="Par500">Changes in mentation:<list list-type="bullet"><list-item><p id="Par501">personality change</p></list-item><list-item><p id="Par502">difficulty with memory</p></list-item><list-item><p id="Par503">emotional lability</p></list-item><list-item><p id="Par504">dementia</p></list-item></list></p></list-item></list></p></list-item><list-item><p id="Par505">AIDS-related PML<list list-type="bullet"><list-item><p id="Par506">weakness (42%)</p></list-item><list-item><p id="Par507">speech abnormalities (40%)</p></list-item><list-item><p id="Par508">cognitive abnormalities (36%)</p></list-item><list-item><p id="Par509">gait abnormalities (29%)</p></list-item><list-item><p id="Par510">sensory loss (19%)</p></list-item><list-item><p id="Par511">visual impairment (19%)</p></list-item><list-item><p id="Par512">seizures</p></list-item><list-item><p id="Par513">diplopia</p></list-item><list-item><p id="Par514">limb incoordination</p></list-item></list></p></list-item><list-item><p id="Par515">PML associated with monoclonal antibody therapy<list list-type="bullet"><list-item><p id="Par516">cognitive disorders (48%)</p></list-item><list-item><p id="Par517">motor abnormalities (37%)</p></list-item><list-item><p id="Par518">language disturbances (31%)</p></list-item><list-item><p id="Par519">visual defects (26%)</p></list-item></list></p></list-item><list-item><p id="Par520">PML&#x02013;IRIS immune reconstitution inflammatory syndrome<list list-type="bullet"><list-item><p id="Par521">Paradoxical worsening of clinical or radiographic finding with recovery of the immune system</p></list-item><list-item><p id="Par522">New or increased neurologic deficits</p></list-item><list-item><p id="Par523">Increase in the number or size of lesions on neuroimaging</p></list-item><list-item><p id="Par524">Contrast enhancement of brain lesions</p></list-item><list-item><p id="Par525">Brain edema</p></list-item><list-item><p id="Par526">Concurrent with diagnosis of PML</p></list-item></list></p></list-item></list>
</p></sec><sec id="Sec112"><title>Neuroimaging Findings</title><p id="Par9011">
<list list-type="bullet"><title>General Imaging Features</title><list-item><p id="Par527">Confluent subcortical white matter lesions, predominantly in parieto-occipital or frontal lobes, U-fibers involved</p></list-item></list>
<list list-type="bullet"><title>CT Non-Contrast-Enhanced (Fig. <xref rid="Fig9" ref-type="fig">26.9a</xref>)</title><list-item><p id="Par528">Multiple hypodensities in white matter</p></list-item><list-item><p id="Par529">No mass effect</p></list-item><list-item><p id="Par530">If bilateral often asymmetric</p></list-item><list-item><p id="Par531">Natalizumab-associated PML often monofocal</p></list-item></list>
<list list-type="bullet"><title>CT Contrast-Enhanced (Fig. <xref rid="Fig9" ref-type="fig">26.9b</xref>)</title><list-item><p id="Par532">Usually no enhancement</p></list-item><list-item><p id="Par533">Enhancement possible in HIV-associated PML and natalizumab-associated PML</p></list-item></list>
<list list-type="bullet"><title>MRI-T2 (Fig. <xref rid="Fig9" ref-type="fig">26.9c</xref>)</title><list-item><p id="Par534">Hyperintense</p></list-item></list>
<list list-type="bullet"><title>MRI-FLAIR (Fig. <xref rid="Fig9" ref-type="fig">26.9d</xref>)</title><list-item><p id="Par535">Hyperintense</p></list-item></list>
<list list-type="bullet"><title>MRI-T1 (Fig. <xref rid="Fig9" ref-type="fig">26.9e</xref>)</title><list-item><p id="Par536">Hypointense</p></list-item></list>
<list list-type="bullet"><title>MRI-T1 Contrast-Enhanced (Fig. <xref rid="Fig9" ref-type="fig">26.9f</xref>)</title><list-item><p id="Par537">Usually no enhancement</p></list-item><list-item><p id="Par538">Enhancement possible in HIV-associated PML and natalizumab-associated PML</p></list-item></list>
<list list-type="bullet"><title>MRI-DWI (Fig. <xref rid="Fig9" ref-type="fig">26.9g</xref>)</title><list-item><p id="Par539">Acute lesions hyperintense</p></list-item></list>
<list list-type="bullet"><title>MRI-ADC (Fig. <xref rid="Fig9" ref-type="fig">26.9h</xref>)</title><list-item><p id="Par540">Acute lesions hypointense</p></list-item></list>
</p></sec><sec id="Sec113"><title>Neuropathology Findings</title><p id="Par483">
<list list-type="bullet"><title>Macroscopic Features (Fig. <xref rid="Fig10" ref-type="fig">26.10a&#x02013;d</xref>)</title><list-item><p id="Par541">Multiple areas of discoloration of the white matter.</p></list-item><list-item><p id="Par542">Sometimes, the white matter may appear softened and mottled.</p></list-item></list>
<list list-type="bullet"><title>Microscopic Features (Fig. <xref rid="Fig10" ref-type="fig">26.10e&#x02013;p</xref>)</title><list-item><p id="Par543">Multiple foci of demyelination in the white matter consisting of loss of myelin sheaths.</p></list-item><list-item><p id="Par544">The oligodendrocytes are enlarged, amphophilic, and contain intranuclear inclusions.</p></list-item><list-item><p id="Par545">Enlarged, bizarre astrocytes.</p></list-item></list>
<fig id="Fig9"><label>Fig. 26.9</label><caption><p>Progressive multifocal leukoencephalopathy (PML). CT non-contrast (<bold>a</bold>), CT contrast (<bold>b</bold>), T2 (<bold>c</bold>), FLAIR (<bold>d</bold>), T1 (<bold>e</bold>), T1 contrast (<bold>f</bold>), DWI (<bold>g</bold>), ADC (<bold>h</bold>)</p></caption><graphic xlink:href="309569_1_En_26_Fig9a_HTML" id="d29e4861"/><graphic xlink:href="309569_1_En_26_Fig9b_HTML" id="d29e4862"/></fig>
<fig id="Fig10"><label>Fig. 26.10</label><caption><p>Progressive multifocal leukoencephalopathy: macroscopically, the white matter shows a moth-eaten appearance (<bold>a</bold>&#x02013;<bold>d</bold>). The myelin of the left hemisphere is completely lost (stain: Woelcke&#x02019;s myelin stain) (<bold>e</bold>, <bold>f</bold>). Histology shows degeneration of myelin accompanied by the presence of reactive astrocytes, bizarre astrocytes/oligodendrocytes with large eccentric cytoplasm and lymphocytic infiltrates (<bold>g</bold>&#x02013;<bold>j</bold>). Reactive astrogliosis (stain: GFAP) (<bold>k</bold>, <bold>l</bold>) and reactive microgliosis (stain: HLA-DRII) (<bold>m</bold>, <bold>n</bold>). Lymphocytes (stain: CD45) (<bold>o</bold>, <bold>p</bold>) are found in the perivascular spaces and within the brain tissue</p></caption><graphic xlink:href="309569_1_En_26_Fig10a_HTML" id="d29e4910"/><graphic xlink:href="309569_1_En_26_Fig10b_HTML" id="d29e4911"/><graphic xlink:href="309569_1_En_26_Fig10c_HTML" id="d29e4912"/></fig>
</p></sec><sec id="Sec21"><title>Molecular Nauropathology</title><p id="Par546">Development of PML (Berger and Khalili <xref ref-type="bibr" rid="CR18">2011</xref>)<list list-type="bullet"><list-item><p id="Par547">infection with JC virus</p></list-item><list-item><p id="Par548">establishment of latent and/or persistent JC virus infection</p></list-item><list-item><p id="Par549">rearrangement of JC virus into a neurotropic strain if initial infection has been with the archetype strain</p></list-item><list-item><p id="Par550">reactivation of the neurotropic JC virus strain from sites of viral persistence/latency</p></list-item><list-item><p id="Par551">entry into the brain</p></list-item><list-item><p id="Par552">establishment of productive infection of oligodendrocytes</p></list-item><list-item><p id="Par553">ineffective immune system that prevents immunosurveillance from eliminating the infection</p></list-item></list></p><p id="Par554">Drugs which cause PML are listed in Table <xref rid="Tab16" ref-type="table">26.16</xref>.<table-wrap id="Tab16"><label>Table 26.16</label><caption><p>Drug-induced cases of PML (Bauer et al. <xref ref-type="bibr" rid="CR12">2015</xref>) reproduced with kind permission by Springer Nature</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Medication</th><th>Treatment</th></tr></thead><tbody><tr><td>Azathioprine</td><td>Transplantation/autoimmune disease</td></tr><tr><td>Cyclosporine</td><td>Transplantation</td></tr><tr><td>Cyclophosphamide</td><td>Cancer/transplantation/autoimmune disease</td></tr><tr><td>Dimethylfumarate</td><td>Autoimmune disease</td></tr><tr><td>Efalizumab</td><td>Autoimmune disease (psoriasis)</td></tr><tr><td>Fingolimod</td><td>Autoimmune disease</td></tr><tr><td>Infliximab</td><td>Autoimmune disease</td></tr><tr><td>Leflunomid</td><td>Autoimmune disease</td></tr><tr><td>Methotrexate</td><td>Cancer/autoimmune disease</td></tr><tr><td>Mycophenolate</td><td>Transplantation/autoimmune disease</td></tr><tr><td>Natalizumab</td><td>Autoimmune disease</td></tr><tr><td>Rituximab</td><td>Cancer/autoimmune disease</td></tr><tr><td>Tacrolimus</td><td>Transplantation</td></tr></tbody></table></table-wrap></p><p id="Par555">The differences between progressive multifocal leukoencephalopathy (PML), progressive multifocal leukoencephalopathy&#x02014;immune reconstitution inflammatory syndrome (PML&#x02013;IRIS) and multiple sclerosis (MS) with regard to anatomical, neuropathological, and MRI features are shown in Table <xref rid="Tab17" ref-type="table">26.17</xref>.<table-wrap id="Tab17"><label>Table 26.17</label><caption><p>Comparative anatomical, neuropathological, and MRI features of progressive multifocal leukoencephalopathy (PML), progressive multifocal leukoencephalopathy&#x02014;immune reconstitution inflammatory syndrome (PML&#x02013;IRIS) and multiple sclerosis (MS) (Bauer et al. <xref ref-type="bibr" rid="CR12">2015</xref>) reproduced with kind permission by Springer Nature</p></caption><table frame="hsides" rules="groups"><thead><tr><th>PML</th><th>PML&#x02013;IRIS</th><th>MS</th></tr></thead><tbody><tr><td colspan="3"><italic>Anatomical features</italic></td></tr><tr><td><p>&#x02022;&#x02003;Lesions mostly reside in cerebral hemispheres but periventricular lesions are rare.</p><p>&#x02022;&#x02003;Lesions predominantly affect the deep and subcortical white matter and can expand into the cortical gray matter.</p><p>&#x02022;&#x02003;Intracortical lesions are present.</p><p>&#x02022;&#x02003;Spinal cord and optic nerves are spared.</p></td><td>&#x02022;&#x02003;Lesion distribution is similar to PML.</td><td><p>&#x02022;&#x02003;Lesions can be found in white and gray matter, but are often found in a periventricular position.</p><p>&#x02022;&#x02003;Unlike in PML, lesions can be found in spinal cord and optic nerves.</p></td></tr><tr><td colspan="3"><italic>Neuropathological features</italic></td></tr><tr><td><p>&#x02022;&#x02003;Demyelinating lesions reveal oligodendrocytes with enlarged nucleus and cytoplasm. The nucleus may show inclusion bodies.</p><p>&#x02022;&#x02003;Oligodendrocytes are mostly found on the border of the lesion.</p><p>&#x02022;&#x02003;Subpial lesions are absent.</p><p>&#x02022;&#x02003;Remyelination is absent.</p><p>&#x02022;&#x02003;Within the demyelinated lesions, large (the so-called bizarre) astrocytes are found.</p><p>&#x02022;&#x02003;Lesions contain low to moderate numbers of T-cells.</p><p>&#x02022;&#x02003;few B-cells</p><p>&#x02022;&#x02003;few plasma cells</p><p>&#x02022;&#x02003;Activated microglial cells and macrophages are present in high numbers.</p></td><td><p>&#x02022;&#x02003;Like PML, lesions contain infected cells, especially on the border.</p><p>&#x02022;&#x02003;In small samples (biopsies) however, infected cells may be low in numbers or may be absent.</p><p>&#x02022;&#x02003;Subpial lesions are absent.</p><p>&#x02022;&#x02003;Remyelination is absent.</p><p>&#x02022;&#x02003;Like in PML, lesions contain bizarre astrocytes.</p><p>&#x02022;&#x02003;Lesions contain extremely high numbers of T-cells and B-cells.</p><p>&#x02022;&#x02003;Numbers of microglia and macrophages do not differ with PML.</p></td><td><p>&#x02022;&#x02003;Unlike in PML, lesions are perivenous and show finger-like extensions (i.e., Dawson fingers).</p><p>&#x02022;&#x02003;Subpial lesions are present and are specific for MS.</p><p>&#x02022;&#x02003;Lesions can show variable remyelination.</p><p>&#x02022;&#x02003;Lesions can show activated astrocytes and/or astrogliosis.</p><p>&#x02022;&#x02003;Extremely large bizarre astrocytes are absent.</p><p>&#x02022;&#x02003;Lesions contain moderate to high numbers of T-cells.</p><p>&#x02022;&#x02003;Low numbers of B-cell</p><p>&#x02022;&#x02003;Low numbers of plasma cells</p><p>&#x02022;&#x02003;Numbers of (foamy) macrophages do not differ from PML or PML&#x02013;IRIS.</p></td></tr><tr><td colspan="3"><italic>MRI features</italic></td></tr><tr><td><p>&#x02022;&#x02003;Usually larger than 3 cm</p><p>&#x02022;&#x02003;Lesions always start in subcortical regions, probably related to a high blood flow.</p><p>&#x02022;&#x02003;Borders are sharp towards the GM and ill-defined towards the WM.</p><p>&#x02022;&#x02003;In first scans of 28% of patients, lesions extend in deep GM.</p><p>&#x02022;&#x02003;23&#x02013;57% of (HIV-associated) cases have contrast-enhancing lesions.</p><p>&#x02022;&#x02003;T1 lesions are mostly hypointense.</p><p>&#x02022;&#x02003;Diffusion-weighted images are always hyperintense.</p><p>&#x02022;&#x02003;Punctate T2-hyperintense lesions can be found in the immediate vicinity of the main lesion.</p></td><td><p>&#x02022;&#x02003;Usually larger than 3 cm</p><p>&#x02022;&#x02003;Lesions always start in subcortical regions, probably related to a high blood flow.</p><p>&#x02022;&#x02003;Borders are sharp towards the GM and ill-defined towards the WM.</p><p>&#x02022;&#x02003;In first scans of 71% of patients, lesions extend in deep GM.</p><p>&#x02022;&#x02003;86% of PML&#x02013;IRIS cases have contrast-enhancing lesions.</p><p>&#x02022;&#x02003;T1 lesions may have hyperintense rims.</p><p>&#x02022;&#x02003;Diffusion-weighted images are always hyperintense.</p><p>&#x02022;&#x02003;Punctate T2-hyperintense lesions can be found in the immediate vicinity of the main lesion.</p></td><td><p>&#x02022;&#x02003;All MRI features seen in PML and/or PML&#x02013;IRIS also can be seen in MS.</p><p>&#x02022;&#x02003;However, MS lesions usually are and stay smaller in size than in PML or PML&#x02013;IRIS.</p><p>&#x02022;&#x02003;Homogeneous or open-ring enhancing lesions are present in MS but not observed in PML.</p></td></tr></tbody></table></table-wrap></p><p id="Par556">Prognostic factors of the evolution of progressive multifocal leukoencephalopathy have been described (Gheuens et al. <xref ref-type="bibr" rid="CR49">2013</xref>) and include:<list list-type="bullet"><list-item><p id="Par557">Favorable factors:<list list-type="bullet"><list-item><p id="Par558">Detectable JCV-specific cellular immune response in blood or CSF</p></list-item><list-item><p id="Par559">Rapid clearance of JCV from CSF</p></list-item><list-item><p id="Par560">CD4 count &#x0003e;200&#x000a0;&#x003bc;L&#x000a0;&#x02212;&#x000a0;1 at onset</p></list-item></list></p></list-item><list-item><p id="Par561">Unfavorable factors:<list list-type="bullet"><list-item><p id="Par562">Undetectable JCV-specific cellular immune response in blood or CSF</p></list-item><list-item><p id="Par563">Mass effect on MRI</p></list-item><list-item><p id="Par564">Posterior fossa lesions</p></list-item><list-item><p id="Par565">High JC viral load in CSF</p></list-item><list-item><p id="Par566">CD4 count &#x0003c;200&#x000a0;&#x003bc;L&#x000a0;&#x02212;&#x000a0;1 at onset</p></list-item></list></p></list-item></list></p></sec></sec><sec id="Sec22"><title>Herpes Simplex Virus (HSV) Encephalitis</title><p id="Par9013">Herpesviruses are<list list-type="bullet"><list-item><p id="Par568">Large, enveloped viruses.</p></list-item><list-item><p id="Par569">Contain double-stranded DNA.</p></list-item><list-item><p id="Par570">150 nm in diameter.</p></list-item><list-item><p id="Par571">DNA core surrounded by an icosadeltahedral capsid containing 162 capsomeres.</p></list-item><list-item><p id="Par572">Capsid is enclosed by a glycoprotein-containing envelope.</p></list-item><list-item><p id="Par573">Encode proteins that manipulate the host cell and immune response.</p></list-item><list-item><p id="Par574">DNA replication and capsid assembly occurs in the nucleus.</p></list-item><list-item><p id="Par575">Virus is released by<list list-type="bullet"><list-item><p id="Par576">Exocytosis</p></list-item><list-item><p id="Par577">Cell lysis</p></list-item><list-item><p id="Par578">Through cell-to-cell bridges</p></list-item></list></p></list-item><list-item><p id="Par579">Cause lytic, persistent, latent, and immortalizing infections</p></list-item></list></p><sec id="Sec114"><title>Clinical Signs and Symptoms</title><p id="Par9015">
<list list-type="bullet"><list-item><p id="Par580">Headache</p></list-item><list-item><p id="Par581">Neck stiffness</p></list-item><list-item><p id="Par582">Drowsiness</p></list-item><list-item><p id="Par583">Coma</p></list-item><list-item><p id="Par584">Dysphagia</p></list-item><list-item><p id="Par585">Hemiparesis</p></list-item><list-item><p id="Par586">Focal seizures</p></list-item></list>
</p></sec><sec id="Sec115"><title>Neuroimaging Findings</title><p id="Par9016">
<list list-type="bullet"><title>General Imaging Features</title><list-item><p id="Par587">Involvement of limbic system and temporal lobe</p></list-item><list-item><p id="Par588">Often hemorrhages and enhancement</p></list-item><list-item><p id="Par589">Often bilateral, but asymmetric</p></list-item></list>
<list list-type="bullet"><title>CT Non-Contrast-Enhanced (Fig. <xref rid="Fig11" ref-type="fig">26.11a</xref>)</title><list-item><p id="Par590">Normal (early) to mild hypodense, swollen temporal lobes and insula</p></list-item></list>
<list list-type="bullet"><title>CT Contrast-Enhanced</title><list-item><p id="Par591">Patchy enhancement possible</p></list-item></list>
<list list-type="bullet"><title>MRI-T2/FLAIR (Fig. <xref rid="Fig11" ref-type="fig">26.11b&#x02013;d</xref>)</title><list-item><p id="Par592">Hyperintense, swollen white matter and cortex of affected areas.</p></list-item><list-item><p id="Par593">Hemorrhages may be hypointense.</p></list-item></list>
<list list-type="bullet"><title>MRI-T1 (Fig. <xref rid="Fig11" ref-type="fig">26.11e</xref>)</title><list-item><p id="Par594">Hypointense edema</p></list-item><list-item><p id="Par595">Loss of gray-white matter differentiation</p></list-item></list>
<list list-type="bullet"><title>MRI-T1 Contrast-Enhanced (Fig. <xref rid="Fig11" ref-type="fig">26.11f</xref>)</title><list-item><p id="Par596">Diffuse enhancement</p></list-item></list>
<list list-type="bullet"><title>MRI-T2&#x02217;/SWI</title><list-item><p id="Par597">Hemorrhages hypointense</p></list-item></list>
<list list-type="bullet"><title>MR-Diffusion Imaging (Fig <xref rid="Fig11" ref-type="fig">26.11g</xref>)</title><list-item><p id="Par598">Often restricted diffusion </p></list-item></list>
<list list-type="bullet"><title>MRI-ADC (Fig. <xref rid="Fig11" ref-type="fig">26.11h</xref>)</title><list-item><p id="Par599">Often restricted diffusion</p></list-item></list>
</p><p id="Par7771">
<list list-type="bullet"><title>Nuclear Medicine Findings (Fig. <xref rid="Fig12" ref-type="fig">26.12</xref>) </title><list-item><p id="Par5991">Decreased FDG uptake</p></list-item><list-item><p id="Par5992">After recovery FDG uptake appears regular</p></list-item></list>
</p></sec><sec id="Sec1199"><title>Neuropathology Findings</title><p id="Par9017">
<list list-type="bullet"><title>Macroscopic Features (Fig. <xref rid="Fig13" ref-type="fig">26.13a, b</xref>)</title><list-item><p id="Par600">Congestion</p></list-item><list-item><p id="Par601">Hemorrhagic necrosis of the<list list-type="bullet"><list-item><p id="Par602">Temporal lobe</p></list-item><list-item><p id="Par603">Insula</p></list-item><list-item><p id="Par604">Cingulate gyrus</p></list-item><list-item><p id="Par605">Posterior orbitofrontal cortex</p></list-item></list></p></list-item></list>
<list list-type="bullet"><title>Microscopic Features (Fig. <xref rid="Fig13" ref-type="fig">26.13c, d</xref>)</title><list-item><p id="Par606">Acute phase<list list-type="bullet"><list-item><p id="Par607">parenchymal inflammation</p></list-item><list-item><p id="Par608">lymphocytes and macrophages in the leptomeninges</p></list-item><list-item><p id="Par609">necrotic cells</p></list-item><list-item><p id="Par610">foci of hemorrhages</p></list-item><list-item><p id="Par611">perivascular and interstitial infiltrate of lymphocytes</p></list-item><list-item><p id="Par612">microglial nodules</p></list-item><list-item><p id="Par613">neuronophagia</p></list-item></list></p></list-item><list-item><p id="Par614">Chronic phase<list list-type="bullet"><list-item><p id="Par615">glial scar tissue</p></list-item><list-item><p id="Par616">clusters of lymphocytes</p></list-item></list></p></list-item></list>
</p></sec><sec id="Sec116"><title>Molecular Neuropathology</title><p id="Par9018">
<list list-type="bullet"><title>Pathogenesis</title><list-item><p id="Par617">Primary mucocutaneous infection<list list-type="bullet"><list-item><p id="Par618">mucocutaneous border of lips or oropharyngeal mucosa</p></list-item></list></p></list-item><list-item><p id="Par619">Latency in trigeminal ganglion<list list-type="bullet"><list-item><p id="Par620">by retrograde axonal transport along sensory fibers to the trigeminal ganglion</p></list-item><list-item><p id="Par621">further replication</p></list-item><list-item><p id="Par622">latent infection (latency-associated transcripts)</p></list-item></list></p></list-item><list-item><p id="Par623">Reactivation of virus<list list-type="bullet"><list-item><p id="Par624">anterograde transport to the skin or mucose</p></list-item><list-item><p id="Par625">development of cold sores</p></list-item><list-item><p id="Par626">reactivation<list list-type="bullet"><list-item><p id="Par627">spontaneously</p></list-item><list-item><p id="Par628">mucocutaneous trauma</p></list-item><list-item><p id="Par629">ultraviolet irradiation</p></list-item><list-item><p id="Par630">emotional stress</p></list-item><list-item><p id="Par631">pyrexia</p></list-item><list-item><p id="Par632">fluctuations in estrogen and progesterone concentrations</p></list-item><list-item><p id="Par633">immunosuppression</p></list-item></list></p></list-item></list></p></list-item></list>
</p></sec><sec id="Sec2116"><title>Treatment and Prognosis</title><p id="Par567">
<list list-type="bullet"><title>Outcome</title><list-item><p id="Par634">Fatal outcome within a few days when untreated</p></list-item><list-item><p id="Par635">Treatment</p></list-item></list>
<fig id="Fig11"><label>Fig. 26.11</label><caption><p>Herpes encephalitis with characteristic involvement of right limbic system, temporal and basal frontal lobe, restricted diffusion and weak enhancement; CT non-contrast (<bold>a</bold>), T2 ax/cor (<bold>b</bold>, <bold>c</bold>), FLAIR (<bold>d</bold>), T1 (<bold>e</bold>), T1 contrast (<bold>f</bold>), DWI (<bold>g</bold>), ADC (<bold>h</bold>)</p></caption><graphic xlink:href="309569_1_En_26_Fig11a_HTML" id="d29e5632"/><graphic xlink:href="309569_1_En_26_Fig11b_HTML" id="d29e5633"/></fig>
<fig id="Fig12"><label>Fig. 26.12</label><caption><p>Herpes encephalitis: decreased FDG uptake (left 3 rows) in a patient during the recovery phase of Herpes simplex encephalitis and regular FDG uptake after recovery (right 3 rows)</p></caption><graphic xlink:href="309569_1_En_26_Fig12_HTML" id="MO12"/></fig>
<fig id="Fig13"><label>Fig. 26.13</label><caption><p>Herpes encephalitis: macroscopically, necrosis is seen in both temporal lobes (arrow) (<bold>a</bold>, <bold>b</bold>). The virus is demonstrated by immunohistochemistry mainly in neurons (<bold>c</bold>, <bold>d</bold>)</p></caption><graphic xlink:href="309569_1_En_26_Fig13_HTML" id="MO13"/></fig>
</p></sec></sec><sec id="Sec23"><title>Tick-Borne Encephalitis</title><p id="Par636">Tick-borne encephalitis (TBE) is an infection of the central nervous system (CNS) caused by tick-borne encephalitis virus (TBEV) and transmitted by ticks, with a variety of clinical manifestations (Table <xref rid="Tab18" ref-type="table">26.18</xref>). The incidence of TBE in Europe is increasing due to an extended season of the infection and the enlargement of endemic areas.<table-wrap id="Tab18"><label>Table 26.18</label><caption><p>Viruses causing tick-borne encephalitis</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Virus</th><th>Brain region affected</th><th>Mortality</th><th>Morbidity</th><th>Geographic distribution</th></tr></thead><tbody><tr><td>Eastern equine encephalitis</td><td/><td>50&#x02013;75%</td><td>90% of survivors have persistent neurologic disability.</td><td><p>&#x02022;&#x02003;Eastern and Gulf coast states of the USA.</p><p>&#x02022;&#x02003;Caribbean</p><p>&#x02022;&#x02003;South America</p></td></tr><tr><td>Western equine encephalitis</td><td><p>&#x02022;&#x02003;Basal ganglia</p><p>&#x02022;&#x02003;Thalamus</p><p>&#x02022;&#x02003;Brain stem</p></td><td>&#x0003c;5%</td><td/><td>&#x02022;&#x02003;Western and Midwestern USA</td></tr><tr><td>St. Louis encephalitis</td><td><p>&#x02022;&#x02003;Midbrain</p><p>&#x02022;&#x02003;Thalamus</p></td><td>&#x0003c;5%</td><td>25% of survivors have persistent neurologic disability.</td><td><p>&#x02022;&#x02003;The USA</p><p>&#x02022;&#x02003;Central America</p><p>&#x02022;&#x02003;South America</p></td></tr><tr><td>Japanese encephalitis</td><td><p>&#x02022;&#x02003;Thalamus</p><p>&#x02022;&#x02003;Substantia nigra</p><p>&#x02022;&#x02003;Brain stem</p><p>&#x02022;&#x02003;Spinal cord</p></td><td>Up to 50%</td><td>High percentage of survivors have persistent neurologic disability.</td><td><p>&#x02022;&#x02003;Southeast Asia</p><p>&#x02022;&#x02003;Bangladesh</p><p>&#x02022;&#x02003;Pakistan</p></td></tr><tr><td>West Nile virus</td><td><p>&#x02022;&#x02003;Thalamus</p><p>&#x02022;&#x02003;Cerebellum</p><p>&#x02022;&#x02003;Substantia nigra</p><p>&#x02022;&#x02003;Pons</p><p>&#x02022;&#x02003;Medulla oblongata</p><p>&#x02022;&#x02003;Spinal cord</p></td><td>3&#x02013;15%</td><td>50&#x02013;75% of survivors have residual neurologic disability.</td><td><p>&#x02022;&#x02003;Africa</p><p>&#x02022;&#x02003;Eastern Europe</p><p>&#x02022;&#x02003;West Asia</p><p>&#x02022;&#x02003;Middle East</p><p>&#x02022;&#x02003;North America</p></td></tr><tr><td>Tick-borne encephalitis</td><td/><td>1&#x02013;10%</td><td>Small percentage develop chronic encephalitis with intractable epilepsy and progressive paralysis (Russian spring-summer encephalitis).</td><td/></tr></tbody></table></table-wrap></p><p id="Par637">Causative agents:<list list-type="bullet"><list-item><p id="Par638">Togaviridae</p></list-item><list-item><p id="Par639">Flaviviridae</p></list-item><list-item><p id="Par640">Reoviridae</p></list-item><list-item><p id="Par641">Bunyaviridae</p></list-item></list></p><p id="Par642">TBE is a caused by flavivirus<list list-type="bullet"><list-item><p id="Par643">Western Europe subtype, tick vector: <italic>Ixodes ricinus</italic></p></list-item><list-item><p id="Par644">Siberian subtype, tick vector: <italic>Ixodes persulcatus</italic></p></list-item><list-item><p id="Par645">Far eastern subtype, tick vector: <italic>Ixodes persulcatus</italic></p></list-item></list></p><sec id="Sec401"><title>Clinical Signs and Symptoms</title><p id="Par8891">
<list list-type="bullet"><list-item><p id="Par647">Meningitis typically manifests with<list list-type="bullet"><list-item><p id="Par648">High fever</p></list-item><list-item><p id="Par649">Headache</p></list-item><list-item><p id="Par650">Nausea</p></list-item><list-item><p id="Par651">Vomiting</p></list-item></list></p></list-item><list-item><p id="Par652">Encephalitis can be manifested by<list list-type="bullet"><list-item><p id="Par653">Impaired consciousness</p></list-item><list-item><p id="Par654">Somnolence</p></list-item><list-item><p id="Par655">Stupor</p></list-item><list-item><p id="Par656">Coma</p></list-item></list></p></list-item><list-item><p id="Par657">Myelitis</p></list-item><list-item><p id="Par658">Other manifestations comprise<list list-type="bullet"><list-item><p id="Par659">Personality changes</p></list-item><list-item><p id="Par660">Behavioral disorders</p></list-item><list-item><p id="Par661">Concentration and cognitive function disturbances</p></list-item><list-item><p id="Par662">Tongue fasciculations and tremor of extremities</p></list-item><list-item><p id="Par663">Focal or generalized seizures</p></list-item><list-item><p id="Par664">Delirium</p></list-item><list-item><p id="Par665">Psychosis</p></list-item></list></p></list-item></list>
</p></sec><sec id="Sec9010"><title>Epidemiology</title><p id="Par1112">
<list list-type="bullet"><title>Incidence</title><list-item><p id="Par646">Highly endemic areas (&#x02265;5 cases/100 000/year)</p></list-item></list>
</p></sec><sec id="Sec8001"><title>Neuroimaging Findings</title><p id="Par8792">
<list list-type="bullet"><title>General Imaging Features</title><list-item><p id="Par667">MRI and CT often normal, rarely lesions in thalamus, cerebellum, or basal ganglia</p></list-item></list>
<list list-type="bullet"><title>CT Non-Contrast-Enhanced</title><list-item><p id="Par668">Usually normal</p></list-item></list>
<list list-type="bullet"><title>MRI-T2/FLAIR (Fig. <xref rid="Fig14" ref-type="fig">26.14a, b</xref>)</title><list-item><p id="Par669">Lesions hyperintense</p></list-item></list>
<list list-type="bullet"><title>MRI-T1 (Fig. <xref rid="Fig14" ref-type="fig">26.14c</xref>)</title><list-item><p id="Par670">Lesions hypointense</p></list-item></list>
<list list-type="bullet"><title>MRI-T1 Contrast-Enhanced (Fig. <xref rid="Fig14" ref-type="fig">26.14d</xref>)</title><list-item><p id="Par671">Meningeal or parenchymal enhancement possible</p></list-item></list>
<list list-type="bullet"><title>MR-Diffusion Imaging (Fig. <xref rid="Fig14" ref-type="fig">26.14e</xref>)</title><list-item><p id="Par672">Restricted diffusion possible</p></list-item></list>
<list list-type="bullet"><title>MRI-ADC (Fig. <xref rid="Fig14" ref-type="fig">26.14f</xref>)</title><list-item><p id="Par673">Restricted diffusion possible</p></list-item></list>
<list list-type="bullet"><title>Nuclear Medicine Imaging Findings (Fig. <xref rid="Fig15" ref-type="fig">26.15</xref>)</title><list-item><p id="Par6731">decreased FDG uptake</p></list-item></list>
</p></sec><sec id="Sec123"><title>Neuropathology Findings</title><p id="Par666">
<list list-type="bullet"><title>Macroscopic Features</title><list-item><p id="Par674">moderate to sever congestion (Fig. <xref rid="Fig15" ref-type="fig">26.15</xref>)</p></list-item><list-item><p id="Par675">petechial hemorrhages</p></list-item></list>
<list list-type="bullet"><title>Microscopic Features (Fig. <xref rid="Fig16" ref-type="fig">26.16a&#x02013;l</xref>)</title><list-item><p id="Par676">lymphocytic infiltrates<list list-type="bullet"><list-item><p id="Par677">leptomeningeal</p></list-item><list-item><p id="Par678">perivascular</p></list-item><list-item><p id="Par679">parenchymal</p></list-item></list></p></list-item><list-item><p id="Par680">microglial nodules and macrophages</p></list-item><list-item><p id="Par681">focal necrosis of white matter myelinated fibers</p></list-item><list-item><p id="Par682">thrombosed small vessels</p></list-item></list>
</p></sec><sec id="Sec121"><title>Molecular Neuropathology</title><p id="Par9026">
<list list-type="bullet"><list-item><p id="Par683">Virus enters the vector (mosquito or tick) while it is feeding on the blood of an infected host.</p></list-item><list-item><p id="Par684">Is transmitted to other hosts in the salivary secretions of the vector.</p></list-item><list-item><p id="Par685">Natural hosts are birds or small mammals (rodents).</p></list-item><list-item><p id="Par686">Humans are dead-end hosts.</p></list-item><list-item><p id="Par687">Virus replicates at the site of host inoculation.</p></list-item><list-item><p id="Par688">Spreads to regional lymph nodes and other lymphoreticular tissues.</p></list-item><list-item><p id="Par689">Disseminates hematogenously to systemic tissues (CNS).</p></list-item></list>
</p></sec><sec id="Sec120"><title>Treatment and Prognosis</title><p id="Par9025">
<list list-type="bullet"><title>Treatment</title><list-item><p id="Par690">No specific drug therapy</p></list-item><list-item><p id="Par691">Corticosteroids</p></list-item><list-item><p id="Par692">Tracheal intubation and respiratory support</p></list-item></list>
<list list-type="bullet"><title>Outcome</title><list-item><p id="Par693">Complete restitution to fatal</p></list-item><list-item><p id="Par694">Prevention:<list list-type="bullet"><list-item><p id="Par695">vaccination</p></list-item></list></p></list-item></list>
<fig id="Fig14"><label>Fig. 26.14</label><caption><p>Tick-borne encephalitis with T2-hyperintensity and mild enhancement of thalami and basal ganglia. T2 (<bold>a</bold>), FLAIR (<bold>b</bold>), T1 (<bold>c</bold>), T1 contrast (<bold>d</bold>), DWI (<bold>e</bold>), ADC (<bold>f</bold>)</p></caption><graphic xlink:href="309569_1_En_26_Fig14a_HTML" id="d29e6162"/><graphic xlink:href="309569_1_En_26_Fig14b_HTML" id="d29e6163"/></fig>
<fig id="Fig15"><label>Fig. 26.15</label><caption><p>Tick-borne encephalitis: totally decreased FDG uptake in cerebral cortex</p></caption><graphic xlink:href="309569_1_En_26_Fig15_HTML" id="MO15"/></fig>
<fig id="Fig16"><label>Fig. 26.16</label><caption><p>Tick-borne encephalitis: histological examination reveals perivascular lymphocytic infiltrates (<bold>a</bold>, <bold>b</bold>) and the presence of gliomesenchymal nodules (<bold>c</bold>, <bold>d</bold>) which may contain multinucleated giant cells (<bold>e</bold>, <bold>f</bold>). The perivascular infiltrates are mainly made up of CD3-positive T-lymphocytes (<bold>g</bold>) which are also homing in the surrounding brain tissue (<bold>h</bold>). Reactive astrogliosis (stain: GFAP) (<bold>i</bold>, <bold>j</bold>) and reactive microgliosis (stain: HLA-DRII) (<bold>k</bold>, <bold>l</bold>) might be moderate</p></caption><graphic xlink:href="309569_1_En_26_Fig16a_HTML" id="d29e6221"/><graphic xlink:href="309569_1_En_26_Fig16b_HTML" id="d29e6222"/></fig>
</p></sec></sec></body><back><ref-list id="Bib1"><title>Selected References</title><ref id="CR1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abe</surname><given-names>H</given-names></name><name><surname>Mehraein</surname><given-names>P</given-names></name><name><surname>Weis</surname><given-names>S</given-names></name></person-group><article-title>Degeneration of the cerebellar dentate nucleus and the inferior olivary nuclei in HIV-1-infected brains: a morphometric analysis</article-title><source>Acta Neuropathol</source><year>1996</year><volume>92</volume><issue>2</issue><fpage>150</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">8841660</pub-id></element-citation></ref><ref id="CR2"><mixed-citation publication-type="other">Adang L, Berger J (2015) Progressive multifocal leukoencephalopathy. F1000Res:4. 10.12688/f1000research.7071.1</mixed-citation></ref><ref id="CR3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aksamit</surname><given-names>AJ</given-names><suffix>Jr</suffix></name></person-group><article-title>Progressive multifocal leukoencephalopathy</article-title><source>Continuum (Minneapolis, Minn)</source><year>2012</year><volume>18</volume><issue>6 Infectious Disease</issue><fpage>1374</fpage><lpage>1391</lpage></element-citation></ref><ref id="CR4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amicizia</surname><given-names>D</given-names></name><name><surname>Domnich</surname><given-names>A</given-names></name><name><surname>Panatto</surname><given-names>D</given-names></name><name><surname>Lai</surname><given-names>PL</given-names></name><name><surname>Cristina</surname><given-names>ML</given-names></name><name><surname>Avio</surname><given-names>U</given-names></name><name><surname>Gasparini</surname><given-names>R</given-names></name></person-group><article-title>Epidemiology of tick-borne encephalitis (TBE) in Europe and its prevention by available vaccines</article-title><source>Hum Vaccin Immunother</source><year>2013</year><volume>9</volume><issue>5</issue><fpage>1163</fpage><lpage>1171</lpage><pub-id pub-id-type="pmid">23377671</pub-id></element-citation></ref><ref id="CR5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ances</surname><given-names>BM</given-names></name><name><surname>Hammoud</surname><given-names>DA</given-names></name></person-group><article-title>Neuroimaging of HIV-associated neurocognitive disorders (HAND)</article-title><source>Curr Opin HIV AIDS</source><year>2014</year><volume>9</volume><issue>6</issue><fpage>545</fpage><lpage>551</lpage><pub-id pub-id-type="pmid">25250553</pub-id></element-citation></ref><ref id="CR6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andreula</surname><given-names>C</given-names></name></person-group><article-title>Cranial viral infections in the adult</article-title><source>Eur Radiol</source><year>2004</year><volume>14</volume><issue>Suppl 3</issue><fpage>E132</fpage><lpage>E144</lpage><pub-id pub-id-type="pmid">14749962</pub-id></element-citation></ref><ref id="CR7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antinori</surname><given-names>A</given-names></name><name><surname>Arendt</surname><given-names>G</given-names></name><name><surname>Becker</surname><given-names>JT</given-names></name><name><surname>Brew</surname><given-names>BJ</given-names></name><name><surname>Byrd</surname><given-names>DA</given-names></name><name><surname>Cherner</surname><given-names>M</given-names></name><name><surname>Clifford</surname><given-names>DB</given-names></name><name><surname>Cinque</surname><given-names>P</given-names></name><name><surname>Epstein</surname><given-names>LG</given-names></name><name><surname>Goodkin</surname><given-names>K</given-names></name><name><surname>Gisslen</surname><given-names>M</given-names></name><name><surname>Grant</surname><given-names>I</given-names></name><name><surname>Heaton</surname><given-names>RK</given-names></name><name><surname>Joseph</surname><given-names>J</given-names></name><name><surname>Marder</surname><given-names>K</given-names></name><name><surname>Marra</surname><given-names>CM</given-names></name><name><surname>McArthur</surname><given-names>JC</given-names></name><name><surname>Nunn</surname><given-names>M</given-names></name><name><surname>Price</surname><given-names>RW</given-names></name><name><surname>Pulliam</surname><given-names>L</given-names></name><name><surname>Robertson</surname><given-names>KR</given-names></name><name><surname>Sacktor</surname><given-names>N</given-names></name><name><surname>Valcour</surname><given-names>V</given-names></name><name><surname>Wojna</surname><given-names>VE</given-names></name></person-group><article-title>Updated research nosology for HIV-associated neurocognitive disorders</article-title><source>Neurology</source><year>2007</year><volume>69</volume><issue>18</issue><fpage>1789</fpage><lpage>1799</lpage><pub-id pub-id-type="pmid">17914061</pub-id></element-citation></ref><ref id="CR8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aurelian</surname><given-names>L</given-names></name></person-group><article-title>HSV-induced apoptosis in herpes encephalitis</article-title><source>Curr Top Microbiol Immunol</source><year>2005</year><volume>289</volume><fpage>79</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">15791952</pub-id></element-citation></ref><ref id="CR9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bale</surname><given-names>JF</given-names><suffix>Jr</suffix></name></person-group><article-title>Congenital cytomegalovirus infection</article-title><source>Handb Clin Neurol</source><year>2014</year><volume>123</volume><fpage>319</fpage><lpage>326</lpage><pub-id pub-id-type="pmid">25015493</pub-id></element-citation></ref><ref id="CR10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baringer</surname><given-names>JR</given-names></name></person-group><article-title>Herpes simplex infections of the nervous system</article-title><source>Neurol Clin</source><year>2008</year><volume>26</volume><issue>3</issue><fpage>657</fpage><lpage>674, viii</lpage><pub-id pub-id-type="pmid">18657720</pub-id></element-citation></ref><ref id="CR11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baskin</surname><given-names>HJ</given-names></name><name><surname>Hedlund</surname><given-names>G</given-names></name></person-group><article-title>Neuroimaging of herpesvirus infections in children</article-title><source>Pediatr Radiol</source><year>2007</year><volume>37</volume><issue>10</issue><fpage>949</fpage><lpage>963</lpage><pub-id pub-id-type="pmid">17572889</pub-id></element-citation></ref><ref id="CR12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>J</given-names></name><name><surname>Gold</surname><given-names>R</given-names></name><name><surname>Adams</surname><given-names>O</given-names></name><name><surname>Lassmann</surname><given-names>H</given-names></name></person-group><article-title>Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome (IRIS)</article-title><source>Acta Neuropathol</source><year>2015</year><volume>130</volume><issue>6</issue><fpage>751</fpage><lpage>764</lpage><pub-id pub-id-type="pmid">26323992</pub-id></element-citation></ref><ref id="CR13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellizzi</surname><given-names>A</given-names></name><name><surname>Anzivino</surname><given-names>E</given-names></name><name><surname>Rodio</surname><given-names>DM</given-names></name><name><surname>Palamara</surname><given-names>AT</given-names></name><name><surname>Nencioni</surname><given-names>L</given-names></name><name><surname>Pietropaolo</surname><given-names>V</given-names></name></person-group><article-title>New insights on human polyomavirus JC and pathogenesis of progressive multifocal leukoencephalopathy</article-title><source>Clin Dev Immunol</source><year>2013</year><volume>2013</volume><fpage>839719</fpage><pub-id pub-id-type="pmid">23690827</pub-id></element-citation></ref><ref id="CR14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beltrami</surname><given-names>S</given-names></name><name><surname>Gordon</surname><given-names>J</given-names></name></person-group><article-title>Immune surveillance and response to JC virus infection and PML</article-title><source>J Neurovirol</source><year>2014</year><volume>20</volume><issue>2</issue><fpage>137</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">24297501</pub-id></element-citation></ref><ref id="CR15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>JR</given-names></name></person-group><article-title>The clinical features of PML</article-title><source>Cleve Clin J Med</source><year>2011</year><volume>78</volume><issue>Suppl 2</issue><fpage>S8</fpage><lpage>S12</lpage><pub-id pub-id-type="pmid">22123935</pub-id></element-citation></ref><ref id="CR16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>JR</given-names></name></person-group><article-title>Progressive multifocal leukoencephalopathy</article-title><source>Handb Clin Neurol</source><year>2014</year><volume>123</volume><fpage>357</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">25015495</pub-id></element-citation></ref><ref id="CR17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>JR</given-names></name></person-group><article-title>Classifying PML risk with disease modifying therapies</article-title><source>Mult Scler Relat Disord</source><year>2017</year><volume>12</volume><fpage>59</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">28283109</pub-id></element-citation></ref><ref id="CR18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>JR</given-names></name><name><surname>Khalili</surname><given-names>K</given-names></name></person-group><article-title>The pathogenesis of progressive multifocal leukoencephalopathy</article-title><source>Discov Med</source><year>2011</year><volume>12</volume><issue>67</issue><fpage>495</fpage><lpage>503</lpage><pub-id pub-id-type="pmid">22204766</pub-id></element-citation></ref><ref id="CR19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>JR</given-names></name><name><surname>Aksamit</surname><given-names>AJ</given-names></name><name><surname>Clifford</surname><given-names>DB</given-names></name><name><surname>Davis</surname><given-names>L</given-names></name><name><surname>Koralnik</surname><given-names>IJ</given-names></name><name><surname>Sejvar</surname><given-names>JJ</given-names></name><name><surname>Bartt</surname><given-names>R</given-names></name><name><surname>Major</surname><given-names>EO</given-names></name><name><surname>Nath</surname><given-names>A</given-names></name></person-group><article-title>PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section</article-title><source>Neurology</source><year>2013</year><volume>80</volume><issue>15</issue><fpage>1430</fpage><lpage>1438</lpage><pub-id pub-id-type="pmid">23568998</pub-id></element-citation></ref><ref id="CR20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birkmann</surname><given-names>A</given-names></name><name><surname>Zimmermann</surname><given-names>H</given-names></name></person-group><article-title>HSV antivirals&#x02014;current and future treatment options</article-title><source>Curr Opin Virol</source><year>2016</year><volume>18</volume><fpage>9</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">26897058</pub-id></element-citation></ref><ref id="CR21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bloom</surname><given-names>DC</given-names></name></person-group><article-title>HSV LAT and neuronal survival</article-title><source>Int Rev Immunol</source><year>2004</year><volume>23</volume><issue>1&#x02013;2</issue><fpage>187</fpage><lpage>198</lpage><pub-id pub-id-type="pmid">14690860</pub-id></element-citation></ref><ref id="CR22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bradshaw</surname><given-names>MJ</given-names></name><name><surname>Venkatesan</surname><given-names>A</given-names></name></person-group><article-title>Herpes simplex virus-1 encephalitis in adults: pathophysiology, diagnosis, and management</article-title><source>Neurotherapeutics</source><year>2016</year><volume>13</volume><issue>3</issue><fpage>493</fpage><lpage>508</lpage><pub-id pub-id-type="pmid">27106239</pub-id></element-citation></ref><ref id="CR23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>JC</given-names></name></person-group><article-title>Herpes simplex virus latency: the DNA repair-centered pathway</article-title><source>Adv Virol</source><year>2017</year><volume>2017</volume><fpage>7028194</fpage><pub-id pub-id-type="pmid">28255301</pub-id></element-citation></ref><ref id="CR24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buttner</surname><given-names>A</given-names></name><name><surname>Mehraein</surname><given-names>P</given-names></name><name><surname>Weis</surname><given-names>S</given-names></name></person-group><article-title>Vascular changes in the cerebral cortex in HIV-1 infection. II An immunohistochemical and lectinhistochemical investigation</article-title><source>Acta Neuropathol</source><year>1996</year><volume>92</volume><issue>1</issue><fpage>35</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">8811123</pub-id></element-citation></ref><ref id="CR25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cantey</surname><given-names>JB</given-names></name><name><surname>Sanchez</surname><given-names>PJ</given-names></name></person-group><article-title>Neonatal herpes simplex virus infections: past progress and future challenges</article-title><source>Pediatr Infect Dis J</source><year>2013</year><volume>32</volume><issue>11</issue><fpage>1205</fpage><lpage>1207</lpage><pub-id pub-id-type="pmid">24141798</pub-id></element-citation></ref><ref id="CR26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carletti</surname><given-names>T</given-names></name><name><surname>Zakaria</surname><given-names>MK</given-names></name><name><surname>Marcello</surname><given-names>A</given-names></name></person-group><article-title>The host cell response to tick-borne encephalitis virus</article-title><source>Biochem Biophys Res Commun</source><year>2017</year><volume>492</volume><issue>4</issue><fpage>533</fpage><lpage>540</lpage><pub-id pub-id-type="pmid">28167278</pub-id></element-citation></ref><ref id="CR27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carroll</surname><given-names>A</given-names></name><name><surname>Brew</surname><given-names>B</given-names></name></person-group><article-title>HIV-associated neurocognitive disorders: recent advances in pathogenesis, biomarkers, and treatment</article-title><source>F1000Res</source><year>2017</year><volume>6</volume><fpage>312</fpage><pub-id pub-id-type="pmid">28413625</pub-id></element-citation></ref><ref id="CR28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chahroudi</surname><given-names>A</given-names></name><name><surname>Silvestri</surname><given-names>G</given-names></name></person-group><article-title>IRIS: the unfortunate rainbow of HIV</article-title><source>Blood</source><year>2012</year><volume>119</volume><issue>13</issue><fpage>2971</fpage><lpage>2972</lpage><pub-id pub-id-type="pmid">22461468</pub-id></element-citation></ref><ref id="CR29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>MF</given-names></name><name><surname>Gill</surname><given-names>AJ</given-names></name><name><surname>Kolson</surname><given-names>DL</given-names></name></person-group><article-title>Neuropathogenesis of HIV-associated neurocognitive disorders: roles for immune activation, HIV blipping and viral tropism</article-title><source>Curr Opin HIV AIDS</source><year>2014</year><volume>9</volume><issue>6</issue><fpage>559</fpage><lpage>564</lpage><pub-id pub-id-type="pmid">25203638</pub-id></element-citation></ref><ref id="CR30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciardi</surname><given-names>A</given-names></name><name><surname>Sinclair</surname><given-names>E</given-names></name><name><surname>Scaravilli</surname><given-names>F</given-names></name><name><surname>Harcourt-Webster</surname><given-names>NJ</given-names></name><name><surname>Lucas</surname><given-names>S</given-names></name></person-group><article-title>The involvement of the cerebral cortex in human immunodeficiency virus encephalopathy: a morphological and immunohistochemical study</article-title><source>Acta Neuropathol</source><year>1990</year><volume>81</volume><issue>1</issue><fpage>51</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">2085094</pub-id></element-citation></ref><ref id="CR31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cinque</surname><given-names>P</given-names></name><name><surname>Koralnik</surname><given-names>IJ</given-names></name><name><surname>Gerevini</surname><given-names>S</given-names></name><name><surname>Miro</surname><given-names>JM</given-names></name><name><surname>Price</surname><given-names>RW</given-names></name></person-group><article-title>Progressive multifocal leukoencephalopathy in HIV-1 infection</article-title><source>Lancet Infect Dis</source><year>2009</year><volume>9</volume><issue>10</issue><fpage>625</fpage><lpage>636</lpage><pub-id pub-id-type="pmid">19778765</pub-id></element-citation></ref><ref id="CR32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clifford</surname><given-names>DB</given-names></name><name><surname>Ances</surname><given-names>BM</given-names></name></person-group><article-title>HIV-associated neurocognitive disorder</article-title><source>Lancet Infect Dis</source><year>2013</year><volume>13</volume><issue>11</issue><fpage>976</fpage><lpage>986</lpage><pub-id pub-id-type="pmid">24156898</pub-id></element-citation></ref><ref id="CR33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corey</surname><given-names>L</given-names></name><name><surname>Wald</surname><given-names>A</given-names></name></person-group><article-title>Maternal and neonatal herpes simplex virus infections</article-title><source>N Engl J Med</source><year>2009</year><volume>361</volume><issue>14</issue><fpage>1376</fpage><lpage>1385</lpage><pub-id pub-id-type="pmid">19797284</pub-id></element-citation></ref><ref id="CR34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del Valle</surname><given-names>L</given-names></name><name><surname>Pina-Oviedo</surname><given-names>S</given-names></name></person-group><article-title>HIV disorders of the brain: pathology and pathogenesis</article-title><source>Front Biosci</source><year>2006</year><volume>11</volume><fpage>718</fpage><lpage>732</lpage><pub-id pub-id-type="pmid">16146764</pub-id></element-citation></ref><ref id="CR35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desai</surname><given-names>DV</given-names></name><name><surname>Kulkarni</surname><given-names>SS</given-names></name></person-group><article-title>Herpes simplex virus: the interplay between HSV, host, and HIV-1</article-title><source>Viral Immunol</source><year>2015</year><volume>28</volume><issue>10</issue><fpage>546</fpage><lpage>555</lpage><pub-id pub-id-type="pmid">26331265</pub-id></element-citation></ref><ref id="CR36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Descamps</surname><given-names>M</given-names></name><name><surname>Hyare</surname><given-names>H</given-names></name><name><surname>Stebbing</surname><given-names>J</given-names></name><name><surname>Winston</surname><given-names>A</given-names></name></person-group><article-title>Magnetic resonance imaging and spectroscopy of the brain in HIV disease</article-title><source>J HIV Ther</source><year>2008</year><volume>13</volume><issue>3</issue><fpage>55</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">19039299</pub-id></element-citation></ref><ref id="CR37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dorrbecker</surname><given-names>B</given-names></name><name><surname>Dobler</surname><given-names>G</given-names></name><name><surname>Spiegel</surname><given-names>M</given-names></name><name><surname>Hufert</surname><given-names>FT</given-names></name></person-group><article-title>Tick-borne encephalitis virus and the immune response of the mammalian host</article-title><source>Travel Med Infect Dis</source><year>2010</year><volume>8</volume><issue>4</issue><fpage>213</fpage><lpage>222</lpage><pub-id pub-id-type="pmid">20970724</pub-id></element-citation></ref><ref id="CR38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eggers</surname><given-names>C</given-names></name><name><surname>Arendt</surname><given-names>G</given-names></name><name><surname>Hahn</surname><given-names>K</given-names></name><name><surname>Husstedt</surname><given-names>IW</given-names></name><name><surname>Maschke</surname><given-names>M</given-names></name><name><surname>Neuen-Jacob</surname><given-names>E</given-names></name><name><surname>Obermann</surname><given-names>M</given-names></name><name><surname>Rosenkranz</surname><given-names>T</given-names></name><name><surname>Schielke</surname><given-names>E</given-names></name><name><surname>Straube</surname><given-names>E</given-names></name></person-group><article-title>HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment</article-title><source>J Neurol</source><year>2017</year><volume>264</volume><issue>8</issue><fpage>1715</fpage><lpage>1727</lpage><pub-id pub-id-type="pmid">28567537</pub-id></element-citation></ref><ref id="CR39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellis</surname><given-names>R</given-names></name><name><surname>Langford</surname><given-names>D</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name></person-group><article-title>HIV and antiretroviral therapy in the brain: neuronal injury and repair</article-title><source>Nat Rev Neurosci</source><year>2007</year><volume>8</volume><issue>1</issue><fpage>33</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">17180161</pub-id></element-citation></ref><ref id="CR40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esiri</surname><given-names>MM</given-names></name><name><surname>Morris</surname><given-names>CS</given-names></name><name><surname>Millard</surname><given-names>PR</given-names></name></person-group><article-title>Fate of oligodendrocytes in HIV-1 infection</article-title><source>AIDS (London, England)</source><year>1991</year><volume>5</volume><issue>9</issue><fpage>1081</fpage><lpage>1088</lpage></element-citation></ref><ref id="CR41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Everall</surname><given-names>I</given-names></name><name><surname>Luthert</surname><given-names>P</given-names></name><name><surname>Lantos</surname><given-names>P</given-names></name></person-group><article-title>A review of neuronal damage in human immunodeficiency virus infection: its assessment, possible mechanism and relationship to dementia</article-title><source>J Neuropathol Exp Neurol</source><year>1993</year><volume>52</volume><issue>6</issue><fpage>561</fpage><lpage>566</lpage><pub-id pub-id-type="pmid">8229074</pub-id></element-citation></ref><ref id="CR42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferenczy</surname><given-names>MW</given-names></name><name><surname>Marshall</surname><given-names>LJ</given-names></name><name><surname>Nelson</surname><given-names>CD</given-names></name><name><surname>Atwood</surname><given-names>WJ</given-names></name><name><surname>Nath</surname><given-names>A</given-names></name><name><surname>Khalili</surname><given-names>K</given-names></name><name><surname>Major</surname><given-names>EO</given-names></name></person-group><article-title>Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain</article-title><source>Clin Microbiol Rev</source><year>2012</year><volume>25</volume><issue>3</issue><fpage>471</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">22763635</pub-id></element-citation></ref><ref id="CR43"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Force WGotAAoNAT</collab></person-group><article-title>Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force</article-title><source>Neurology</source><year>1991</year><volume>41</volume><issue>6</issue><fpage>778</fpage><lpage>785</lpage><pub-id pub-id-type="pmid">2046917</pub-id></element-citation></ref><ref id="CR44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fournier</surname><given-names>A</given-names></name><name><surname>Martin-Blondel</surname><given-names>G</given-names></name><name><surname>Lechapt-Zalcman</surname><given-names>E</given-names></name><name><surname>Dina</surname><given-names>J</given-names></name><name><surname>Kazemi</surname><given-names>A</given-names></name><name><surname>Verdon</surname><given-names>R</given-names></name><name><surname>Mortier</surname><given-names>E</given-names></name><name><surname>de La Blanchardiere</surname><given-names>A</given-names></name></person-group><article-title>Immune reconstitution inflammatory syndrome unmasking or worsening AIDS-related progressive multifocal leukoencephalopathy: a literature review</article-title><source>Front Immunol</source><year>2017</year><volume>8</volume><fpage>577</fpage><pub-id pub-id-type="pmid">28588577</pub-id></element-citation></ref><ref id="CR45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garden</surname><given-names>GA</given-names></name></person-group><article-title>Microglia in human immunodeficiency virus-associated neurodegeneration</article-title><source>Glia</source><year>2002</year><volume>40</volume><issue>2</issue><fpage>240</fpage><lpage>251</lpage><pub-id pub-id-type="pmid">12379911</pub-id></element-citation></ref><ref id="CR46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gartner</surname><given-names>S</given-names></name></person-group><article-title>HIV infection and dementia</article-title><source>Science (New York, NY)</source><year>2000</year><volume>287</volume><issue>5453</issue><fpage>602</fpage><lpage>604</lpage></element-citation></ref><ref id="CR47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gelman</surname><given-names>BB</given-names></name><name><surname>Guinto</surname><given-names>FC</given-names><suffix>Jr</suffix></name></person-group><article-title>Morphometry, histopathology, and tomography of cerebral atrophy in the acquired immunodeficiency syndrome</article-title><source>Ann Neurol</source><year>1992</year><volume>32</volume><issue>1</issue><fpage>31</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">1642470</pub-id></element-citation></ref><ref id="CR48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gendelman</surname><given-names>HE</given-names></name><name><surname>Lipton</surname><given-names>SA</given-names></name><name><surname>Tardieu</surname><given-names>M</given-names></name><name><surname>Bukrinsky</surname><given-names>MI</given-names></name><name><surname>Nottet</surname><given-names>HS</given-names></name></person-group><article-title>The neuropathogenesis of HIV-1 infection</article-title><source>J Leukoc Biol</source><year>1994</year><volume>56</volume><issue>3</issue><fpage>389</fpage><lpage>398</lpage><pub-id pub-id-type="pmid">8083614</pub-id></element-citation></ref><ref id="CR49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gheuens</surname><given-names>S</given-names></name><name><surname>Wuthrich</surname><given-names>C</given-names></name><name><surname>Koralnik</surname><given-names>IJ</given-names></name></person-group><article-title>Progressive multifocal leukoencephalopathy: why gray and white matter</article-title><source>Annu Rev Pathol</source><year>2013</year><volume>8</volume><fpage>189</fpage><lpage>215</lpage><pub-id pub-id-type="pmid">23092189</pub-id></element-citation></ref><ref id="CR50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilden</surname><given-names>DH</given-names></name></person-group><article-title>Brain imaging abnormalities in CNS virus infections</article-title><source>Neurology</source><year>2008</year><volume>70</volume><issue>1</issue><fpage>84</fpage><pub-id pub-id-type="pmid">18166713</pub-id></element-citation></ref><ref id="CR51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gnann</surname><given-names>JW</given-names><suffix>Jr</suffix></name><name><surname>Whitley</surname><given-names>RJ</given-names></name></person-group><article-title>Herpes simplex encephalitis: an update</article-title><source>Curr Infect Dis Rep</source><year>2017</year><volume>19</volume><issue>3</issue><fpage>13</fpage><pub-id pub-id-type="pmid">28251511</pub-id></element-citation></ref><ref id="CR52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gougeon</surname><given-names>ML</given-names></name></person-group><article-title>Alarmins and central nervous system inflammation in HIV-associated neurological disorders</article-title><source>J Intern Med</source><year>2017</year><volume>281</volume><issue>5</issue><fpage>433</fpage><lpage>447</lpage><pub-id pub-id-type="pmid">27862491</pub-id></element-citation></ref><ref id="CR53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>F</given-names></name><name><surname>Gherardi</surname><given-names>R</given-names></name><name><surname>Scaravilli</surname><given-names>F</given-names></name></person-group><article-title>The neuropathology of the acquired immune deficiency syndrome (AIDS). A review</article-title><source>Brain J Neurol</source><year>1988</year><volume>111</volume><issue>Pt 2</issue><fpage>245</fpage><lpage>266</lpage></element-citation></ref><ref id="CR54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>F</given-names></name><name><surname>Lescs</surname><given-names>MC</given-names></name><name><surname>Keohane</surname><given-names>C</given-names></name><name><surname>Paraire</surname><given-names>F</given-names></name><name><surname>Marc</surname><given-names>B</given-names></name><name><surname>Durigon</surname><given-names>M</given-names></name><name><surname>Gherardi</surname><given-names>R</given-names></name></person-group><article-title>Early brain changes in HIV infection: neuropathological study of 11 HIV seropositive, non-AIDS cases</article-title><source>J Neuropathol Exp Neurol</source><year>1992</year><volume>51</volume><issue>2</issue><fpage>177</fpage><lpage>185</lpage><pub-id pub-id-type="pmid">1538241</pub-id></element-citation></ref><ref id="CR55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>F</given-names></name><name><surname>Chretien</surname><given-names>F</given-names></name><name><surname>Vallat-Decouvelaere</surname><given-names>AV</given-names></name><name><surname>Scaravilli</surname><given-names>F</given-names></name></person-group><article-title>The changing pattern of HIV neuropathology in the HAART era</article-title><source>J Neuropathol Exp Neurol</source><year>2003</year><volume>62</volume><issue>5</issue><fpage>429</fpage><lpage>440</lpage><pub-id pub-id-type="pmid">12769183</pub-id></element-citation></ref><ref id="CR56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grosche</surname><given-names>L</given-names></name><name><surname>Kummer</surname><given-names>M</given-names></name><name><surname>Steinkasserer</surname><given-names>A</given-names></name></person-group><article-title>What goes around, comes around&#x02014;HSV-1 replication in monocyte-derived dendritic cells</article-title><source>Front Microbiol</source><year>2017</year><volume>8</volume><fpage>2149</fpage><pub-id pub-id-type="pmid">29163433</pub-id></element-citation></ref><ref id="CR57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartman</surname><given-names>EA</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name></person-group><article-title>Update on PML: lessons from the HIV uninfected and new insights in pathogenesis and treatment</article-title><source>Curr HIV/AIDS Rep</source><year>2008</year><volume>5</volume><issue>3</issue><fpage>112</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">18627659</pub-id></element-citation></ref><ref id="CR58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holt</surname><given-names>JL</given-names></name><name><surname>Kraft-Terry</surname><given-names>SD</given-names></name><name><surname>Chang</surname><given-names>L</given-names></name></person-group><article-title>Neuroimaging studies of the aging HIV-1-infected brain</article-title><source>J Neurovirol</source><year>2012</year><volume>18</volume><issue>4</issue><fpage>291</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">22653528</pub-id></element-citation></ref><ref id="CR59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honce</surname><given-names>JM</given-names></name><name><surname>Nagae</surname><given-names>L</given-names></name><name><surname>Nyberg</surname><given-names>E</given-names></name></person-group><article-title>Neuroimaging of natalizumab complications in multiple sclerosis: PML and other associated entities</article-title><source>Mult Scler Int</source><year>2015</year><volume>2015</volume><fpage>809252</fpage><pub-id pub-id-type="pmid">26483978</pub-id></element-citation></ref><ref id="CR60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>S</given-names></name><name><surname>Banks</surname><given-names>WA</given-names></name></person-group><article-title>Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications</article-title><source>Brain Behav Immun</source><year>2015</year><volume>45</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">25449672</pub-id></element-citation></ref><ref id="CR61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horger</surname><given-names>M</given-names></name><name><surname>Beck</surname><given-names>R</given-names></name><name><surname>Fenchel</surname><given-names>M</given-names></name><name><surname>Ernemann</surname><given-names>U</given-names></name><name><surname>Nagele</surname><given-names>T</given-names></name><name><surname>Brodoefel</surname><given-names>H</given-names></name><name><surname>Heckl</surname><given-names>S</given-names></name></person-group><article-title>Imaging findings in tick-borne encephalitis with differential diagnostic considerations</article-title><source>AJR Am J Roentgenol</source><year>2012</year><volume>199</volume><issue>2</issue><fpage>420</fpage><lpage>427</lpage><pub-id pub-id-type="pmid">22826407</pub-id></element-citation></ref><ref id="CR62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horger</surname><given-names>M</given-names></name><name><surname>Beschorner</surname><given-names>R</given-names></name><name><surname>Beck</surname><given-names>R</given-names></name><name><surname>Nagele</surname><given-names>T</given-names></name><name><surname>Schulze</surname><given-names>M</given-names></name><name><surname>Ernemann</surname><given-names>U</given-names></name><name><surname>Heckl</surname><given-names>S</given-names></name></person-group><article-title>Common and uncommon imaging findings in progressive multifocal leukoencephalopathy (PML) with differential diagnostic considerations</article-title><source>Clin Neurol Neurosurg</source><year>2012</year><volume>114</volume><issue>8</issue><fpage>1123</fpage><lpage>1130</lpage><pub-id pub-id-type="pmid">22771304</pub-id></element-citation></ref><ref id="CR63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>XT</given-names></name></person-group><article-title>HIV-1 tat-mediated calcium dysregulation and neuronal dysfunction in vulnerable brain regions</article-title><source>Curr Drug Targets</source><year>2016</year><volume>17</volume><issue>1</issue><fpage>4</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">26028040</pub-id></element-citation></ref><ref id="CR64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Itoh</surname><given-names>K</given-names></name><name><surname>Mehraein</surname><given-names>P</given-names></name><name><surname>Weis</surname><given-names>S</given-names></name></person-group><article-title>Neuronal damage of the substantia nigra in HIV-1 infected brains</article-title><source>Acta Neuropathol</source><year>2000</year><volume>99</volume><issue>4</issue><fpage>376</fpage><lpage>384</lpage><pub-id pub-id-type="pmid">10787036</pub-id></element-citation></ref><ref id="CR65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jelcic</surname><given-names>I</given-names></name><name><surname>Jelcic</surname><given-names>I</given-names></name><name><surname>Faigle</surname><given-names>W</given-names></name><name><surname>Sospedra</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>R</given-names></name></person-group><article-title>Immunology of progressive multifocal leukoencephalopathy</article-title><source>J Neurovirol</source><year>2015</year><volume>21</volume><issue>6</issue><fpage>614</fpage><lpage>622</lpage><pub-id pub-id-type="pmid">25740538</pub-id></element-citation></ref><ref id="CR66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jellinger</surname><given-names>KA</given-names></name><name><surname>Setinek</surname><given-names>U</given-names></name><name><surname>Drlicek</surname><given-names>M</given-names></name><name><surname>Bohm</surname><given-names>G</given-names></name><name><surname>Steurer</surname><given-names>A</given-names></name><name><surname>Lintner</surname><given-names>F</given-names></name></person-group><article-title>Neuropathology and general autopsy findings in AIDS during the last 15 years</article-title><source>Acta Neuropathol</source><year>2000</year><volume>100</volume><issue>2</issue><fpage>213</fpage><lpage>220</lpage><pub-id pub-id-type="pmid">10963370</pub-id></element-citation></ref><ref id="CR67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>YC</given-names></name><name><surname>Feng</surname><given-names>H</given-names></name><name><surname>Lin</surname><given-names>YC</given-names></name><name><surname>Guo</surname><given-names>XR</given-names></name></person-group><article-title>New strategies against drug resistance to herpes simplex virus</article-title><source>Int J Oral Sci</source><year>2016</year><volume>8</volume><issue>1</issue><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">27025259</pub-id></element-citation></ref><ref id="CR68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joseph</surname><given-names>J</given-names></name><name><surname>Colosi</surname><given-names>DA</given-names></name><name><surname>Rao</surname><given-names>VR</given-names></name></person-group><article-title>HIV-1 induced CNS dysfunction: current overview and research priorities</article-title><source>Curr HIV Res</source><year>2016</year><volume>14</volume><issue>5</issue><fpage>389</fpage><lpage>399</lpage><pub-id pub-id-type="pmid">27009096</pub-id></element-citation></ref><ref id="CR69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaiser</surname><given-names>R</given-names></name></person-group><article-title>Tick-borne encephalitis</article-title><source>Infect Dis Clin N Am</source><year>2008</year><volume>22</volume><issue>3</issue><fpage>561</fpage><lpage>575, x</lpage></element-citation></ref><ref id="CR70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kastrup</surname><given-names>O</given-names></name><name><surname>Wanke</surname><given-names>I</given-names></name><name><surname>Maschke</surname><given-names>M</given-names></name></person-group><article-title>Neuroimaging of infections</article-title><source>NeuroRx</source><year>2005</year><volume>2</volume><issue>2</issue><fpage>324</fpage><lpage>332</lpage><pub-id pub-id-type="pmid">15897953</pub-id></element-citation></ref><ref id="CR71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kastrup</surname><given-names>O</given-names></name><name><surname>Wanke</surname><given-names>I</given-names></name><name><surname>Maschke</surname><given-names>M</given-names></name></person-group><article-title>Neuroimaging of infections of the central nervous system</article-title><source>Semin Neurol</source><year>2008</year><volume>28</volume><issue>4</issue><fpage>511</fpage><lpage>522</lpage><pub-id pub-id-type="pmid">18843578</pub-id></element-citation></ref><ref id="CR72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaul</surname><given-names>M</given-names></name><name><surname>Garden</surname><given-names>GA</given-names></name><name><surname>Lipton</surname><given-names>SA</given-names></name></person-group><article-title>Pathways to neuronal injury and apoptosis in HIV-associated dementia</article-title><source>Nature</source><year>2001</year><volume>410</volume><issue>6831</issue><fpage>988</fpage><lpage>994</lpage><pub-id pub-id-type="pmid">11309629</pub-id></element-citation></ref><ref id="CR73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ketzler</surname><given-names>S</given-names></name><name><surname>Weis</surname><given-names>S</given-names></name><name><surname>Haug</surname><given-names>H</given-names></name><name><surname>Budka</surname><given-names>H</given-names></name></person-group><article-title>Loss of neurons in the frontal cortex in AIDS brains</article-title><source>Acta Neuropathol</source><year>1990</year><volume>80</volume><issue>1</issue><fpage>92</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">2360420</pub-id></element-citation></ref><ref id="CR74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolson</surname><given-names>DL</given-names></name></person-group><article-title>Neuropathogenesis of central nervous system HIV-1 infection</article-title><source>Clin Lab Med</source><year>2002</year><volume>22</volume><issue>3</issue><fpage>703</fpage><lpage>717</lpage><pub-id pub-id-type="pmid">12244593</pub-id></element-citation></ref><ref id="CR75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolson</surname><given-names>D</given-names></name></person-group><article-title>Neurologic complications in persons with HIV infection in the era of antiretroviral therapy</article-title><source>Top Antivir Med</source><year>2017</year><volume>25</volume><issue>3</issue><fpage>97</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">28820724</pub-id></element-citation></ref><ref id="CR76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kozlowski</surname><given-names>PB</given-names></name><name><surname>Sher</surname><given-names>JH</given-names></name><name><surname>Rao</surname><given-names>C</given-names></name><name><surname>Anzil</surname><given-names>PA</given-names></name><name><surname>Wrzolek</surname><given-names>MA</given-names></name><name><surname>Sharer</surname><given-names>L</given-names></name><name><surname>Cho</surname><given-names>ES</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Weidenheim</surname><given-names>KM</given-names></name><name><surname>Llena</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Central nervous system in pediatric AIDS. Results from Neuropathologic Pediatric AIDS Registry</article-title><source>Ann N Y Acad Sci</source><year>1993</year><volume>693</volume><fpage>295</fpage><lpage>296</lpage><pub-id pub-id-type="pmid">8267284</pub-id></element-citation></ref><ref id="CR77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamers</surname><given-names>SL</given-names></name><name><surname>Rose</surname><given-names>R</given-names></name><name><surname>Ndhlovu</surname><given-names>LC</given-names></name><name><surname>Nolan</surname><given-names>DJ</given-names></name><name><surname>Salemi</surname><given-names>M</given-names></name><name><surname>Maidji</surname><given-names>E</given-names></name><name><surname>Stoddart</surname><given-names>CA</given-names></name><name><surname>McGrath</surname><given-names>MS</given-names></name></person-group><article-title>The meningeal lymphatic system: a route for HIV brain migration?</article-title><source>J Neurovirol</source><year>2016</year><volume>22</volume><issue>3</issue><fpage>275</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">26572785</pub-id></element-citation></ref><ref id="CR78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langford</surname><given-names>TD</given-names></name><name><surname>Letendre</surname><given-names>SL</given-names></name><name><surname>Larrea</surname><given-names>GJ</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name></person-group><article-title>Changing patterns in the neuropathogenesis of HIV during the HAART era</article-title><source>Brain Pathol (Zurich, Switzerland)</source><year>2003</year><volume>13</volume><issue>2</issue><fpage>195</fpage><lpage>210</lpage></element-citation></ref><ref id="CR79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laothamatas</surname><given-names>J</given-names></name><name><surname>Hemachudha</surname><given-names>T</given-names></name><name><surname>Mitrabhakdi</surname><given-names>E</given-names></name><name><surname>Wannakrairot</surname><given-names>P</given-names></name><name><surname>Tulayadaechanont</surname><given-names>S</given-names></name></person-group><article-title>MR imaging in human rabies</article-title><source>AJNR Am J Neuroradiol</source><year>2003</year><volume>24</volume><issue>6</issue><fpage>1102</fpage><lpage>1109</lpage><pub-id pub-id-type="pmid">12812933</pub-id></element-citation></ref><ref id="CR80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laothamatas</surname><given-names>J</given-names></name><name><surname>Sungkarat</surname><given-names>W</given-names></name><name><surname>Hemachudha</surname><given-names>T</given-names></name></person-group><article-title>Neuroimaging in rabies</article-title><source>Adv Virus Res</source><year>2011</year><volume>79</volume><fpage>309</fpage><lpage>327</lpage><pub-id pub-id-type="pmid">21601052</pub-id></element-citation></ref><ref id="CR81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname><given-names>LT</given-names></name><name><surname>Spudich</surname><given-names>SS</given-names></name></person-group><article-title>HIV-associated neurologic disorders and central nervous system opportunistic infections in HIV</article-title><source>Semin Neurol</source><year>2016</year><volume>36</volume><issue>4</issue><fpage>373</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">27643907</pub-id></element-citation></ref><ref id="CR82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>AJ</given-names></name><name><surname>Panos</surname><given-names>SE</given-names></name><name><surname>Horvath</surname><given-names>S</given-names></name></person-group><article-title>Genetic, transcriptomic, and epigenetic studies of HIV-associated neurocognitive disorder</article-title><source>J Acquir Immune Defic Syndr</source><year>2014</year><volume>65</volume><issue>4</issue><fpage>481</fpage><lpage>503</lpage><pub-id pub-id-type="pmid">24583618</pub-id></element-citation></ref><ref id="CR83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindquist</surname><given-names>L</given-names></name></person-group><article-title>Tick-borne encephalitis</article-title><source>Handb Clin Neurol</source><year>2014</year><volume>123</volume><fpage>531</fpage><lpage>559</lpage><pub-id pub-id-type="pmid">25015503</pub-id></element-citation></ref><ref id="CR84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liner</surname><given-names>KJ</given-names><suffix>2nd</suffix></name><name><surname>Ro</surname><given-names>MJ</given-names></name><name><surname>Robertson</surname><given-names>KR</given-names></name></person-group><article-title>HIV, antiretroviral therapies, and the brain</article-title><source>Curr HIV/AIDS Rep</source><year>2010</year><volume>7</volume><issue>2</issue><fpage>85</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">20425562</pub-id></element-citation></ref><ref id="CR85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipton</surname><given-names>SA</given-names></name></person-group><article-title>HIV-related neurotoxicity</article-title><source>Brain Pathol (Zurich, Switzerland)</source><year>1991</year><volume>1</volume><issue>3</issue><fpage>193</fpage><lpage>199</lpage></element-citation></ref><ref id="CR86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>E</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Xiong</surname><given-names>H</given-names></name></person-group><article-title>Oligodendrocyte injury and pathogenesis of HIV-1-associated neurocognitive disorders</article-title><source>Brain Sci</source><year>2016</year><volume>6</volume><issue>3</issue><fpage>E23</fpage><pub-id pub-id-type="pmid">27455335</pub-id></element-citation></ref><ref id="CR87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez-Labrador</surname><given-names>FX</given-names></name><name><surname>Berenguer</surname><given-names>M</given-names></name><name><surname>Navarro</surname><given-names>D</given-names></name></person-group><article-title>Overcoming drug resistance in HSV, CMV, HBV and HCV infection</article-title><source>Future Microbiol</source><year>2015</year><volume>10</volume><issue>11</issue><fpage>1759</fpage><lpage>1766</lpage><pub-id pub-id-type="pmid">26522939</pub-id></element-citation></ref><ref id="CR88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louboutin</surname><given-names>JP</given-names></name><name><surname>Strayer</surname><given-names>DS</given-names></name></person-group><article-title>Blood-brain barrier abnormalities caused by HIV-1 gp120: mechanistic and therapeutic implications</article-title><source>Sci J</source><year>2012</year><volume>2012</volume><fpage>482575</fpage></element-citation></ref><ref id="CR89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malik</surname><given-names>S</given-names></name><name><surname>Eugenin</surname><given-names>EA</given-names></name></person-group><article-title>Mechanisms of HIV neuropathogenesis: role of cellular communication systems</article-title><source>Curr HIV Res</source><year>2016</year><volume>14</volume><issue>5</issue><fpage>400</fpage><lpage>411</lpage><pub-id pub-id-type="pmid">27009098</pub-id></element-citation></ref><ref id="CR90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marban</surname><given-names>C</given-names></name><name><surname>Forouzanfar</surname><given-names>F</given-names></name><name><surname>Ait-Ammar</surname><given-names>A</given-names></name><name><surname>Fahmi</surname><given-names>F</given-names></name><name><surname>El Mekdad</surname><given-names>H</given-names></name><name><surname>Daouad</surname><given-names>F</given-names></name><name><surname>Rohr</surname><given-names>O</given-names></name><name><surname>Schwartz</surname><given-names>C</given-names></name></person-group><article-title>Targeting the brain reservoirs: toward an HIV cure</article-title><source>Front Immunol</source><year>2016</year><volume>7</volume><fpage>397</fpage><pub-id pub-id-type="pmid">27746784</pub-id></element-citation></ref><ref id="CR91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maschke</surname><given-names>M</given-names></name><name><surname>Kastrup</surname><given-names>O</given-names></name><name><surname>Forsting</surname><given-names>M</given-names></name><name><surname>Diener</surname><given-names>HC</given-names></name></person-group><article-title>Update on neuroimaging in infectious central nervous system disease</article-title><source>Curr Opin Neurol</source><year>2004</year><volume>17</volume><issue>4</issue><fpage>475</fpage><lpage>480</lpage><pub-id pub-id-type="pmid">15247545</pub-id></element-citation></ref><ref id="CR92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Achim</surname><given-names>CL</given-names></name><name><surname>Ge</surname><given-names>N</given-names></name><name><surname>DeTeresa</surname><given-names>R</given-names></name><name><surname>Terry</surname><given-names>RD</given-names></name><name><surname>Wiley</surname><given-names>CA</given-names></name></person-group><article-title>Spectrum of human immunodeficiency virus-associated neocortical damage</article-title><source>Ann Neurol</source><year>1992</year><volume>32</volume><issue>3</issue><fpage>321</fpage><lpage>329</lpage><pub-id pub-id-type="pmid">1416802</pub-id></element-citation></ref><ref id="CR93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Ge</surname><given-names>N</given-names></name><name><surname>Morey</surname><given-names>M</given-names></name><name><surname>DeTeresa</surname><given-names>R</given-names></name><name><surname>Terry</surname><given-names>RD</given-names></name><name><surname>Wiley</surname><given-names>CA</given-names></name></person-group><article-title>Cortical dendritic pathology in human immunodeficiency virus encephalitis</article-title><source>Lab Invest</source><year>1992</year><volume>66</volume><issue>3</issue><fpage>285</fpage><lpage>291</lpage><pub-id pub-id-type="pmid">1538584</pub-id></element-citation></ref><ref id="CR94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>M</given-names></name><name><surname>Nath</surname><given-names>A</given-names></name></person-group><article-title>Neurologic consequences of the immune reconstitution inflammatory syndrome (IRIS)</article-title><source>Curr Neurol Neurosci Rep</source><year>2010</year><volume>10</volume><issue>6</issue><fpage>467</fpage><lpage>475</lpage><pub-id pub-id-type="pmid">20697980</pub-id></element-citation></ref><ref id="CR95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McRae</surname><given-names>M</given-names></name></person-group><article-title>HIV and viral protein effects on the blood brain barrier</article-title><source>Tissue Barriers</source><year>2016</year><volume>4</volume><issue>1</issue><fpage>e1143543</fpage><pub-id pub-id-type="pmid">27141423</pub-id></element-citation></ref><ref id="CR96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meeker</surname><given-names>RB</given-names></name><name><surname>Asahchop</surname><given-names>E</given-names></name><name><surname>Power</surname><given-names>C</given-names></name></person-group><article-title>The brain and HAART: collaborative and combative connections</article-title><source>Curr Opin HIV AIDS</source><year>2014</year><volume>9</volume><issue>6</issue><fpage>579</fpage><lpage>584</lpage><pub-id pub-id-type="pmid">25275707</pub-id></element-citation></ref><ref id="CR97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menendez</surname><given-names>CM</given-names></name><name><surname>Carr</surname><given-names>DJJ</given-names></name></person-group><article-title>Defining nervous system susceptibility during acute and latent herpes simplex virus-1 infection</article-title><source>J Neuroimmunol</source><year>2017</year><volume>308</volume><fpage>43</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">28302316</pub-id></element-citation></ref><ref id="CR98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molloy</surname><given-names>ES</given-names></name><name><surname>Calabrese</surname><given-names>CM</given-names></name><name><surname>Calabrese</surname><given-names>LH</given-names></name></person-group><article-title>The risk of progressive multifocal leukoencephalopathy in the biologic era: prevention and management</article-title><source>Rheum Dis Clin N Am</source><year>2017</year><volume>43</volume><issue>1</issue><fpage>95</fpage><lpage>109</lpage></element-citation></ref><ref id="CR99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monaco</surname><given-names>MC</given-names></name><name><surname>Major</surname><given-names>EO</given-names></name></person-group><article-title>Immune system involvement in the pathogenesis of JC virus induced PML: what is learned from studies of patients with underlying diseases and therapies as risk factors</article-title><source>Front Immunol</source><year>2015</year><volume>6</volume><fpage>159</fpage><pub-id pub-id-type="pmid">25972864</pub-id></element-citation></ref><ref id="CR100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navia</surname><given-names>BA</given-names></name><name><surname>Cho</surname><given-names>ES</given-names></name><name><surname>Petito</surname><given-names>CK</given-names></name><name><surname>Price</surname><given-names>RW</given-names></name></person-group><article-title>The AIDS dementia complex: II. Neuropathology</article-title><source>Ann Neurol</source><year>1986</year><volume>19</volume><issue>6</issue><fpage>525</fpage><lpage>535</lpage><pub-id pub-id-type="pmid">3014994</pub-id></element-citation></ref><ref id="CR101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navia</surname><given-names>BA</given-names></name><name><surname>Jordan</surname><given-names>BD</given-names></name><name><surname>Price</surname><given-names>RW</given-names></name></person-group><article-title>The AIDS dementia complex: I. Clinical features</article-title><source>Ann Neurol</source><year>1986</year><volume>19</volume><issue>6</issue><fpage>517</fpage><lpage>524</lpage><pub-id pub-id-type="pmid">3729308</pub-id></element-citation></ref><ref id="CR102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>AM</given-names></name><name><surname>Manabe</surname><given-names>YC</given-names></name><name><surname>Lucas</surname><given-names>SB</given-names></name></person-group><article-title>Immune reconstitution inflammatory syndrome (IRIS): what pathologists should know</article-title><source>Semin Diagn Pathol</source><year>2017</year><volume>34</volume><issue>4</issue><fpage>340</fpage><lpage>351</lpage><pub-id pub-id-type="pmid">28552210</pub-id></element-citation></ref><ref id="CR103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Netravathi</surname><given-names>M</given-names></name><name><surname>Mahadevan</surname><given-names>A</given-names></name><name><surname>Satishchandra</surname><given-names>P</given-names></name><name><surname>Shobha</surname><given-names>N</given-names></name><name><surname>Mailankody</surname><given-names>P</given-names></name><name><surname>Kandavel</surname><given-names>T</given-names></name><name><surname>Jitender</surname><given-names>S</given-names></name><name><surname>Anantaram</surname><given-names>G</given-names></name><name><surname>Nagarathna</surname><given-names>S</given-names></name><name><surname>Govekar</surname><given-names>S</given-names></name><name><surname>Ravikumar</surname><given-names>BV</given-names></name><name><surname>Ravi</surname><given-names>V</given-names></name><name><surname>Shankar</surname><given-names>SK</given-names></name></person-group><article-title>Progressive multifocal leukoencephalopathy (PML) associated with HIV Clade C&#x02013;is not uncommon</article-title><source>J Neurovirol</source><year>2013</year><volume>19</volume><issue>3</issue><fpage>198</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">23700233</pub-id></element-citation></ref><ref id="CR104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicoll</surname><given-names>MP</given-names></name><name><surname>Proenca</surname><given-names>JT</given-names></name><name><surname>Efstathiou</surname><given-names>S</given-names></name></person-group><article-title>The molecular basis of herpes simplex virus latency</article-title><source>FEMS Microbiol Rev</source><year>2012</year><volume>36</volume><issue>3</issue><fpage>684</fpage><lpage>705</lpage><pub-id pub-id-type="pmid">22150699</pub-id></element-citation></ref><ref id="CR105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nightingale</surname><given-names>S</given-names></name><name><surname>Winston</surname><given-names>A</given-names></name><name><surname>Letendre</surname><given-names>S</given-names></name><name><surname>Michael</surname><given-names>BD</given-names></name><name><surname>McArthur</surname><given-names>JC</given-names></name><name><surname>Khoo</surname><given-names>S</given-names></name><name><surname>Solomon</surname><given-names>T</given-names></name></person-group><article-title>Controversies in HIV-associated neurocognitive disorders</article-title><source>Lancet Neurol</source><year>2014</year><volume>13</volume><issue>11</issue><fpage>1139</fpage><lpage>1151</lpage><pub-id pub-id-type="pmid">25316020</pub-id></element-citation></ref><ref id="CR106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oster</surname><given-names>S</given-names></name><name><surname>Christoffersen</surname><given-names>P</given-names></name><name><surname>Gundersen</surname><given-names>HJ</given-names></name><name><surname>Nielsen</surname><given-names>JO</given-names></name><name><surname>Pakkenberg</surname><given-names>B</given-names></name><name><surname>Pedersen</surname><given-names>C</given-names></name></person-group><article-title>Cerebral atrophy in AIDS: a stereological study</article-title><source>Acta Neuropathol</source><year>1993</year><volume>85</volume><issue>6</issue><fpage>617</fpage><lpage>622</lpage><pub-id pub-id-type="pmid">8337940</pub-id></element-citation></ref><ref id="CR107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavlovic</surname><given-names>D</given-names></name><name><surname>Patera</surname><given-names>AC</given-names></name><name><surname>Nyberg</surname><given-names>F</given-names></name><name><surname>Gerber</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name></person-group><article-title>Progressive multifocal leukoencephalopathy: current treatment options and future perspectives</article-title><source>Ther Adv Neurol Disord</source><year>2015</year><volume>8</volume><issue>6</issue><fpage>255</fpage><lpage>273</lpage><pub-id pub-id-type="pmid">26600871</pub-id></element-citation></ref><ref id="CR108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Persidsky</surname><given-names>Y</given-names></name><name><surname>Gendelman</surname><given-names>HE</given-names></name></person-group><article-title>Mononuclear phagocyte immunity and the neuropathogenesis of HIV-1 infection</article-title><source>J Leukoc Biol</source><year>2003</year><volume>74</volume><issue>5</issue><fpage>691</fpage><lpage>701</lpage><pub-id pub-id-type="pmid">14595004</pub-id></element-citation></ref><ref id="CR109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pires de Mello</surname><given-names>CP</given-names></name><name><surname>Bloom</surname><given-names>DC</given-names></name><name><surname>Paixao</surname><given-names>IC</given-names></name></person-group><article-title>Herpes simplex virus type-1: replication, latency, reactivation and its antiviral targets</article-title><source>Antivir Ther</source><year>2016</year><volume>21</volume><issue>4</issue><fpage>277</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">26726828</pub-id></element-citation></ref><ref id="CR110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>VR</given-names></name><name><surname>Ruiz</surname><given-names>AP</given-names></name><name><surname>Prasad</surname><given-names>VR</given-names></name></person-group><article-title>Viral and cellular factors underlying neuropathogenesis in HIV associated neurocognitive disorders (HAND)</article-title><source>AIDS Res Ther</source><year>2014</year><volume>11</volume><fpage>13</fpage><pub-id pub-id-type="pmid">24894206</pub-id></element-citation></ref><ref id="CR111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reyes</surname><given-names>MG</given-names></name><name><surname>Faraldi</surname><given-names>F</given-names></name><name><surname>Senseng</surname><given-names>CS</given-names></name><name><surname>Flowers</surname><given-names>C</given-names></name><name><surname>Fariello</surname><given-names>R</given-names></name></person-group><article-title>Nigral degeneration in acquired immune deficiency syndrome (AIDS)</article-title><source>Acta Neuropathol</source><year>1991</year><volume>82</volume><issue>1</issue><fpage>39</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">1950477</pub-id></element-citation></ref><ref id="CR112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rocha</surname><given-names>AJ</given-names></name><name><surname>Littig</surname><given-names>IA</given-names></name><name><surname>Nunes</surname><given-names>RH</given-names></name><name><surname>Tilbery</surname><given-names>CP</given-names></name></person-group><article-title>Central nervous system infectious diseases mimicking multiple sclerosis: recognizing distinguishable features using MRI</article-title><source>Arq Neuropsiquiatr</source><year>2013</year><volume>71</volume><issue>9b</issue><fpage>738</fpage><lpage>746</lpage><pub-id pub-id-type="pmid">24141516</pub-id></element-citation></ref><ref id="CR113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roizman</surname><given-names>B</given-names></name><name><surname>Whitley</surname><given-names>RJ</given-names></name></person-group><article-title>An inquiry into the molecular basis of HSV latency and reactivation</article-title><source>Annu Rev Microbiol</source><year>2013</year><volume>67</volume><fpage>355</fpage><lpage>374</lpage><pub-id pub-id-type="pmid">24024635</pub-id></element-citation></ref><ref id="CR114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rozenberg</surname><given-names>F</given-names></name><name><surname>Deback</surname><given-names>C</given-names></name><name><surname>Agut</surname><given-names>H</given-names></name></person-group><article-title>Herpes simplex encephalitis: from virus to therapy</article-title><source>Infect Disord Drug Targets</source><year>2011</year><volume>11</volume><issue>3</issue><fpage>235</fpage><lpage>250</lpage><pub-id pub-id-type="pmid">21488834</pub-id></element-citation></ref><ref id="CR115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ru</surname><given-names>W</given-names></name><name><surname>Tang</surname><given-names>SJ</given-names></name></person-group><article-title>HIV-associated synaptic degeneration</article-title><source>Mol Brain</source><year>2017</year><volume>10</volume><issue>1</issue><fpage>40</fpage><pub-id pub-id-type="pmid">28851400</pub-id></element-citation></ref><ref id="CR116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rumboldt</surname><given-names>Z</given-names></name></person-group><article-title>Imaging of topographic viral CNS infections</article-title><source>Neuroimaging Clin N Am</source><year>2008</year><volume>18</volume><issue>1</issue><fpage>85</fpage><lpage>92; viii</lpage><pub-id pub-id-type="pmid">18319156</pub-id></element-citation></ref><ref id="CR117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruzek</surname><given-names>D</given-names></name><name><surname>Dobler</surname><given-names>G</given-names></name><name><surname>Donoso Mantke</surname><given-names>O</given-names></name></person-group><article-title>Tick-borne encephalitis: pathogenesis and clinical implications</article-title><source>Travel Med Infect Dis</source><year>2010</year><volume>8</volume><issue>4</issue><fpage>223</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">20970725</pub-id></element-citation></ref><ref id="CR118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryan</surname><given-names>LA</given-names></name><name><surname>Cotter</surname><given-names>RL</given-names></name><name><surname>Zink</surname><given-names>WE</given-names><suffix>2nd</suffix></name><name><surname>Gendelman</surname><given-names>HE</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name></person-group><article-title>Macrophages, chemokines and neuronal injury in HIV-1-associated dementia</article-title><source>Cell Mol Biol (Noisy-le-Grand)</source><year>2002</year><volume>48</volume><issue>2</issue><fpage>137</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">11995633</pub-id></element-citation></ref><ref id="CR119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabri</surname><given-names>F</given-names></name><name><surname>Titanji</surname><given-names>K</given-names></name><name><surname>De Milito</surname><given-names>A</given-names></name><name><surname>Chiodi</surname><given-names>F</given-names></name></person-group><article-title>Astrocyte activation and apoptosis: their roles in the neuropathology of HIV infection</article-title><source>Brain Pathol (Zurich, Switzerland)</source><year>2003</year><volume>13</volume><issue>1</issue><fpage>84</fpage><lpage>94</lpage></element-citation></ref><ref id="CR120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahraian</surname><given-names>MA</given-names></name><name><surname>Radue</surname><given-names>EW</given-names></name><name><surname>Eshaghi</surname><given-names>A</given-names></name><name><surname>Besliu</surname><given-names>S</given-names></name><name><surname>Minagar</surname><given-names>A</given-names></name></person-group><article-title>Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis</article-title><source>Eur J Neurol</source><year>2012</year><volume>19</volume><issue>8</issue><fpage>1060</fpage><lpage>1069</lpage><pub-id pub-id-type="pmid">22136455</pub-id></element-citation></ref><ref id="CR121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez</surname><given-names>AB</given-names></name><name><surname>Kaul</surname><given-names>M</given-names></name></person-group><article-title>Neuronal stress and injury caused by HIV-1, cART and drug abuse: converging contributions to HAND</article-title><source>Brain Sci</source><year>2017</year><volume>7</volume><issue>3</issue><fpage>E25</fpage><pub-id pub-id-type="pmid">28241493</pub-id></element-citation></ref><ref id="CR122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saylor</surname><given-names>D</given-names></name><name><surname>Dickens</surname><given-names>AM</given-names></name><name><surname>Sacktor</surname><given-names>N</given-names></name><name><surname>Haughey</surname><given-names>N</given-names></name><name><surname>Slusher</surname><given-names>B</given-names></name><name><surname>Pletnikov</surname><given-names>M</given-names></name><name><surname>Mankowski</surname><given-names>JL</given-names></name><name><surname>Brown</surname><given-names>A</given-names></name><name><surname>Volsky</surname><given-names>DJ</given-names></name><name><surname>McArthur</surname><given-names>JC</given-names></name></person-group><article-title>HIV-associated neurocognitive disorder&#x02014;pathogenesis and prospects for treatment</article-title><source>Nat Rev Neurol</source><year>2016</year><volume>12</volume><issue>4</issue><fpage>234</fpage><lpage>248</lpage><pub-id pub-id-type="pmid">26965674</pub-id></element-citation></ref><ref id="CR123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwab</surname><given-names>N</given-names></name><name><surname>Schneider-Hohendorf</surname><given-names>T</given-names></name><name><surname>Melzer</surname><given-names>N</given-names></name><name><surname>Cutter</surname><given-names>G</given-names></name><name><surname>Wiendl</surname><given-names>H</given-names></name></person-group><article-title>Natalizumab-associated PML: challenges with incidence, resulting risk, and risk stratification</article-title><source>Neurology</source><year>2017</year><volume>88</volume><issue>12</issue><fpage>1197</fpage><lpage>1205</lpage><pub-id pub-id-type="pmid">28228564</pub-id></element-citation></ref><ref id="CR124"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senocak</surname><given-names>E</given-names></name><name><surname>Oguz</surname><given-names>KK</given-names></name><name><surname>Ozgen</surname><given-names>B</given-names></name><name><surname>Kurne</surname><given-names>A</given-names></name><name><surname>Ozkaya</surname><given-names>G</given-names></name><name><surname>Unal</surname><given-names>S</given-names></name><name><surname>Cila</surname><given-names>A</given-names></name></person-group><article-title>Imaging features of CNS involvement in AIDS</article-title><source>Diagn Interv Radiol (Ankara, Turkey)</source><year>2010</year><volume>16</volume><issue>3</issue><fpage>193</fpage><lpage>200</lpage></element-citation></ref><ref id="CR125"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>R</given-names></name><name><surname>Bag</surname><given-names>AK</given-names></name><name><surname>Chapman</surname><given-names>PR</given-names></name><name><surname>Cure</surname><given-names>JK</given-names></name></person-group><article-title>Imaging manifestations of progressive multifocal leukoencephalopathy</article-title><source>Clin Radiol</source><year>2010</year><volume>65</volume><issue>6</issue><fpage>431</fpage><lpage>439</lpage><pub-id pub-id-type="pmid">20451009</pub-id></element-citation></ref><ref id="CR126"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>SK</given-names></name></person-group><article-title>Overview on the tricks of HIV tat to hit the blood brain barrier</article-title><source>Curr HIV Res</source><year>2016</year><volume>14</volume><issue>5</issue><fpage>382</fpage><lpage>388</lpage><pub-id pub-id-type="pmid">27719664</pub-id></element-citation></ref><ref id="CR127"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smit</surname><given-names>R</given-names></name><name><surname>Postma</surname><given-names>MJ</given-names></name></person-group><article-title>Review of tick-borne encephalitis and vaccines: clinical and economical aspects</article-title><source>Expert Rev Vaccines</source><year>2015</year><volume>14</volume><issue>5</issue><fpage>737</fpage><lpage>747</lpage><pub-id pub-id-type="pmid">25427237</pub-id></element-citation></ref><ref id="CR128"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sotrel</surname><given-names>A</given-names></name><name><surname>Dal Canto</surname><given-names>MC</given-names></name></person-group><article-title>HIV-1 and its causal relationship to immunosuppression and nervous system disease in AIDS: a review</article-title><source>Hum Pathol</source><year>2000</year><volume>31</volume><issue>10</issue><fpage>1274</fpage><lpage>1298</lpage><pub-id pub-id-type="pmid">11070121</pub-id></element-citation></ref><ref id="CR129"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steiner</surname><given-names>I</given-names></name><name><surname>Berger</surname><given-names>JR</given-names></name></person-group><article-title>Update on progressive multifocal leukoencephalopathy</article-title><source>Curr Neurol Neurosci Rep</source><year>2012</year><volume>12</volume><issue>6</issue><fpage>680</fpage><lpage>686</lpage><pub-id pub-id-type="pmid">22991070</pub-id></element-citation></ref><ref id="CR130"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subbiah</surname><given-names>P</given-names></name><name><surname>Mouton</surname><given-names>P</given-names></name><name><surname>Fedor</surname><given-names>H</given-names></name><name><surname>McArthur</surname><given-names>JC</given-names></name><name><surname>Glass</surname><given-names>JD</given-names></name></person-group><article-title>Stereological analysis of cerebral atrophy in human immunodeficiency virus-associated dementia</article-title><source>J Neuropathol Exp Neurol</source><year>1996</year><volume>55</volume><issue>10</issue><fpage>1032</fpage><lpage>1037</lpage><pub-id pub-id-type="pmid">8858000</pub-id></element-citation></ref><ref id="CR131"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taba</surname><given-names>P</given-names></name><name><surname>Schmutzhard</surname><given-names>E</given-names></name><name><surname>Forsberg</surname><given-names>P</given-names></name><name><surname>Lutsar</surname><given-names>I</given-names></name><name><surname>Ljostad</surname><given-names>U</given-names></name><name><surname>Mygland</surname><given-names>A</given-names></name><name><surname>Levchenko</surname><given-names>I</given-names></name><name><surname>Strle</surname><given-names>F</given-names></name><name><surname>Steiner</surname><given-names>I</given-names></name></person-group><article-title>EAN consensus review on prevention, diagnosis and management of tick-borne encephalitis</article-title><source>Eur J Neurol</source><year>2017</year><volume>24</volume><issue>10</issue><fpage>1214</fpage><lpage>e1261</lpage><pub-id pub-id-type="pmid">28762591</pub-id></element-citation></ref><ref id="CR132"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>CS</given-names></name><name><surname>Koralnik</surname><given-names>IJ</given-names></name></person-group><article-title>Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis</article-title><source>Lancet Neurol</source><year>2010</year><volume>9</volume><issue>4</issue><fpage>425</fpage><lpage>437</lpage><pub-id pub-id-type="pmid">20298966</pub-id></element-citation></ref><ref id="CR1320"><mixed-citation publication-type="other">Tardieu M (1999) HIV-1-related central nervous system diseases. Curr Opin Neurol 4:377&#x02013;81</mixed-citation></ref><ref id="CR133"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tenhula</surname><given-names>WN</given-names></name><name><surname>Xu</surname><given-names>SZ</given-names></name><name><surname>Madigan</surname><given-names>MC</given-names></name><name><surname>Heller</surname><given-names>K</given-names></name><name><surname>Freeman</surname><given-names>WR</given-names></name><name><surname>Sadun</surname><given-names>AA</given-names></name></person-group><article-title>Morphometric comparisons of optic nerve axon loss in acquired immunodeficiency syndrome</article-title><source>Am J Ophthalmol</source><year>1992</year><volume>113</volume><issue>1</issue><fpage>14</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">1370189</pub-id></element-citation></ref><ref id="CR134"><mixed-citation publication-type="other">Thellman NM, Triezenberg SJ (2017) Herpes simplex virus establishment, maintenance, and reactivation: in vitro modeling of latency. Pathogens (Basel, Switzerland) 6(3). 10.3390/pathogens6030028</mixed-citation></ref><ref id="CR135"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>PM</given-names></name><name><surname>Jahanshad</surname><given-names>N</given-names></name></person-group><article-title>Novel neuroimaging methods to understand how HIV affects the brain</article-title><source>Curr HIV/AIDS Rep</source><year>2015</year><volume>12</volume><issue>2</issue><fpage>289</fpage><lpage>298</lpage><pub-id pub-id-type="pmid">25902966</pub-id></element-citation></ref><ref id="CR136"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tselis</surname><given-names>AC</given-names></name></person-group><article-title>Cytomegalovirus infections of the adult human nervous system</article-title><source>Handb Clin Neurol</source><year>2014</year><volume>123</volume><fpage>307</fpage><lpage>318</lpage><pub-id pub-id-type="pmid">25015492</pub-id></element-citation></ref><ref id="CR137"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uzasci</surname><given-names>L</given-names></name><name><surname>Nath</surname><given-names>A</given-names></name><name><surname>Cotter</surname><given-names>R</given-names></name></person-group><article-title>Oxidative stress and the HIV-infected brain proteome</article-title><source>J Neuroimmune Pharmacol</source><year>2013</year><volume>8</volume><issue>5</issue><fpage>1167</fpage><lpage>1180</lpage><pub-id pub-id-type="pmid">23475542</pub-id></element-citation></ref><ref id="CR138"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vago</surname><given-names>L</given-names></name><name><surname>Bonetto</surname><given-names>S</given-names></name><name><surname>Nebuloni</surname><given-names>M</given-names></name><name><surname>Duca</surname><given-names>P</given-names></name><name><surname>Carsana</surname><given-names>L</given-names></name><name><surname>Zerbi</surname><given-names>P</given-names></name><name><surname>D'Arminio-Monforte</surname><given-names>A</given-names></name></person-group><article-title>Pathological findings in the central nervous system of AIDS patients on assumed antiretroviral therapeutic regimens: retrospective study of 1597 autopsies</article-title><source>AIDS (London, England)</source><year>2002</year><volume>16</volume><issue>14</issue><fpage>1925</fpage><lpage>1928</lpage></element-citation></ref><ref id="CR139"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vartak-Sharma</surname><given-names>N</given-names></name><name><surname>Nooka</surname><given-names>S</given-names></name><name><surname>Ghorpade</surname><given-names>A</given-names></name></person-group><article-title>Astrocyte elevated gene-1 (AEG-1) and the A(E)Ging HIV/AIDS-HAND</article-title><source>Prog Neurobiol</source><year>2017</year><volume>157</volume><fpage>133</fpage><lpage>157</lpage><pub-id pub-id-type="pmid">27090750</pub-id></element-citation></ref><ref id="CR140"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vera</surname><given-names>JH</given-names></name><name><surname>Ridha</surname><given-names>B</given-names></name><name><surname>Gilleece</surname><given-names>Y</given-names></name><name><surname>Amlani</surname><given-names>A</given-names></name><name><surname>Thorburn</surname><given-names>P</given-names></name><name><surname>Dizdarevic</surname><given-names>S</given-names></name></person-group><article-title>PET brain imaging in HIV-associated neurocognitive disorders (HAND) in the era of combination antiretroviral therapy</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2017</year><volume>44</volume><issue>5</issue><fpage>895</fpage><lpage>902</lpage><pub-id pub-id-type="pmid">28058461</pub-id></element-citation></ref><ref id="CR141"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verma</surname><given-names>R</given-names></name></person-group><article-title>MRI features of Japanese encephalitis</article-title><source>BMJ Case Rep</source><year>2012</year><volume>2012</volume><fpage>bcr0320126088</fpage></element-citation></ref><ref id="CR142"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Stulpnagel</surname><given-names>C</given-names></name><name><surname>Winkler</surname><given-names>P</given-names></name><name><surname>Koch</surname><given-names>J</given-names></name><name><surname>Zeches-Kansy</surname><given-names>C</given-names></name><name><surname>Schottler-Glas</surname><given-names>A</given-names></name><name><surname>Wolf</surname><given-names>G</given-names></name><name><surname>Niller</surname><given-names>HH</given-names></name><name><surname>Staudt</surname><given-names>M</given-names></name><name><surname>Kluger</surname><given-names>G</given-names></name><name><surname>Rostasy</surname><given-names>K</given-names></name></person-group><article-title>MRI-imaging and clinical findings of eleven children with tick-borne encephalitis and review of the literature</article-title><source>Eur J Paediatr Neurol</source><year>2016</year><volume>20</volume><issue>1</issue><fpage>45</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">26586340</pub-id></element-citation></ref><ref id="CR143"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wattjes</surname><given-names>MP</given-names></name><name><surname>Richert</surname><given-names>ND</given-names></name><name><surname>Killestein</surname><given-names>J</given-names></name><name><surname>de Vos</surname><given-names>M</given-names></name><name><surname>Sanchez</surname><given-names>E</given-names></name><name><surname>Snaebjornsson</surname><given-names>P</given-names></name><name><surname>Cadavid</surname><given-names>D</given-names></name><name><surname>Barkhof</surname><given-names>F</given-names></name></person-group><article-title>The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy</article-title><source>Mult Scler (Houndmills, Basingstoke, England)</source><year>2013</year><volume>19</volume><issue>14</issue><fpage>1826</fpage><lpage>1840</lpage></element-citation></ref><ref id="CR144"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weis</surname><given-names>S</given-names></name><name><surname>Haug</surname><given-names>H</given-names></name></person-group><article-title>Capillaries in the human cerebral cortex: a quantitative electronmicroscopical study</article-title><source>Acta Stereologica</source><year>1989</year><volume>8</volume><fpage>139</fpage><lpage>144</lpage></element-citation></ref><ref id="CR145"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weis</surname><given-names>S</given-names></name><name><surname>Haug</surname><given-names>H</given-names></name><name><surname>Budka</surname><given-names>H</given-names></name></person-group><article-title>Astroglial changes in the cerebral cortex of AIDS brains: a morphometric and immunohistochemical investigation</article-title><source>Neuropathol Appl Neurobiol</source><year>1993</year><volume>19</volume><issue>4</issue><fpage>329</fpage><lpage>335</lpage><pub-id pub-id-type="pmid">8232753</pub-id></element-citation></ref><ref id="CR146"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weis</surname><given-names>S</given-names></name><name><surname>Haug</surname><given-names>H</given-names></name><name><surname>Budka</surname><given-names>H</given-names></name></person-group><article-title>Neuronal damage in the cerebral cortex of AIDS brains: a morphometric study</article-title><source>Acta Neuropathol</source><year>1993</year><volume>85</volume><issue>2</issue><fpage>185</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">8442409</pub-id></element-citation></ref><ref id="CR147"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weis</surname><given-names>S</given-names></name><name><surname>Llenos</surname><given-names>IC</given-names></name><name><surname>B&#x000fc;ttner</surname><given-names>A</given-names></name><name><surname>Rebhan</surname><given-names>A</given-names></name><name><surname>Soreth</surname><given-names>D</given-names></name><name><surname>Mehraein</surname><given-names>P</given-names></name></person-group><article-title>Macroscopic morphometry of human brains in neurodegeneration</article-title><source>Acta Stereologica</source><year>1993</year><volume>12</volume><fpage>299</fpage><lpage>304</lpage></element-citation></ref><ref id="CR148"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weis</surname><given-names>S</given-names></name><name><surname>Neuhaus</surname><given-names>B</given-names></name><name><surname>Mehraein</surname><given-names>P</given-names></name></person-group><article-title>Activation of microglia in HIV-1 infected brains is not dependent on the presence of HIV-1 antigens</article-title><source>Neuroreport</source><year>1994</year><volume>5</volume><issue>12</issue><fpage>1514</fpage><lpage>1516</lpage><pub-id pub-id-type="pmid">7948851</pub-id></element-citation></ref><ref id="CR149"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weis</surname><given-names>S</given-names></name><name><surname>Haug</surname><given-names>H</given-names></name><name><surname>Budka</surname><given-names>H</given-names></name></person-group><article-title>Vascular changes in the cerebral cortex in HIV-1 infection: I. A morphometric investigation by light and electron microscopy</article-title><source>Clin Neuropathol</source><year>1996</year><volume>15</volume><issue>6</issue><fpage>361</fpage><lpage>366</lpage><pub-id pub-id-type="pmid">8937785</pub-id></element-citation></ref><ref id="CR150"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weller</surname><given-names>SK</given-names></name><name><surname>Coen</surname><given-names>DM</given-names></name></person-group><article-title>Herpes simplex viruses: mechanisms of DNA replication</article-title><source>Cold Spring Harb Perspect Biol</source><year>2012</year><volume>4</volume><issue>9</issue><fpage>a013011</fpage><pub-id pub-id-type="pmid">22952399</pub-id></element-citation></ref><ref id="CR151"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>MK</given-names></name><name><surname>Khalili</surname><given-names>K</given-names></name></person-group><article-title>Pathogenesis of progressive multifocal leukoencephalopathy&#x02014;revisited</article-title><source>J Infect Dis</source><year>2011</year><volume>203</volume><issue>5</issue><fpage>578</fpage><lpage>586</lpage><pub-id pub-id-type="pmid">21227915</pub-id></element-citation></ref><ref id="CR152"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>MK</given-names></name><name><surname>Sariyer</surname><given-names>IK</given-names></name><name><surname>Gordon</surname><given-names>J</given-names></name><name><surname>Delbue</surname><given-names>S</given-names></name><name><surname>Pietropaolo</surname><given-names>V</given-names></name><name><surname>Berger</surname><given-names>JR</given-names></name><name><surname>Khalili</surname><given-names>K</given-names></name></person-group><article-title>Diagnostic assays for polyomavirus JC and progressive multifocal leukoencephalopathy</article-title><source>Rev Med Virol</source><year>2016</year><volume>26</volume><issue>2</issue><fpage>102</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">26663440</pub-id></element-citation></ref><ref id="CR153"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiley</surname><given-names>CA</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Morey</surname><given-names>M</given-names></name><name><surname>Lemere</surname><given-names>C</given-names></name><name><surname>DeTeresa</surname><given-names>R</given-names></name><name><surname>Grafe</surname><given-names>M</given-names></name><name><surname>Hansen</surname><given-names>L</given-names></name><name><surname>Terry</surname><given-names>R</given-names></name></person-group><article-title>Neocortical damage during HIV infection</article-title><source>Ann Neurol</source><year>1991</year><volume>29</volume><issue>6</issue><fpage>651</fpage><lpage>657</lpage><pub-id pub-id-type="pmid">1909852</pub-id></element-citation></ref><ref id="CR154"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>KC</given-names></name><name><surname>Hickey</surname><given-names>WF</given-names></name></person-group><article-title>Central nervous system damage, monocytes and macrophages, and neurological disorders in AIDS</article-title><source>Annu Rev Neurosci</source><year>2002</year><volume>25</volume><fpage>537</fpage><lpage>562</lpage><pub-id pub-id-type="pmid">12052920</pub-id></element-citation></ref><ref id="CR155"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>AC</given-names></name><name><surname>Mohr</surname><given-names>I</given-names></name></person-group><article-title>A cultured affair: HSV latency and reactivation in neurons</article-title><source>Trends Microbiol</source><year>2012</year><volume>20</volume><issue>12</issue><fpage>604</fpage><lpage>611</lpage><pub-id pub-id-type="pmid">22963857</pub-id></element-citation></ref><ref id="CR156"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wohlschlaeger</surname><given-names>J</given-names></name><name><surname>Wenger</surname><given-names>E</given-names></name><name><surname>Mehraein</surname><given-names>P</given-names></name><name><surname>Weis</surname><given-names>S</given-names></name></person-group><article-title>White matter changes in HIV-1 infected brains: a combined gross anatomical and ultrastructural morphometric investigation of the corpus callosum</article-title><source>Clin Neurol Neurosurg</source><year>2009</year><volume>111</volume><issue>5</issue><fpage>422</fpage><lpage>429</lpage><pub-id pub-id-type="pmid">19185416</pub-id></element-citation></ref><ref id="CR157"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zambito Marsala</surname><given-names>S</given-names></name><name><surname>Pistacchi</surname><given-names>M</given-names></name><name><surname>Gioulis</surname><given-names>M</given-names></name><name><surname>Mel</surname><given-names>R</given-names></name><name><surname>Marchini</surname><given-names>C</given-names></name><name><surname>Francavilla</surname><given-names>E</given-names></name></person-group><article-title>Neurological complications of tick borne encephalitis: the experience of 89 patients studied and literature review</article-title><source>Neurol Sci</source><year>2014</year><volume>35</volume><issue>1</issue><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">24170165</pub-id></element-citation></ref><ref id="CR158"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zayyad</surname><given-names>Z</given-names></name><name><surname>Spudich</surname><given-names>S</given-names></name></person-group><article-title>Neuropathogenesis of HIV: from initial neuroinvasion to HIV-associated neurocognitive disorder (HAND)</article-title><source>Curr HIV/AIDS Rep</source><year>2015</year><volume>12</volume><issue>1</issue><fpage>16</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">25604237</pub-id></element-citation></ref></ref-list></back></article>